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Epithelial ovarian carcinomas (EOC) comprise five main histological subtypes, each displaying 
distinct pathological, molecular and clinical characteristics. Endometrioid ovarian carcinomas 
(EnOC) account for 10% of EOC and have been historically under-investigated. They typically 
present as early stage, grade 1 or 2 (low grade) tumours arising from endometriosis, and are 
associated with excellent clinical outcomes. However, Grade 3 (high grade) EnOC, as well as 
the even rarer de-differentiated carcinomas, can be challenging to differentiate from high grade 
serous ovarian carcinomas (HGSOC) based on morphology alone.  Through the refinement 
of EnOC diagnostic criteria, several studies have now demonstrated that many previously 
diagnosed high grade EnOC are in fact HGSOC. This is further supported by gene expression 
profiling studies demonstrating that a proportion of high grade EnOC cluster together with 
HGSOC.  As such, true high grade EnOC are increasingly rare and are associated with poor 
prognosis.  WT1 immunohistochemistry (IHC) is a useful tool to discriminate high grade EnOC 
(WT1 negative (WT1-ve)) from HGSOC (WT1 positive), reducing inter-observer variation. 
To date, clinical and molecular characterisation of EnOC has been confounded by the 
inclusion of historically misclassified HGSOC in older studies. Mutational analysis performed 
by more recent studies have either only been applied to low grade EnOC, or lack information 
on grade or diagnostic criteria used. As a result, the molecular landscape and clinical 
behaviour of EnOC, in particular high grade EnOC, is not well defined.   
In this study, tumours historically diagnosed as EnOC were identified through the Edinburgh 
Ovarian Cancer Database. Contemporary pathology review was performed utilising WT1 and 
p53 IHC. WT1-ve EnOC of all grades, and WT1-ve tumours with high grade serous and 
undifferentiated morphology were identified and included in the primary analysis. Clinical 
characteristics of the primary cohort were extracted from the database. Survival analysis was 
performed and responses to chemotherapy and endocrine therapy recorded. 63 tumours from 
the primary cohort underwent DNA extraction and whole exome sequencing (WES); 
comprising all WT1-ve tumours with mutant p53 expression on immunohistochemistry 
(p53mut(IHC)) (n=28), all WT1-ve high grade carcinomas with p53 wild-type expression on 
immunohistochemistry (p53wt (IHC)) (n=12) alongside a randomly selected subset of WT1-ve 
p53wt (IHC) low grade EnOC tumours (23 of 87 cases, 26.4%). Supervised mutational and copy 
number analysis was performed across 75 commonly mutated genes previously reported in 
endometrial, ovarian or pan cancer studies and molecular subgroups were identified. 
Unsupervised clustering analysis validated these molecular subgroups. Hormone receptor 
expression levels (oestrogen receptor (ER), progesterone receptor (PR) and androgen 
receptor (AR)) were evaluated as histoscores in the primary cohort. Multivariable survival 
analysis, accounting for stage, residual disease, decade of diagnosis. grade and age, was 
performed on resulting molecular and hormone receptor subgroups. 
Between May 1980 and December 2013, 125 WT1-ve tumours were identified. Overall five year 
disease specific survival (DSS) was 73.2% with the most favourable prognosis in those with 
early stage disease. Five year DSS in patients with advanced stage p53wt (IHC) low grade EnOC 
was 50.0%. Late relapses beyond five years were common in early stage disease. Patients 
with stage IV disease had poor prognosis with median DSS of less than one year. Radiological 
and CA125 response rates to platinum based chemotherapy in evaluable tumours was 44.5% 
and 69.3%, respectively. Median duration of endocrine therapy in evaluable tumours was 317 
days (range 35 – 615 days). Of the 61 tumours successfully sequenced, TP53 mutations 
(TP53mut) were the most common (45.9%); followed by mutations in EnOC-associated genes 
(ARID1A (41.0%), CTNNB1 (31.1%), PTEN (24.6%) and PIK3CA (23.0%)). Only TP53mut 
status was independently associated with shortened DSS (HR=0.35, 95% CI 0.14-0.83, 
P=0.018). Copy number analysis revealed significantly more alterations in the TP53mut tumours 
compared to TP53wt tumours (P <0.0001), with a particular enrichment of variation across 
EnOC-associated genes in the TP53mut subgroup with no EnOC-associated gene mutations. 
The majority of the primary cohort expressed ER and PR whereas AR expression was low. A 
PR histoscore of >150, when compared to a PR histoscore ≤ 150, was found to be 
independently associated with DSS, whereas no associations were observed with ER or AR 
expression levels. In particular, patients with stage II EnOC and a PR histoscore of >150 
displayed a ten year DSS of over 90%.   
Through this study, TP53 mutation status and a PR histoscore of greater than 150 were 
identified as independent predictors of survival.  This demonstrates EnOC to be a 
heterogeneous disease with distinct molecular and hormone receptor subgroups that 
demonstrate differential clinical outcome. Patients with TP53 mutated and/or low PR 
expression EnOC have inferior prognosis and the development of novel therapeutic agents 
should be focused on these groups which display the greatest unmet need.  
  
Lay Summary 
Epithelial ovarian cancer was historically thought to be one disease and its treatment a ‘one 
size fits all’ approach comprised of aggressive surgery and platinum based chemotherapy. 
However, it is now recognised to be made up of five different diseases, namely, high grade 
serous (HGSOC) (80%), low grade serous (5%), endometrioid (EnOC) (10%), clear cell (10%) 
and mucinous ovarian cancers (3%). Each subtype has its own unique molecular origins, 
clinical behaviour and responses to treatment.  
EnOC is a rare subtype of ovarian cancer which is usually diagnosed as early stage (disease 
confined to the ovary that has not spread), slow growing (grade 1 and 2) disease associated 
with excellent outcomes following surgery and chemotherapy. A small proportion are also 
diagnosed as fast growing (grade 3) disease which have a poorer prognosis. However, it can 
be challenging to tell the difference between the microscopic appearances of grade 3 EnOC 
and the most common subtype of ovarian cancer, HGSOC. Through refinements in the 
diagnosis of these tumours and the use of molecular testing, it is now recognised that many 
historically diagnosed grade 3 EnOC are in fact HGSOC. Studies have demonstrated that 
using Wilm’s tumour 1 (WT1) antibody stains can help differentiate grade 3 EnOC (WT1 
negative) from HGSOC (WT1 positive). The molecular profile, clinical outcomes and 
chemotherapy responses of EnOC, are therefore less well understood as many older studies 
were contaminated with misdiagnosed HGSOC. The aim of this study was to understand the 
clinical behaviour and genetic make-up of EnOC diagnosed using modern criteria, as well as 
to identify molecular prognostic factors which may help individualise treatments for patients. 
In this study, historically diagnosed EnOC were identified between May 1980 and December 
2013 through the Edinburgh Ovarian Cancer Database. Using modern diagnostic criteria, 125 
EnOC were identified and clinical characteristics of these tumours were recorded. 63 tumours 
were sent for genetic profiling through a process called whole exome sequencing. Each 
tumour was stained for the presence of hormone receptors which include the oestrogen 
receptor (ER), progesterone receptor (PR) and the androgen receptor (AR). 
Through this work, distinct molecular groups within EnOC were identified. Each of these 
groups displayed different clinical outcomes. Patients’ whose tumours contained TP53 
mutations and low levels of PR staining did not survive as long as those without TP53 
mutations and high levels of PR staining. These two factors may thus provide additional 
prognostic information which may help to individualise treatments for patients. In particular, it 
may help identify a group of patients who may be able to avoid chemotherapy after surgery, 
sparing them the toxicities of treatment.  
 
In conclusion, this study demonstrates EnOC to be a heterogeneous disease made up of 
different molecular and hormonal subgroups. Testing for TP53 mutations and levels of PR may 
help guide the prognosis of patients with EnOC, however bigger studies are needed to confirm 
these findings. Further work should focus on the development of novel anti-cancer treatments 
for subgroups of EnOC which demonstrate the poorest prognosis.   
 
  
Table of Contents  
List of Tables 1 
List of Figures 2 
List of Appendices 4 
List of Abbreviations and Acronyms 5 
1. Introduction 9 
1.1 Epithelial ovarian cancer 10 
1.2 Clinical management 12 
1.2.1 Surgery in early stage disease 12 
1.2.2 Surgery in advanced stage disease 12 
1.2.3 Adjuvant chemotherapy 13 
1.2.4 Intraperitoneal chemotherapy 14 
1.2.5 Relapsed disease 15 
1.2.6 Bevacizumab 16 
1.2.6.1 Bevacizumab in first line treatment 16 
1.2.6.2 Bevacizumab in relapsed disease 17 
1.2.7 Secondary and tertiary cytoreductive surgery 18 
1.2.8 Endocrine therapy 18 
1.2.9 PARP inhibitors 18 
1.3 Hormones and ovarian cancer 19 
1.3.1 Hormone receptor expression in EOC 19 
1.3.2 Endocrine sensitivity of EOC 23 
1.4 Histological subtypes of epithelial ovarian cancer 27 
1.4.1 High grade serous carcinoma 27 
1.4.1.2 BRCA mutated HGSOC and implications of management 28 
1.4.2 Low grade serous carcinoma 30 
1.4.3 Clear cell carcinoma 31 
1.4.4 Mucinous carcinoma 32 
1.5 Endometrioid ovarian carcinoma 33 
1.5.1 Histogenesis 33 
1.5.2 Grading 34 
1.5.3 Pathology 35 
1.5.4 Diagnostic challenges in Endometrioid Ovarian Carcinomas 36 
1.5.4.1 Role of WT1 in differentiating high grade EnOC versus HGSOC 36 
1.5.4.2 De-differentiated carcinomas 37 
1.5.4.3 Pseudo-endometrioid colorectal metastases 38 
1.5.5 Hormone receptor expression 39 
1.5.6 Clinical characteristics 41 
1.5.7 Clinical Management 43 
1.5.7.1 Surgery in early stage EnOC 43 
 
 
1.5.7.2 Adjuvant chemotherapy in early stage EnOC 44 
1.5.7.3 Management of advanced stage EnOC 46 
1.5.7.4 Platinum sensitivity of EnOC 47 
1.5.8 Genetic profile of EnOC and comparisons with EnEC 47 
1.5.8.1 PTEN and PIK3CA 49 
1.5.8.2 ARID1A 50 
1.5.8.3 CTNNB1 51 
1.5.8.4 KRAS 52 
1.5.8.5 Mismatch repair deficiency and microsatellite instability 53 
1.5.8.5.1 Mismatch repair deficiency in EnOC 55 
1.5.8.6 Molecular stratification of endometrial carcinomas and EnOC 56 
1.5.9 Aims and hypothesis 61 
2. Materials and Methods 62 
2.1 Ethical approval 63 
2.2 Pathology review 63 
2.3 Immunohistochemistry 67 
2.3.1 WT1 and p53 IHC staining 67 
2.3.2 CK7 and CK20 immuno-staining 69 
2.4 Clinical data extraction 70 
2.5 Tissue Microarray construction 72 
2.5.1 TMA immunohistochemistry 72 
2.5.1.1 Hormone receptors (ER, PR and AR) 72 
2.5.1.2 Mismatch repair proteins 74 
2.5.1.3 Beta-catenin 76 
2.5.1.4 PTEN 77 
2.5.1.5 ARID1A 78 
2.5.1.6 PIK3CA 78 
2.6 Tumour FFPE macro-dissection and DNA extraction 79 
2.7 Whole exome sequencing 80 
2.8 Variant calling and classification 81 
2.9 Analysis of mutational status 82 
2.10 Unsupervised clustering analysis 82 
2.11 Copy number variation (CNV) detection 82 
2.12 Statistical Analysis 82 
3. Clinical characteristics of EnOC 83 
3.1 Introduction 84 
3.2 Clinical characteristics 86 
3.2.1 Therapy received (WT1 negative cohort) 89 
3.2.2 Overall Survival 91 
3.2.3 Survival by stage 91 
 
 
3.2.4 Other clinical variables of prognosis 91 
3.3 Characteristics and survival of stage I disease 95 
3.4 Patterns of relapse in early stage disease 96 
3.5 Platinum responses 98 
3.5.1 Stage IV disease 98 
3.6 Discussion 99 
3.7 Conclusion 103 
4. Hormone receptor expression and endocrine sensitivity in EnOC 104 
4.1 Introduction 105 
4.2 Results 106 
4.2.1 Hormone receptor expression in  EnOC 106 
4.2.2 Hormone receptor expression and survival 108 
4.2.3 Endocrine sensitivity in EnOC 113 
4.3 Discussion 115 
4.4 Conclusion 117 
5. Single nucleotide variant and copy number analysis 118 
5.1 Introduction 119 
5.2 Results 120 
5.3 Molecular landscape 120 
5.3.1 Mutational and Immunohistochemical correlation 122 
5.3.1 POLE mutations 124 
5.3.2 Mutations in Mismatch repair genes and BRCA mutations 125 
5.3.1 Prognostic impact of TP53, ARID1A and CTNNB1 mutation status 128 
5.4 A molecular taxonomy for classifying EnOC 131 
5.5 WT1 positive low grade endometrioid ovarian carcinomas 136 
5.6 Copy number variants across molecular subgroups of EnOC 137 
5.7 Hormone receptor expression in TP53 mutant and TP53 wild-type status tumours 138 
5.8 Discussion 139 
5.9 Study Limitations 147 
5.10 Conclusion 148 
6. Final Discussion 149 
6.1 Discussion 150 
7. Appendices 154 
7.1 Appendix A 156 
7.2 Appendix B 162 
7.3 Appendix C 164 
7.4 Appendix D 166 
8. References 168 
1 
 
List of Tables 
Table 1: ER and PR expression in histological subtypes of epithelial ovarian carcinomas in the Ovarian Tumour Tissue Analysis consortium study. 
Table 2: Studies evaluating ER and PR as a prognostic marker in epithelial ovarian carcinoma.      
Table 3: Studies evaluating AR as a prognostic biomarker in epithelial ovarian carcinoma.       
Table 4: A selection of trials evaluating endocrine therapy in epithelial ovarian carcinoma.       
Table 5: Studies of AR expression in EnOC.         
Table 6: Clinical characteristics of the WT1 negative cohort (A) and classical low grade EnOC (B).          
Table 7: Treatment received by the WT1 negative cohort (A) and classical low grade EnOC (B).          
Table 8: Survival by stage in the WT1 negative cohort (n=125)            
Table 9: Survival by stage in classical low grade EnOC (n=87).           
Table 10: Univariable analysis of clinical prognostic variables.           
Table 11: Characteristics of stage IA/IB disease (n=22).          
Table 12: Characteristics of stage IC disease (n=28).           
Table 13: Patterns of relapse in early stage disease (n=22).          
Table 14: Pathology of recurrent disease (n=13).           
Table 15: Radiological and CA125 response to platinum chemotherapy.          
Table 16: Univariable and multivariable analysis of hormone receptor expression and survival in the WT1 negative cohort and classical low grade EnOC cohort.  
Table 17: Clinical characteristics of strong (histoscore>150) and weak (histoscore≤150) PR expression.      
Table 18: Treatment summary for endocrine therapy received.          
Table 19: Correlation of tissue microarray immunohistochemistry and mutation status.         
Table 20: POLE mutations in EnOC.          
Table 21: Tumours with inactivation of mismatch repair (MMR) genes and/or loss of MMR on immunohistochemistry.     
Table 22: Clinical pathological and genomic characteristics of tumours with BRCA mutations.        
Table 23: Univariable and multivariable survival analysis of mutations in EnOC.      
Table 24: Clinical characteristics of the molecular groups in EnOC.          
Table 25: Relapse free survival and disease specific survival in the molecular groups of EnOC.       





List of Figures 
Figure 1: Five year age-standardised net survival for epithelial ovarian cancer (1971-2011) 
Figure 2: Progression free survival of molecular groups identified from the endometrial TCGA.  
Figure 3: PROMISE algorithm reflecting the molecular groups identified in the endometrial TCGA. 
Figure 4: (A) Mutation profiles of six stage I grade 1 and 2 EnOC identified through whole exome sequencing analysis of paired tumour and normal 
samples. (B) Mutation profiles of 14 EnOC (unknown grade) identified through target gene sequencing.  
Figure 5: Molecular subgroups of EnOC (labelled as ENOC in Wang et al Nature 2017).  
Figure 6: Oncoplot displaying frequent mutations in EnOC in MSI-high versus MSS tumours.  
Figure 7: Oncoplot displaying non-synonymous mutations identified following whole genome sequencing (n=28; black box) and massively targeted 
parallel sequencing (n=8; grey box) identified in EnOC. 
Figure 8: Consort diagram of the pathology review process. 
Figure 9: H+E stain of grade 1 EnOC (A) arising from adjacent endometrioisis (B). H+E stain of grade 1 EnOC (C). 
Figure 10: H+E stain of grade 2 (A) and grade 3 EnOC (B). 
Figure 11: H+E stain of WT1 negative carcinoma with high grade serous ovarian morphology (A), 
and WT1 negative undifferentiated ovarian carcinoma (B). 
        
Figure 12: (i): Diffusely strong nuclear positive WT1 immunohistochemistry stain (A) with negative non-vascular stroma (B). (ii): Negative WT1 
immunohistochemistry stain (A) with positive vascular endothelial cells as an internal control (B). 
Figure 13: (i): Aberrant diffuse p53 immunohistochemistry stain. (ii): Null p53 immunohistochemistry stain (A) with positive stroma (B) as an internal 
control.  
Figure 14: Wild-type p53 expression on immunohistochemistry with variable nuclear staining. 
Figure 15: CK7 positive immunohistochemistry (A), CK20 negative immunohistochemistry (B). 
Figure 16: Examples of IHC stain interpretation for ER, PR and AR: A: histoscore 300, B: histoscore 150, C: histoscore 0 with positive stroma cells as an 
internal control. 
Figure 17: Example of MMR IHC staining of all 4 antibodies in the same tumour: Intact MLH1 and MSH2 with positive nuclear staining, loss of 
MSH2 and MSH6 with positive stromal cells as an internal control.  
  
Figure 18: Example of β -catenin IHC stain patterns: A: normal membranous staining of beta-catenin. B: nuclear staining (black arrows) of beta-catenin 
indicating a mutation in CTNNB1. 
Figure 19: Example of PTEN IHC stain patterns. A: normal nuclear and membranous staining of PTEN. B: loss of nuclear PTEN staining with positive 
stromal cells as internal control. 
Figure 20: Example of ARID1A IHC stain patterns. A: normal nuclear staining. B: loss of nuclear staining with positive stromal cells as internal control. 
Figure 21: Site of metastases in Stage IV disease.                 
Figure 22: Overall disease specific survival (A) and relapse free survival (B) in the WT1 negative cohort. 




Figure 24: Disease specific survival (A) and relapse free survival (B) by stage in the WT1 negative cohort. 
Figure 25: Disease specific survival (A) and relapse free survival (B) by stage in the classical low grade EnOC cohort.  
Figure 26: Spread of ER, PR and AR immunohistochemical expression in the WT1 negative cohort (A, B and C) and classical low grade EnOC cohort (D, 
E and F), respectively. 
Figure 27: Distribution of strong (histoscore≥150) and weak (histoscore<150) ER and PR in the WT1 negative cohort and classical low grade EnOC 
cohort.  
Figure 28: Disease specific survival (A) and relapse free survival (B) by strong (histoscore >150) and weak (histoscore ≤150) PR expression. 
Figure 29: Kaplan Meier survival curves for disease specific survival (A, C, E) and relapse free survival (B, D, E) for PR expression by stage. 
Figure 30: Lollipop plot of the 5 most commonly mutated genes in EnOC. 
Figure 31: Mutational and immunohistochemical correlation of mismatch repair (MMR), beta-catenin, ARID1A and PTEN proteins. 
Figure 32: POLE mutations and mutational load.                 
Figure 33: Disease specific survival (A) and relapse free survival (B) for TP53 wild-type status versus TP53 mutant status tumours. 
Figure 34: Disease specific survival and relapse free survival by stage in TP53 wild-type versus TP53 mutant status tumours. 
Figure 35: Oncoplot displaying single nucleotide variant frequencies identify distinct molecular groups in EnOC.  
Figure 36: Plot of unsupervised hierarchical clustering of Pearson’s correlation scores across the top 100 genes mutated across the whole exome 
dataset against the molecular groups identified in Figure 35. 
  
Figure 37: Kaplan Meier survival curves for disease specific survival and relapse free survival for each of the molecular groups in EnOC. 
Figure 38: Oncoplot of the molecular groups identified in EnOC with all 6 WT1 positive low grade EnOC clustering in the EnOClike: ARID1Awt group. 








List of Appendices 
Appendix A:  Whole exome sequencing report 
Appendix B:  List of commonly mutated genes previously reported in either endometrial, ovarian or pan cancer studies. 
Appendix C:  Endocrine treatment in high grade serous ovarian carcinoma; quantification of efficacy and identification of response predictors. 














List of Abbreviations and Acronyms 
AGO Arbeitsgemeinschaft Gynäkologische Onkologie 
AKT Protein kinase B 
APC Adenomatous Polyposis Coli  
AR Androgen Receptor 
ARID1A AT-rich interacting domain-containing protein 1A  
ATM Ataxia-Telangiectasia mutated 
ATR Ataxia telangiectasia and Rad3-related 
BRAF Proto-oncogene B-Raf and v-Raf murine sarcoma viral oncogene homolog B 
BRCA Breast cancer gene 
BRG1 Brahma-related gene-1 
CA125 Cancer Antigen 125  
CA19.9 Cancer Antigen 19-9 
CCNE1 Cyclin E1 
CCOC Clear Cell Ovarian Carcinoma 
CDKN1A Cyclin Dependent Kinase Inhibitor 1A 
CDX2 Caudal Type Homeobox 2  
CEA Carcinoembryonic antigen 
CK20 Cytokeratin 20 
CK7 Cytokeratin 7 
CN Copy number 
CR Complete response 
CSMD3 CUB And Sushi Multiple Domains 3 
CTNNB1 Catenin Beta 1 
DFS Disease Free Survival 
dMMR Mismatch Repair Deficient 
DNA Deoxyribonucleic acid 
DPC4/SMAD4 Deleted in Pancreatic Cancer-4/SMAD family member 4 
DSS Disease Specific Survival 
EnOC Endometrioid Ovarian Carcinoma 
EnEC Endometrioid Endometrial Carcinoma 
EMSY EMSY Transcriptional Repressor, BRCA2 Interacting 
EOC Epithelial Ovarian Cancer 
ER Oestrogen Receptor 
6 
 
ET Endocrine Therapy 
FAT3 FAT Atypical Cadherin 3 
FBXW7 F-box and WD repeat domain containing 7 
FFPE Formalin fixed paraffin embedded  
FIGO  International Federation of Gynecology and Obstetrics 
GCIG Gynecologic Cancer InterGroup  
GOG Gynecologic Oncology Group 
H&E Haemotoxylin and Eosin  
HER2 Human epidermal growth factor receptor 2 
HGSOC High Grade Serous Ovarian Carcinoma 
HR Hazard Ratio 
HRAS Harvey rat sarcoma viral oncogene homolog 
HRR Homologous recombination repair 




KRAS Kirsten rat sarcoma viral oncogene 
LGSOC Low Grade Serous Ovarian Carcinoma 
LS Lynch Syndrome 
MAPK Mitogen-activated protein kinase 
MuOC Mucinous Ovarian Carcinoma 
MEK Mitogen-activated protein kinase 
MLH1 MutL homolog 1 
MLH3 MutL Homolog 3 
MMR Mismatch Repair 
EORTC  European Organisation for Research and Treatment of Cancer 
mRNA messenger Ribonucleic Acid 
MSH2 MutS protein homolog 2 
MSH3 MutS Homolog 3 
MSH6 MutS Homolog 6 
MSI Microsatellite instability 
MSS Microsatellite Stable 
NACT Neoadjuvant Chemotherapy 
NF1 Neurofibromatosis type 1 
7 
 
NRAS Neuroblastoma RAS viral oncogene homolog 
OS Overall Survival 
PARP Poly (adenosine diphosphate) ribose polymerase  
PAX2 Paired box gene 2 
PAX8 Paired box gene 8 
PD Progressive disease 
PDL-1 Programmed cell death 1 ligand 1  
PFI Platinum Free Interval 
PFS Progression Free Survival 
PI3k/AKT  Phosphatidylinositol 3-kinase/protein kinase B 
PIK3CA Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha 
PIK3IP1 Phosphoinositide-3-Kinase Interacting Protein 1 
pMMR Mismatch Repair Proficient 
PMS2 PMS1 Homolog 2 
PPP2R1A Protein phosphatase 2 scaffold subunits 
PR Progesterone Receptor 
PR Partial response 
PTEN Phosphatase and tensin homolog 
RB1 Retinoblastoma 1 
RECIST Response Evaluation Criteria In Solid Tumours 
RFS Relapse Free Survival 
ROCA Risk of Ovarian Cancer Algorithm   
RPL22 Ribosomal Protein L22 
SD Stable Disease 
SEEC Synchronous Endometrioid Endometrial Carcinomas 
SEER Surveillance, Epidemiology, and End Results 
SET Solid, pseudo-Endometrioid and/or Transitional-cell-like  
SMAD3 SMAD family member 3 
SMARCA4 
SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, 
subfamily A, member 4 
SMARCB1 SWI/SNF Related, Matrix Associated, Actin Dependent Regulator Of Chromatin, 
subfamily B, member 1  
SWI/SNF Switch/Sucrose Non-fermenting  
TCGA The Cancer Genome Atlas 
TMA Tissue Microarray 
8 
 
TMB Tumour Mutation Burden 
TP53 Tumour protein p53 
UC Undifferentiated Carcinomas 
VEGF Vascular endothelial growth factor 
WHO World Health Organisation 













































1.1 Epithelial ovarian cancer 
Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy and the seventh most 
common cause of female cancers worldwide. In 2018, there were 295,414 newly diagnosed women 
worldwide with 184,799 deaths from this disease alone [1]. In the United Kingdom, EOC accounts for 
4% of all new cancer diagnoses in females.  As of 2016, 7500 new cases were diagnosed with a 
projected rise of 15% by the year 2035. The incidence of EOC increases with age with the vast majority 
of women diagnosed in their sixth and seventh decade in life.  
Overall, survival in EOC has doubled over the last forty years with five year survival of 46% compared 
to 21% in the early 1970s (Figure 1). Stage is the most important determinant of survival with five year 
survival of stage I disease at 90% falling significantly to less than 10% in stage IV disease.  
 
Figure 1: Five year age-standardised net survival for epithelial ovarian cancer (1971-2011)  
(Cancer Research UK: URL: https://www.cancerresearchuk.org/health-professional/cancer-
statistics/statistics-by-cancer-type/ovarian-cancer/survival#ref-2. Accessed January 2020. )  
 
EOC is difficult to diagnose due to its location and non-specific presenting symptoms, as such most 
women with EOC will present at an advanced stage with poor prognosis [2]. The cancer antigen 125 
(CA125) is a serum glycoprotein biomarker that is raised at diagnosis in 50% of women with early stage 
EOC and 85% of advanced stage EOC [2].  It can also be expressed by benign conditions such as 
ovarian cysts, pelvic inflammatory disease, endometriosis and uterine fibroids, and as such has a very 
poor positive predictive value of less than 5% when used as a screening test.  Longitudinal 
measurements of CA125 have been shown to improve the detection of EOC compared with a defined 
threshold [3]. This led to the development of the Risk of Ovarian Cancer Algorithm (ROCA), 
incorporating serial CA125 levels, age and statistical risk of having a rapid rise in CA125 above 
baseline, to assist in tailoring the frequency and type of investigations [4]. The UK Collaborative Trial of 
Ovarian Cancer Screening compared multimodality screening (CA125 testing and transvaginal 
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ultrasound utilising ROCA versus ultrasound alone versus no screening [5]. No differences in relative 
mortality reduction was observed between the groups. However a pre-specified analysis of the cohort 
excluding prevalent cases at diagnosis found a 28% mortality reduction in years 7-14. The trial 
concluded that longer follow up was required to determine the efficacy and cost effectiveness of 
screening for EOC. The large Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial 
performed earlier in the United States also found an apparent mortality benefit in years 7-14 for ovarian 
cancer screening however no differences were observed at extended follow up (median 15 years) [6]. 
At present, routine multimodality screening is currently not recommended for the general population. 
There is now firm evidence that EOC is made up of five main histological subtypes: high grade serous 
ovarian carcinoma (HGSOC) (70%), low grade serous ovarian carcinoma (LGSOC)(<5%), endometrioid 
ovarian carcinoma (EnOC) (10%), clear cell ovarian carcinoma (CCOC)(10%) and mucinous ovarian 
carcinomas (MuOC) (3%) [7]. Each histological subtype is molecularly diverse and has distinct biology 
and clinical behaviours. They also differ in their pre-cursor lesions, site of origin, stage of presentation, 
chemotherapy-responsiveness and prognosis [8]. Despite this, the primary management of all EOCs 
remains largely identical with aggressive cytoreductive surgery and platinum-based chemotherapy as 
standard of care. However, it now clear that each histological sub-type warrants an individualised 
approach in its management.  
In the following sections, the general management of EOC is discussed followed by a detailed overview 

















1.2 Clinical management  
1.2.1 Surgery in early stage disease 
The International Federation of Gynecology and Obstetrics (FIGO) stage is a powerful prognostic 
indicator in EOC. The aim of surgery in early stage disease is not only to resect the tumour but to 
perform adequate staging.  In Europe, comprehensive surgical staging of early stage disease (Stage 
IA-IIA) involves a midline laparotomy, bilateral salpingo-oopherectomy, hysterectomy, infracolic 
omentectomy, biopsies of suspicious nodules within the peritoneum and iliac and retro-peritoneal lymph 
node sampling [9].Bulky lymph nodes should be surgically resected.  Comprehensive surgical staging 
has been shown to upstage up to 30% of patients depending on histological sub-type [10, 11]. It is thus 
vital in providing accurate prognostic information and influencing the need and type of post-operative 
treatment.  
Whilst lymph node sampling is widely accepted as part of comprehensive surgical staging in early stage 
disease, systematic aortic and pelvic lymphadenectomy is controversial. Studies have shown up to 24% 
of apparent early stage patients are upstaged following removal of lymph nodes (i.e. occult stage III 
disease)[12-15], and retrospective analyses have demonstrated a survival benefit of this procedure[16].  
Only one prospective randomised phase III study led by Maggioni et al of systemic lymphadenectomy 
versus lymph node sampling in early stage EOC has been performed to date [17]. This trial found a 
greater number of patients with positive lymph nodes in those undergoing lymphadenectomy versus 
lymph node sampling (22% versus 9%; P=0.007). However only a trend was observed for progression 
free survival (PFS) and overall survival (OS). This trial was only powered to detect a 10% difference in 
the frequency of lymph node metastases as it was deemed unfeasible to be powered for survival. 
Furthermore, lymphadenectomy was associated with greater surgical morbidity.  As such, systemic 
lymphadenectomy in early stage disease is not routinely performed in Europe.  
1.2.2 Surgery in advanced stage disease 
In addition to stage, the extent of residual disease following surgical cytoreduction in advanced stage 
disease (stage IIB-IV) is an important independent prognostic indicator in EOC [18, 19]. Aggressive 
surgical cytoreduction in EOC reduces tumour bulk thus synchronising cell growth, increasing 
chemotherapy concentrations and reducing the development of resistant clones [19]. Complete 
macroscopic surgical cytoreduction (0cm) confers the best prognosis, whereas the survival benefit of 
1-10mm compared to more than 1cm residual tumour is marginal [18].  
The aim of surgery in advanced stage EOC is therefore complete macroscopic cytoreduction. Surgical 
procedures which may be required to achieve this include peritoneal stripping, bowel and diaphragmatic 
resection, splenectomy and resection of bulky lymph nodes [2]. Lymphadenectomy with 
macroscopically normal lymph nodes confers no OS benefit [20]. Occasionally, neoadjuvant 
chemotherapy (NACT) can be employed to render the disease operable and improve the chances of 
an R0 resection. The EORTC 55971 (Neoadjuvant Chemotherapy or Primary Surgery in Stage IIIC or IV 
Ovarian Cancer) [21] and CHORUS trial (Primary chemotherapy versus primary surgery for newly 
diagnosed advanced ovarian cancer) [22] were two large randomised phase III trials which showed no 
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differences in PFS or OS in patients who underwent upfront primary cytoreductive surgery compared 
to NACT and delayed surgery. Lower rates of peri-operative complications and post-operative deaths 
were also found in the NACT arm. The main criticism were the short median operating times of less 
than 3 hours in both trials, suggesting that maximal surgical effort was not employed.  
Pre-planned pooled subgroup analyses of both trials did however demonstrate that patients with stage 
IV disease had both PFS and OS benefit with NACT over primary surgery, whereas stage IIIC patients 
with lower disease bulk (largest metastatic tumour <5cm) had superior PFS with primary surgery over 
NACT but no OS benefit [23]. No differences were observed for stage IIIC disease with larger 
metastases (≥5 cm) [23]. In clinical practice, NACT is reserved for patients with stage IV disease, poor 
performance status, or in stage III disease in which complete macroscopic cytoreduction is not 
achievable. 
1.2.3 Adjuvant chemotherapy 
The two pivotal trials which provide evidence for the use of adjuvant platinum based chemotherapy in 
early stage EOC are the ICON1 (International Collaborative Ovarian Neoplasm trial 1: a randomized 
trial of adjuvant chemotherapy in women with early-stage ovarian cancer) [24] and ACTION trials 
(Impact of Adjuvant Chemotherapy and Surgical Staging in Early-Stage Ovarian Carcinoma: European 
Organisation for Research and Treatment of Cancer–Adjuvant Chemotherapy in Ovarian Neoplasm 
Trial) [25]. In both trials which were run in parallel, a total of 925 patients were randomised to receive 
at least 6 cycles of post-operative platinum based chemotherapy (at least 4 cycles in the ACTION trial) 
versus observation. Combined survival analyses of both trials showed a significant improvement in 
recurrence-free survival (76% vs 65%; HR=0.64, P=0.001) and OS at five years (82% vs 
74%; HR=0.67, P=0.008) with adjuvant chemotherapy. This effect remained consistent even at ten 
years with estimated HR of 0.72 for OS and 0.67 for PFS [26].  
However, these trials have been criticised for a number of reasons. ICON1 had a broad entry criteria 
which included patients with both good prognosis as well as patients who did not undergo 
comprehensive surgical staging. Furthermore, only a third of patients in the ACTION trial had successful 
surgical staging despite maximum surgical effort [27]. Retrospective analyses of the ACTION trial 
demonstrated a relapse free survival (RFS) and OS benefit in those who were sub-optimally staged, 
but not in the optimally staged group. Furthermore, these trials did not distinguish between the 
histological subtypes of EOC which have diverse chemotherapy sensitivities. In clinical practice, six 
cycles of platinum-based adjuvant chemotherapy is the recommendation for patients with grade 3, stage 
IC-IIA disease or CCOC [2].  
In advanced stage disease (stage IIB-IV), the addition of paclitaxel to platinum following surgical 
cytoreduction has been evaluated in four phase III randomised controlled trials.  The GOG 111 
(Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and 
stage IV ovarian cancer) [28] and OV-10 trials (Randomized Intergroup trial of cisplatin-paclitaxel versus 
cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer) [29] demonstrated a 
survival benefit whereas the GOG 132 (Phase III randomized study of cisplatin versus paclitaxel versus 
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cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a Gynecologic 
Oncology Group study) [30] and ICON3 trial (Paclitaxel plus carboplatin versus standard chemotherapy 
with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with 
ovarian cancer: the ICON3 randomised trial) [31] demonstrated no survival differences between 
platinum chemotherapy versus the platinum/taxane combination.  The main reasons for differential 
outcomes between the 4 trials were due to differences in the control arms, patient entry criteria, doses 
of cisplatin and paclitaxel used, and a significant proportion of crossover to the experimental arm. 
 In clinical practice, the use of doublet chemotherapy is considered standard of care worldwide as long 
as patients are deemed fit enough for treatment. This practice has also been largely extrapolated to 
early stage disease and the addition of a taxane to a platinum backbone is considered routine in this 
setting.  
1.2.4 Intraperitoneal chemotherapy 
As most EOC will relapse within the peritoneal cavity, intraperitoneal (IP) chemotherapy has been 
investigated as an alternative route of treatment delivery with the aim of delivering higher concentrations 
of chemotherapy to ovarian tumours, whilst minimising systemic toxicity [32]. When compared to 
intravenous delivery, IP cisplatin demonstrates a 10-20 fold increase in IP concentration when 
compared to plasma [33, 34]. Similarly, IP paclitaxel also demonstrated a 1000 fold increase in IP 
concentration over plasma [35, 36]. Small tumours of less than 5mm as well as avascular tumours are 
more likely to demonstrate this biological advantage compared to bulky or well-perfused tumours.  
The three largest randomised phase III clinical trials performed demonstrated that IP chemotherapy 
improved OS over IV chemotherapy in patients with advanced EOC following optimal surgical 
cytoreduction.  They were GOG 104 (IV cisplatin 100 mg/m2/IV cyclophosphamide 600 mg/m2 versus 
IP cisplatin 100 mg/m2/IV cyclophosphamide 600 mg/m2), GOG 114 (IV cisplatin 75mg/m2/IV paclitaxel 
135mg/m2 (24 hours) versus IV carboplatin AUC 9 (2 cycles)/IP cisplatin 100mg/m2 /IV paclitaxel 
135mg/m2 (24 hours)) and GOG 172 (IV cisplatin 75mg/m2/IV paclitaxel 135mg/m2  (24 hours) versus 
IP cisplatin 10 mg/m2 /IV paclitaxel 135mg/m2 (24 hours)/IP paclitaxel 60mg/m2 (day 8)) [37].  In the 
latest GOG 172 trial, the OS benefit of IP chemotherapy over IV was 66.9 months compared to 
49.5months (P=0.0076). These results led to a National Cancer Institute alert in 2006 which reported 
on a meta-analyses of 7 randomised trials of IP chemotherapy. This showed that IP chemotherapy 
reduced the risk of death by 21% (HR=0.79 (95%CI 0.70-0.89) and conferred a survival advantage of 
approximately 12 months.  
However, each trial sustained a number of criticisms. In particular, the IP arm of the GOG172 arm was 
criticised for including a weekly schedule of IP paclitaxel (60mg/m2 on day 8), and higher doses of IP 
cisplatin (100mg/m2) compared to the three weekly schedule of the control arm (IV cisplatin 75mg/m2 
and IV paclitaxel 135mg/m2 over 24 hours). These variables may have confounded the improvement in 
OS of IP over IV chemotherapy. In response to this, the GOG 252 trial was the fourth randomised phase 
III trial comparing three weekly IV carboplatin AUC 6/ weekly IV paclitaxel 80mg/m2 versus three weekly 
IP carboplatin AUC 6/weekly IV paclitaxel 80mg/m2 versus three weekly IV paclitaxel 135 mg/m2 day 1 
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(3 hours)/IP cisplatin 75mg/m2 day 2/IP paclitaxel 60mg/m2 day 8 [38]. All three arms included a weekly 
schedule of paclitaxel and included the use of bevacizumab. Notably, the IP dose of cisplatin was 
reduced to 75mg/m2 and the infusion time of paclitaxel was reduced to 3 hours. This trial demonstrated 
no difference in PFS and OS data is still immature.  
To date, the role of intraperitoneal chemotherapy in advanced stage disease remains uncertain. 
Furthermore, IP chemotherapy is associated with greater toxicity, risk of catheter complications and 
inconvenience to patients. As such, it is not considered standard of care and its use not widely adopted. 
1.2.5 Relapsed disease 
Up to 80% of patients with advanced stage EOC (most of which are HGSOC) will exhibit high response 
rates to initial platinum chemotherapy. However, most patients will eventually relapse within 3 years of 
diagnosis [8]. Further treatment for relapsed disease is only initiated upon symptomatic relapse rather 
than on the basis of a raised CA125 alone. No survival difference was demonstrated in the MRC OVO5: 
EORTC 5595 clinical trial when comparing patients who had chemotherapy initiated upon CA125 only 
asymptomatic relapse versus those with symptomatic relapse [39]. With time, the interval between each 
treatment gradually shortens with reducing efficacy and greater toxicity. The choice of 
chemotherapeutic agents in relapsed EOC is based on the platinum-free interval (PFI) which has been 
shown to be directly proportional to tumour response rates to platinum agents [40].  This has been 
historically classified as platinum sensitive (PFI greater than 12 months), partially platinum sensitive 
(PFI 6 to 12 months), platinum resistant (PFI less than 6 months), and platinum refractory (no response 
to first line platinum chemotherapy), although a recognised continuum exists [41].  
1.2.5.1 Platinum sensitive and partially platinum sensitive disease 
Patients with platinum sensitive and partially platinum sensitive relapsed disease are often re-
challenged with three weekly platinum doublet chemotherapy with the likely-hood of response over 50% 
in this setting. The ICON4 and AGO-OVAR-2.2 trials which were run in parallel,  showed that carboplatin 
and paclitaxel was superior to single agent carboplatin (hazard ratio 0.82 [95% CI 0.69-0.97], p=0.02) 
[42]. This corresponded to an improvement in median OS of five months (29 vs 24 months [1-11) with 
a seven percent improvement at two years (57% versus 50% [95% CI for difference 1-12]) [42]. Of note, 
over 70% of patients had a PFI of greater than 12 months. The Calypso trial was another randomised 
phase III trial which showed that carboplatin and pegylated liposomal doxorubicin was non-inferior (HR 
0.99; P=0.94), and also demonstrated a PFS benefit (HR 0.82; P=0.005), when compared to carboplatin 
and paclitaxel [43, 44]. The PFS benefit was also found to be more pronounced in the partially sensitive 
cohort (HR 0.73). Furthermore, the carboplatin/paclitaxel arm of this trial had higher frequencies of 
treatment discontinuation due to non-haematological toxicity (15% versus 6%; P<0.001), as well as 
higher rates of grade 2 to 4 neuro toxicity (26.9% versus 4.9%), compared to the carboplatin/ pegylated 
liposomal doxorubicin arm. In view of this, carboplatin and pegylated liposomal doxorubicin is thus the 




1.2.5.2 Platinum resistant and refractory disease 
Patients with platinum resistant or refractory disease are a poor prognostic group with a median OS of 
approximately 12 months with low response rates to chemotherapy of between 10-15 % [45]. There is 
little data supporting the optimal sequencing of chemotherapy agents in platinum resistant EOC.  The 
majority of data are derived from early phase (I/II) trials, or from sub-group analysis of platinum resistant 
cohorts in randomised phase III trials [46-48]. Platinum resistance can be overcome by dose dense 
scheduling of platinum or taxanes (weekly carboplatin/paclitaxel; weekly paclitaxel; weekly 
cisplatin/etoposide) [49], and other options include pegylated liposomal doxorubicin and topotecan. In 
general, single chemotherapeutic agents are used rather than multi-agent chemotherapy as they 
increase toxicity without additional survival benefit.  
Only a handful of randomised phase III studies have been performed specifically in platinum resistant 
disease alone [45, 50]. The only trial that demonstrated an improvement in PFS was the AURELIA 
study of investigators’ choice of chemotherapy with or without bevacizumab in platinum resistant EOC. 
Sub-group analysis demonstrated an OS benefit when paclitaxel was used [51] (to be discussed in 
greater detail in section 1.2.6). As such, the use of paclitaxel with bevacizumab is being increasingly 
favoured as the first treatment of choice in platinum resistant EOC.  
1.2.6 Bevacizumab  
The vascular endothelial growth factor (VEGF) is commonly expressed in EOC and is responsible for 
stimulating angiogenesis, a mechanism of tumour growth and metastases [52]. High VEGF expression 
and angiogenesis is associated with disease extent and poor survival [53, 54]. Bevacizumab is a 
humanised monoclonal antibody which targets VEGF and its role in the front line and relapsed settings 
of EOC has been evaluated in 4 pivotal phase 3 trials. 
1.2.6.1 Bevacizumab in first line treatment 
Both GOG-0218 [55] and ICON7 [56] were randomised controlled trials evaluating bevacizumab in the 
first line treatment of patients with advanced EOC (stage III/IV) following maximal primary cytoreductive 
surgery. In both trials, PFS was the primary end point and post-operative chemotherapy used was 6 
cycles of post-operative carboplatin (AUC 6) and paclitaxel (175mg/m2). In GOG-0218, the 3 trial arms 
were 1) chemotherapy and placebo, followed by maintenance placebo, 2) chemotherapy and 
bevacizumab ( from cycle 2 to 6) followed by maintenance placebo, and 3) chemotherapy and 
bevacizumab (from cycle 2 to 6) following by maintenance bevacizumab alone. In ICON7, the 2 trial 
arms were 1) chemotherapy and placebo (5-6 cycles) followed by maintenance placebo, and 2) 
chemotherapy and bevacizumab (5-6 cycles) followed by maintenance bevacizumab. In GOG-0218, 
bevacizumab was delivered at a three weekly dose of 15mg/m2 for up to 16 cycles in the maintenance 
period, whereas the dose in ICON7 was lower at 7.5mg/m2 delivered for up to 12 cycles in the 
maintenance phase.  
In GOG-0218, an overall median PFS benefit (14.1 versus 10.3 months, HR 0.717, p<0.001) was 
observed [55].  In ICON7, an initial PFS benefit was observed (HR0.81, p=0.04) after 19.4 months [56], 
but lost significance after 48.9 months follow up (P=0.25) [57]. No differences in OS was observed for 
17 
 
both trials (GOG-0218: P=0.53; ICON 7: P=0.85). However, in ICON7, a pre-defined poor prognosis 
subgroup of patients (defined as stage IV, inoperable stage III or sub-optimally cyto-reduced (>1cm) 
stage III) demonstrated a median PFS (15.9 versus 10.5 months, HR 0.68, 95% CI 0.55-0.85; P<0.001) 
and median OS benefit (39.7 month versus 30.3 months, HR0.78, CI 0.63-0.97, P=0.01) in those who 
received bevacizumab over placebo [56, 57]. A subsequent unplanned analysis of stage IV patients in 
the GOG-0218 study also demonstrated an OS benefit in those who received maintenance 
bevacizumab over placebo (HR0.72, CI 0.53-0.97) [58], supporting its front line use in poor prognostic 
patients as defined in ICON7. These findings also support the biological need for angiogenesis in 
proliferating tumours for efficacy to be demonstrated. Further to this, several studies have been 
performed exploring the differential impact of bevacizumab on molecular subtypes of HGSOC [59, 60].  
1.2.6.2 Bevacizumab in relapsed disease 
The OCEANS trial was a phase III clinical trial which recruited patients with platinum sensitive EOC 
who were randomised to receive carboplatin (AUC4), gemcitabine (1000mg/m2) alone or with 
bevacizumab (15mg/m2) until disease progression or toxicity [61]. The primary endpoint of the trial, 
PFS, was found to be significantly longer in those who received bevacizumab over those who received 
placebo (12.4 versus 8.4 months, HR 0.484, P<0.0001). There was no difference in OS [62]. 
The AURELIA trial recruited patients with platinum resistant EOC who were randomised to receive 
chemotherapy of investigators choice (pegylated liposomal doxorubicin, weekly paclitaxel, or 
topotecan) alone, or with bevacizumab (10mg/kg 2 weekly with chemotherapy, or 15mg/kg three weekly 
during the maintenance phase) until disease progression or toxicity [45]. Median PFS was improved in 
the bevacizumab group over placebo (6.7 versus 3.4 months, HR0.48, P<0.001), no OS benefit was 
seen although it is worth noting 40% of patients in the placebo group crossed over to receive 
bevacizumab.  An exploratory analysis found a greater treatment effect on PFS (median 10.4 versus 3.8 
months; HR 0.46; 95%CI 0.30-0.71) and OS (median 22.4 versus 13.2 months; HR 0.65; 95% CI, 0.42 
to 1.02) observed in those who received paclitaxel together with bevacizumab [51]. It is however worth 
noting that patients were stratified but not randomised by physician’s choice of chemotherapy. Weekly 
paclitaxel also demonstrates an anti-angiogenic effect which has been shown to be due to down 
regulation of VEGF as well as its tendency to accumulate in endothelial cells [63]. These findings from 
the AURELIA trial may thus be due to enhanced angiogenesis and synergy with this combination. 
Furthermore, a pre-specified analyses in the AURELIA trials found the use of bevacizumab reduced the 
incidence of paracentesis with each cycle compared to the use of chemotherapy alone. The use of 
bevacizumab is thus recommended in patients with platinum resistant disease with paclitaxel as the 
preferred choice of chemotherapy backbone. Patients with recurrent ascites are thus more likely to 






1.2.7 Secondary and tertiary cytoreductive surgery 
There is emerging evidence to support the role of secondary cytoreductive surgery for relapsed disease 
in well-selected patients. 
The DESKTOP I study was a retrospective analysis of 267 patients with platinum sensitive relapsed 
EOC who had undergone secondary cytoreductive surgery [64]. Complete surgical cytoreduction was 
the only factor associated with a significant improvement in OS compared with post-operative residual 
disease (45.2 vs 19.7 months; HR 3.71; p<0.0001). This study also derived the German Gynaecological 
Oncology Working Group (AGO) score to help predict resectability. Components of the score were 
previous complete surgical resection, good performance status and the absence of ascites.  
The DESKTOP II study conducted prospective validation of the AGO score in platinum sensitive 
relapsed ovarian cancer patients [65]. It found that more than two thirds of patients at first relapse with 
a positive AGO score achieved complete cytoreduction. The study also evaluated the safety and 
feasibility of surgery in these patients with an 11% rate of second surgery and 0.8% peri-operative 
mortality rate.   
Two phase III randomised trials have been performed to evaluate the role of secondary cytoreductive 
surgery. DESKTOP III compared cytoreductive surgery followed by platinum chemotherapy versus 
chemotherapy alone in patients with platinum sensitive relapsed EOC with a positive AGO score [66]. 
This trial showed a 5.6 month PFS benefit (19.6 versus 14 months; P<0.001) and 7.1 months 
improvement in time to next therapy (21 versus 13.9 months; P<0.001) in those who had complete 
secondary surgical cytoreduction. OS data is currently immature.  In the USA, the GOG-0213 trial is 
another phase III trial in platinum sensitive relapsed EOC with a two part randomisation [67]. The first 
evaluates the role of concurrent and maintenance bevacizumab compared to platinum-doublet 
chemotherapy alone, and second part explores the role of secondary cytoreductive surgery. In the latter, 
patients with investigator-determined resectable disease were randomised as per the DESKTOP III 
trial. No differences in PFS and OS were observed in the whole cohort and subgroup analyses are 
currently awaited.  
At present, the results of the DESKTOP III trial support the use of secondary cytoreductive surgery in 
well-selected patients in order to improve PFS. The final OS results will help determine its role as a 
standard of care.  
1.2.8 Endocrine therapy 
This is discussed in detail in section 1.3. 
1.2.9 PARP inhibitors 





1.3 Hormones and ovarian cancer 
Epidemiological studies have shown that steroid hormones are intrinsically linked to the development 
and promotion of EOC [68]. Hormonal risk factors include the use of hormone replacement therapy 
(HRT) and nulliparity [69], whereas the use of the oral contraceptive pill [70, 71], tubal ligation [72], and 
younger age at pregnancy have been shown to be protective [73]. Patients with a hyper-androgenic 
state, such as those with polycystic ovarian syndrome [74] and truncal obesity [75], have also been 
found to have a higher incidence of EOC. 
In particular, the association of HRT use in post-menopausal women and the development of EOC has 
been extensively investigated. A meta-analysis of 52 epidemiological studies which included 12110 
women was performed by the Collaborative Group on Epidemiological Studies of Ovarian Cancer 
demonstrated a number of findings [69]. It found that the risk of EOC was greater in those who had ever 
used HRT (current or recent use) compared to never users. This was highest for serous (HR1.53, 
p<0.0001)) and EnOC (HR1.42; p<0.0001) in current or recent users of HRT, with no effect on CCOC 
and MuOC. Interestingly, although the risk of developing EOC declined with time, the risk remained 
even after ten years following cessation of HRT. In a similar large scale analysis of 23257 women, the 
duration of oral contraceptive use correlated with the magnitude of EOC risk reduction (P<0.0001) [70]. 
This beneficial effect was observed on all histological subtypes of EOC apart from MuOC. Interestingly, 
this risk reduction persisted for more than 30 years but the effect was attenuated over time.  
1.3.1 Hormone receptor expression in EOC   
Most EOC express hormone receptors, of which ER and PR have been most studied.  ER is made up 
of two isoforms, ER-alpha (ERand ER-beta (ER). ER is a transcription factor which is ligand-
activated and regulates gene expression in response to oestrogen and other extra-cellular signals [76]. 
It is the isoform most clearly linked to the endocrine responsiveness in EOC (discussed in section 1.3.2). 
The role of ER is however less well understood. It is expressed at high levels on the surface of normal 
ovarian cells, whilst reduced expression is found in EOC [77] with even lower levels found in 
metastasises [78]. This observation suggests that ER may play a tumour suppressor role [79]. PR 
expression is regulated by the ERα gene, and is a surrogate for a functionally intact ER pathway [80]. 
In contrast to ER, activation of PR inhibits cell proliferation. In breast cancer, PR activation changes 
the pattern of ER chromatin binding, which result in the increased expression of anti-proliferative 
genes [80]. Similarly in ovarian cancer, activation of PR has been shown to induce cell apoptosis. 
The expression of ER (referred to as ER from this point) and PR vary across the histological subtypes 
of EOC (Table 1). The Ovarian Tumour Tissue Analysis consortium study was the largest study of 3000 
women to evaluate this [81]. A three-tier scoring system was used: negative (<1% nuclear stain), weak 
(1-50% nuclear stain), and strong (≥50% nuclear stain). Strong or weak ER expression was highest in 
HGSOC (80.7%; 60.2% strong, 20.5% weak), LGSOC (87.6%; 71.2% strong, 16.4% weak), and EnOC 
(76.6%; 60.2% strong, 16.4% weak), with lowest levels in MuOC (15.7% strong, 5.1% weak) and CCOC 
(13.7% strong; 5.8% weak).  In contrast, strong or weak PR staining was highest for EnOC (67.4%; 
44.4% strong, 23.0% weak), LGSOC (57·4%; 32.7% strong, 24.8% weak), moderate for HGSOC 
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(31·1%; 7.5% strong, 23.7% weak), and lowest for MuOC (16·4%; 8.7% strong, 7.7% weak) and CCOC 
(8·0%; 3.0% strong, 5.0% weak). 
Co-expression of ER and PR was most common in EnOC (81.6%), LGSOC (61.9%) and MuOC 
(63.2%), and lowest for HGSOC (34.3%) and CCOC (32.4%). Other studies which distinguish between 
histological subtypes also support this data [82, 83].  
 
Table 1: ER and PR expression in histological subtypes of epithelial ovarian carcinomas in the  
Ovarian Tumour Tissue Analysis consortium study [81]. 
Type ER PR  
  Negative Strong Weak Negative Strong Weak 
High grade serous 19% 60% 21% 69% 7% 24% 
Low grade serous 13% 71% 16% 43%  33% 25% 
Endometrioid 23% 60% 16% 33%  44% 23% 
Clear cell 81% 14% 6% 92% 3% 5% 
Mucinous 79%  16% 5% 84%;  9% 8% 
Legend: Strong = ≥50% nuclear stain; Weak = 1-50% nuclear stain; ER=oestrogen receptor; 




















The prognostic role of ER and PR has been evaluated in several heterogeneous studies with conflicting 
results (Table 2). Most of these trials included all histological subtypes, and in particular, did not 
differentiate between HGSOC and LGSOC which have vastly different biology and prognosis [84]. They 
also used different methods and thresholds in defining receptor positivity, factors which may limit the 
interpretation of these studies. Meta-analysis of 23 studies performed by Zhaojun et el found PR but 
not ER was prognostic in EOC [85]. This finding is akin to ER positive breast cancers where high PR 
expression is associated with more indolent disease, whereas PR negative tumours are more 
biologically aggressive [86].  
 In the Ovarian Tumour Tissue Analysis, the prognostic value of ER and PR differed across histological 
subtypes [81]. Strong PR but not weak PR or any ER expression (strong or weak) was independently 
associated with survival in HGSOC. In contrast, both strong and weak ER and PR expression were 
independently prognostic in EnOC. There were no differences for LGSOC, MuOC or CCOC.   
 
Table 2: Studies evaluating ER and PR as a prognostic marker in epithelial ovarian carcinoma. 
Study N Pathology IHC threshold Independent association with OS 
Lee et al 
2005[87] 
322 76.7% serous >10% PR but not ER. 
Høgdall et al 
2007[88] 
582 57% serous ≥10% 
ER alone, PR alone, and in 
combination. 
Liu et al 
2009[89] 
148 100% G3 serous ≥1% 
Neither ER nor PR. Trend for OS 
observed for age ≤ 5five years. 
Nodin et al 
2010[90] 
154 58.4% serous >10% Neither ER or PR. 
Burges et al 
2010[91] 
100 100% serous ≥10% ER alone but not PR. 
Lenhard et al 
2012[92] 




PRβ but not ER. 
Sieh et al 
2013[81] 
2933 59.4% HGSOC 
<1%; 1-50%; 
≥50%  
Strong PR in HGSOC, any ER and PR 
in EnOC, no differences for LGSOC, 
MuOC, or CCOC. 
Matsuo et al 
2014[93] 
221 100% HGSOC 
≥ 5% with stain 
intensity of  
≥ 1 + 
Neither ER or PR. 
De Toledo et al 
2014[94] 
152 44.1% serous Allred score≥4 Neither ER or PR. 




and EnOC (26%) 
≥10% PR but not ER. 
van Kruchten 
et al 2015[95] 




Neither ER or PR. 
Feng et al 
2016[96] 
875 100% HGSOC >10% PR but not ER. 
Legend: G=grade; N=number; IHC=immunohistochemistry; HGSOC=high grade serous ovarian carcinoma; 
EnOC=endometrioid ovarian carcinoma; LGSOC=low grade serous ovarian carcinoma; MuOC=mucinous 
ovarian carcinoma; CCOC=clear cell ovarian carcinoma; ER=oestrogen receptor; PR=progesterone receptor; 






In contrast to ER and PR, the androgen receptor (AR) has been less researched. AR plays a role in 
promoting cell proliferation and reducing cell death [97]. In its basal inactive state, AR is bound to heat 
shock protein and other cellular components [98]. Androgens actives AR which triggers downstream 
cell signalling events which include dissociation from the heat shock protein, phosphorylation and 
dimerization [98]. This culminates in nuclear translocation of AR which binds to targeted DNA 
sequences, known as androgen response elements, as well as other co-factors [98]. This AR complex 
can then regulate gene expression of the cell through targeted gene transcription [99]. In ovarian cancer 
cell lines, androgens has been shown to promote motility and invasion, suggesting that AR activation 
may result in a more aggressive ovarian cancer phenotype [100]. 
AR expression in EOC has been mainly evaluated in small studies with frequencies between 43.5-86% 
[90, 99, 101-103].  Studies have shown that AR is differentially expressed across histological subtypes 
[99]. In general, higher expression was found in serous tumours compared to non-serous tumours, 
however the distinction between HGSOC and LGSOC was often not made [87, 94, 102]. Another large 
study of 876 HGSOC demonstrated AR expression in 35.6% of tumours. Furthermore, no association 
between AR expression and FIGO stage was demonstrated [96].  
The prognostic value of AR has been met with conflicting results (Table 3). Similar to ER and PR, this 
is likely due to heterogeneity of the studies with respect to histological subtype and methods and 
thresholds used to define AR positivity. The largest of these studies performed in one histological 
subtype was by Feng et al of 875 HGSOC [96]. Here, AR positivity (>10% of tumour cells stained) 
was independently associated with OS. Interestingly, tumours which were AR positive but ER and PR 
negative demonstrated superior survival compared to other combinations of hormone receptor 
positivity.  Similar conclusions regarding the independent prognostic value of AR in HGSOC were 
made in Martins et al [104]. 
Table 3: Studies evaluating AR as a prognostic biomarker in epithelial ovarian carcinoma. 
Study N IHC threshold Pathology 
Independent association with 
survival 
Lee et al 2005[87] 322 >10% 76.7% serous No 
De Toledo et al 
2014[94] 
152 Allred score≥4 44.1% serous No 
Van Kruchten et al 
2015[95] 
121 ≥ 10% 70% serous 
No 
 
Nodin et al 2010[90] 154 >10% 58.4% serous Prolonged DSS in serous tumours 




high AR= ≥50% 
100% HGSOC 
Low AR associated with shorter OS 
 
Jonsson et al 
2015[83] 




AR expression alone, and co-
expression with PR, was 
associated with five year PFS and 
OS 
Feng et al 2016[96] 875 >10% 100% HGSOC AR associated with OS 
Gomora et al 
2018[105] 
81 Histoscore>30 36% HGSOC  
Legend: IHC=immunohistochemistry; EOC=epithelial ovarian carcinoma; HGSOC=high grade serous ovarian 
carcinoma; AR=androgen receptor; PR=progesterone receptor; PFS=progression free survival;  




1.3.2 Endocrine sensitivity of EOC 
The degree of ERα expression mediates the response to endocrine therapy in EOC. The first pre-clinical 
studies of endocrine therapy in ovarian cancer demonstrated a proliferative effect on ERα positive 
ovarian cancer cell lines by oestrogen and the anti-mitogenic effect of tamoxifen in these cell lines [106, 
107]. Conversely, there was no effect of E2 on ERα negative or ERpositive cell lines. ERα induced 
gene expression changes observed in these ovarian cancer cell lines have also been shown to be 
blocked by the tamoxifen [108]. In a Japanese study, treatment with aromatase inhibitor demonstrated 
an improvement in survival of strongly ER-alpha positive OVCAR-3 human ovarian cancer cells 
compared to weakly ER positive ovarian cancer cells in xenograft models [109]. This improvement in 
survival was associated with an improvement in angiogenesis and ascites in the strongly ER positive 
xenografted mice. 
The role of endocrine therapy in EOC has been investigated in over 50 phase II clinical trials. These 
trials of investigating different endocrine therapy agents used were highly heterogeneous. They 
included all histological subtypes and were mostly performed in heavily pre-treated patients. In 
particular, most were un-selected for ER status and in those who were, different ER measurement 
thresholds were used to define receptor positivity. As such, low response rates of 0% to 18% and 
moderate disease stabilisation rates of 20% to 50% have been observed (Table 4). Furthermore, no 
survival benefit was demonstrated in the only phase III randomised clinical trial performed of tamoxifen 
versus chemotherapy in patients with platinum resistant EOC [110]. The use of endocrine therapy is 
















Table 4: A selection of trials evaluating endocrine therapy in epithelial ovarian carcinoma. 




















 100%    RECIST 18% 38% 56% 
Bowman 
2002 






 50% Ca125 8% 24% 32% 
    UICC 0% 20% 20% 
Smyth 
2007 






  46% 
Ca125 17% 26% 43% 








stain 100% 100% 
Ca125 UK UK UK 





































RECIST 0% 0% 27% 
Legend: ET= endocrine therapy; N=number; Path=pathology; ER+=oestrogen receptor positive; Crit. = criteria; 
ORR=objective response rate; SD=stable disease; CBR=clinical benefit rate; RECIST=response evaluation 
criteria in solid tumours; UICC= union for international cancer control; H-score=histoscore; Tam=tamoxifen; 














However, there is now emerging retrospective data to support the use of endocrine therapy specifically 
in LGSOC in both the relapsed [118] and first-line maintenance settings [119]. The first and largest 
retrospective study was performed by the MD Anderson group of 64 women with relapsed LGSOC who 
received a total of 89 separate endocrine regimens [118]. There was an ORR of 9% (2 CR, and 6 PR) 
with a disease stabilisation rate of 62%, amounting to a CBR (CR+PR+SD) of 71%. 61% of patients 
remained on endocrine therapy at least six months or more. The overall median time to progression 
was 7.4 months (95% CI 6.0-8.9). 
This study prompted a further retrospective analysis by the MD Anderson group evaluating the role of 
maintenance endocrine therapy in the first line management of LGSOC [119]. Inclusion criteria were 
patients with stage II to IV LGOSC who had an attempt at primary cytoreductive surgery followed by 
platinum based chemotherapy and with sufficient clinical information at follow up. Between 1981 and 
2013, 203 patients were included in this study. 74% of patients had no residual disease and 26% had 
residual disease following adjuvant chemotherapy. Patients who received maintenance endocrine 
therapy within 3 months of completing post-operative chemotherapy (n=70; 54% letrozole, 29% 
tamoxifen, 3% anastrazole, 6% leuprolide acetate) were compared to those who underwent observation 
(n=133).  
The median duration of endocrine therapy was 33.3 months (range 1-223 months). There was a 
significantly improved median PFS in patients who received maintenance endocrine therapy compared 
to the observation group of 64.9 months versus 26.4 months (p<0.001), respectively. The effect was 
more marked in patients who were disease free post chemotherapy as compared to those who had 
persistent disease with a PFS of 81.1 months versus 30.0 months (p<0.001) and  38.1 months versus 
15.2 months (p<0.001), respectively. In the multivariable cox proportional regression analysis, patients 
who received maintenance endocrine therapy were less likely to experience disease progression as 
compared to those who did not (HR 0.44; 95% CI, 0.31 to 0.63, p<0.001).  
Although there were no differences in OS between the two groups, there were significant differences 
when patients were stratified for residual disease post chemotherapy. The median OS in those with no 
residual disease and residual disease post chemotherapy  was 191.3 months versus 106.8 months and 
93.3 months versus 44.4 months (p=0.014), respectively.  These two pivotal studies have demonstrated 
that the use of endocrine therapy plays a role in the management of LGSOC in both the relapse and 
maintenance settings. In response to this data, prospective clinical trials evaluating the role of 
maintenance letrozole in LGSOC are currently being designed.  
Similar data is emerging in HGSOC. Heinzelmann-Schwarz et al was a retrospective study which 
compared the use of maintenance letrozole versus observation in 50 patients with HGSOC [120]. Here, 
patients who received maintenance letrozole had a significantly longer RFS compared to the 
observation group. At 24 months, 60% of the letrozole group were relapse free compared to 38.5% in 
the control group (P=0.035). This effect was also maintained in the small cohort who received 
concurrent bevacizumab for residual disease. At 12 months, 87.5% of the letrozole group was relapse 
free compared to 20.8% of the control cohort (P=0.026). The authors conclude that this data is 
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hypothesis generating and that prospective clinical trials of maintenance letrozole in HGSOC are 
warranted. The studies performed by Gershenson et al and Heinzelmann-Schwarz et al illustrate the 
importance of evaluating the role of endocrine therapy in histological sub-type specific clinical trials.  
There has also been interest in the use of androgen blockade in EOC as studies have found AR 
expression to be a biological marker for androgen sensitivity [121]. The CORAL phase II trial evaluated 
abiraterone in AR positive EOC. 83% of this study cohort was HGSOC and 47% of patients received 3 
or more prior lines of therapy [122]. Only one patient (2%) had a response to therapy which occurred in 
an AR positive LGSOC with a duration of therapy of 47 weeks. In the AR positive cohort (>10% staining), 
there was a prolonged period of disease control of 6 months or greater in 14% of patients. Unfortunately, 























1.4 Histological subtypes of epithelial ovarian cancer 
The management of EOC has started to account for biological differences of each subtype. Here, the 
different clinical and molecular differences between each subtype and how this is being used to guide 
treatment strategies are discussed. 
1.4.1 High grade serous carcinoma 
The majority of patients with EOC are diagnosed with HGSOC (70%) [8]. These are biologically 
aggressive tumours which commonly present with advanced staged (stage III/IV) disease.  They display 
exquisite sensitivity to platinum-based chemotherapy with response rates in the region of 80% in the 
first line setting [8].  However despite this, most patients will recur within the first three years of diagnosis 
and ultimately die of their disease. 
 
Contrary to its name, most HGSOC originate from the fimbrial end of the fallopian tube with serous tubal 
intra-epithelial carcinoma (STIC) as its precursor lesion [123, 124]. This was first discovered in patients 
with germline BRCA mutations who underwent prophylactic salpingo-oopherectomy [125-128]. 
Pathologically, HGSOC also display a myriad of architectural variants, including papillary, nested, 
cribriform, glandular, solid and single cells. It displays marked atypia with greater than 12 mitoses per 
10 high power fields, and typically expresses WT1, p53, MIB1, Her-2 neu, c-kit, bcl-2 and p16 on 
immunohistochemistry [129].  
 
It is molecularly characterised by ubiquitous TP53 mutations [130], which are thought to be an early 
event in its pathogenesis [124].  It is also one of the most chromosomally unstable tumours with 
extensive copy number changes and loss of heterozygosity, as well as defects in DNA repair pathways 
[131], sharing molecular similarities to basal-like breast cancer [132]. Around half of all HGSOC display 
homologous recombination repair (HRR) deficiency [131], a crucial repair mechanism of double strand 
DNA breaks, due to mutations in key HRR genes. Of these, germline mutations in BRCA1 and BRCA2 
(gBRCA1/2) comprise 15% of HGSOC, with another 5-10% due to somatic BRCA (sBRCA1/2) 
mutations and epigenetic modifications such as silencing of the BRCA protein through BRCA1 
methylation [131]. The remaining mutations in HRR genes include EMSY  (8% amplification), PTEN 
(7% loss), RAD51C (3% hypermethylated), ATM, ATR, CHEK1 and CHEK2 (2%) and fanconi anaemia 
genes (5%) [131]. 30% of the remaining non-HRR deficient HGSOC have CCNE1 amplification which 
has been found to confers platinum resistance and a poorer prognosis [133, 134]. Other significantly 
mutated genes include RB1, NF1, FAT3, CSMD3, CABRA6 and CSK12 [131] . Recently, 
comprehensive copy number profiling of 117 HGSOC was performed as part of the BRITROC study, 
followed by validation in another 527 cases [135]. This study found distinct copy number signatures to 






1.4.1.2 BRCA mutated HGSOC and implications of management 
Patients with gBRCA1/2 mutations are most commonly diagnosed with HGSOC, whilst associations 
with EnOC and CCOC are very rare [136]. These patients have a cumulative lifetime risk of other 
malignancies, most commonly breast cancer (65% BRCA1, 45% BRCA2). Besides the familial 
implications of this diagnosis, patients with gBRCA1/2 mutated HGSOC also display distinct clinical 
characteristics and treatment responses. When compared to gBRCA1/2 wild-type patients, they are 
more likely to present at a younger age with a higher frequency of visceral metastases [137]. They also 
display superior platinum sensitivity in the first line setting and at subsequent relapses [138]. This is 
further supported by studies which demonstrate that reversion mutations of BRCA1/2 and other HRR 
genes, thus restoring HRR, are associated with platinum resistance [139]. Furthermore, patients with 
gBRCA1/2 HGSOC demonstrate longer platinum free intervals and have superior OS [140]. This 
survival advantage is maintained out to ten years in patients with gBRCA1 mutations, however becomes 
less marked and eventually reverses for gBRCA2 [141].  
 
BRCA1 and BRCA2 are key proteins involved in repairing double strand DNA breaks through the HRR 
pathway. As discussed in section 1.4.1, mutations in gBRCA1/2 as well as other HRR genes render 
EOC HRR deficient. PARP inhibitors exploit this characteristic by inhibiting single-strand DNA repair. 
As a result, gBRCA-mutated ovarian cancer cells are forced to utilise non-homologous end joining repair 
pathways which are error prone resulting in cell death caused by synthetic lethality [142]. gBRCA-
mutated normal cells are however still able to utilise the HRR pathway to repair double strand DNA 
breaks even if the PARP 1 and 2 proteins are inhibited.  This differential effect results in gBRCA-mutated 
ovarian cancer cells being 1000 times more sensitive to PARP inhibitors as compared to gBRCA-
mutated normal cells [142]. 
 
Olaparib was the first PARP inhibitor developed. Early phase clinical trials demonstrated striking single 
agent activity in just over a third of gBRCA1/2 mutated heavily pre-treated patients with EOC [143, 144]. 
A correlation was found between platinum sensitivity and the extent of response to olaparib. In the 
pivotal phase II trial Study 19, patients who were unselected for gBRCA1/2 mutation status with 
platinum-sensitive relapsed HGSOC who had responded to chemotherapy were randomised to receive 
maintenance olaparib, or placebo [145]. Patients who received olaparib had a significantly longer 
median PFS over those received placebo (8.4 versus 4.8 months; HR 0.35; p<0.001). The treatment 
effect was greater in gBRCA1/2-mutated patients (median PFS 11.2 versus 4.3 months, HR 0.18; 
p<0.0001), although was still maintained but less marked in the gBRCA1/2 wild-type population (HR 
0.54; P=0.0075). Interestingly, 11% remained on drug for over 6 years [146].  
This prompted the design of two confirmatory studies, the SOLO1 and SOLO2 trials, which evaluated 
the role of maintenance olaparib in both somatic and gBRCA1/2-mutated ovarian cancer patients in the 
first- and second-line settings, respectively. In SOLO2, the olaparib group had a significantly longer 
median PFS of 19.1 months compared to 5.5 months in the placebo group (HR0.3, p<0.0002) [147]. An 
improvement in median OS of 12.9 months was also observed in those who received olaparib (HR 
0.74). In SOLO1, two years of maintenance olaparib in the first line setting demonstrated a superior 
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PFS with a median of nearly three years over the placebo group (HR 0.3, p<0.001) [148]. The survival 
curves remained separated at three years suggesting ongoing response despite cessation of the drug, 
however OS data is currently awaited. Olaparib is now licensed as maintenance therapy in both the first 
line and relapsed settings in somatic and gBRCA1/2-mutated ovarian cancers. 
It is also recognised that non-gBRCA1/2 mutated HGSOC that are HRR deficient also display a similar 
phenotype to that of gBRCA1/2 mutant tumours. This phenotype, termed ‘BRCA-ness’, has led to 
interest in identifying additional molecular sub-groups of HRR deficient HGSOC which may also benefit 
from PARP inhibitors. Phase III clinical trials of other PARP inhibitors, namely rucaparib [149], and 
niraparib [150], have been performed to investigate this. The NOVA trial randomised both gBRCA1/2 
mutated and non-gBRCA1/2 mutated HGSOC to receive maintenance niraparib versus placebo 
following a response to platinum chemotherapy in platinum sensitive relapsed EOC [150]. Patients who 
received niraparib had a longer PFS then the placebo group. Patients with both gBRCA1/2 mutated 
(HR 0.27, 95%CI 0.17-0.41; P<0.001) and non-gBRCA1/2 mutated EOC (HR 0.45; 95% CI, 0.34 to 
0.61; P<0.001) demonstrated a PFS benefit. Within the non-gBRCA1/2 mutated group, HRR deficient 
tumours sustained a greater benefit from niraparib (HR 0.38; 95% CI, 0.24 to 0.59, p<0.001). Similar 
results were observed in the ARIEL3 trial of maintenance rucaparib versus placebo in the platinum 
sensitive relapsed setting following a response to platinum based chemotherapy [149]. Both niraparib 
and rucaparib are now licensed for maintenance use in platinum sensitive recurrent HGSOC following 
a response to platinum chemotherapy regardless of gBRCA mutation status. Most recently, both 
niraparib [151] and olaparib [152] have demonstrated improvements in PFS over placebo when used 
as first line maintenance therapy in patients with advanced stage HGSOC following surgery and 
response to platinum-based chemotherapy in an ‘all-comer’ population and its licensed use in the first 
line setting is currently awaited. 
The current landscape of PARP inhibitor trials are investigating how to enhance the efficacy and 
overcome resistance to PARP inhibition. There is also considerable interest in the use of immune 
checkpoint inhibitors in combination with PARP inhibitors. HRR deficient tumours have been shown to 
have greater neo-antigens and tumour infiltrating lymphocytes compared to HRR proficient tumours 
[153, 154]. The expression of programmed cell death 1 ligand 1 (PDL-1) has also been shown to be 








1.4.2 Low grade serous carcinoma 
LGSOC make up 10% of all EOC. It has only emerged as its own disease entity in the last decade 
following a revision of the original Silverberg three-tiered grading system [156] for serous carcinomas 
to the two-tiered grading system led by Malpica et al [157]. This grading system which relies on nuclear 
atypia and mitotic rate, has been shown to be reproducible with minimal inter- and intra-observer 
variation [158]. The ensuing research has demonstrated HGSOC and LGSOC to be distinct diseases 
in terms of its pre-cursor lesions, molecular alterations, treatment responses and patient outcomes [84].  
In contrast to HGSOC, LGSOC are associated with younger age of diagnosis and poor platinum 
sensitivity with response rates of 5 % [159-161]. Although it is associated with prolonged survival 
(median OS of 82 months), the majority of women unfortunately still die of their disease [84]. LGSOC 
is thought to arise either de novo or from serous borderline tumours (SBT) [162]. This is supported by 
gene expression profiling which has found LGSOC to cluster together with SBT, but separately from 
HGSOC [163, 164]. In contrast to HGSOC, LGSOC have been found to be genomically stable [165] 
and usually exhibit p53 wild-type expression on immunohistochemistry (IHC).  In addition, they have 
higher expression of ER, PR [166] and PAX2 [167] as well as over expression of anterior gradient 
homolog 3 and insulin-like growth factor 1[168] when compared to HGSOC. 
Activating mutations in the mitogen-activated protein kinase (MAPK) pathway are common in the 
pathogenesis of LGSOC. 20-40% have KRAS mutations whilst BRAF mutations occur in five percent 
of cases [84]. NRAS mutations have been reported in 9-15% of LGSOC with adjacent SBTs as 
compared to 0% in SBT [169], postulating this as a possible driver mutation in the pathogenesis of 
LGSOC. In view of the cumulating data supporting activation of the MAPK pathway in LGSOC, clinical 
trials of mitogen-activated protein kinase enzyme (MEK) inhibitors have been performed [170]. 
Recently, the MEK inhibitor trametinib has been found to improve response rates and PFS over 
physician’s choice of therapy (letrozole, tamoxifen, weekly paclitaxel, pegylated lipo-doxorubicin, 
topotecan) in relapsed LGSOC (PFS: 13.0 vs 7.2 months; HR 0.48; 95% CI, 0.36-0.64; P < .0001) [171], 
though OS data is awaited. There is also retrospective data to support the use of ET both as 
maintenance therapy or treatment of relapsed LGSOC and is now commonly used as the first therapy 
of choice in relapsed disease given is low toxicity profile [118, 119]. The value of adjuvant chemotherapy 
in this subtype is also starting to be questioned and phase III trials comparing adjuvant ET to platinum 










1.4.3 Clear cell carcinoma 
CCOC make up 10% of EOC and are most prevalent in the Japanese population with an incidence of 
nearly 25% [173]. Histologically, they are made up of cells with prominent cell membranes and abundant 
clear cytoplasm, with hobnail cells as a common feature [174]. They also display characteristic 
morphology consisting of a mix of glandular, tubulocystic, solid and papillary architecture [129]. 
Although CCOC display a low mitotic rate and are usually well differentiated, they are recommended 
an assignment of grade 3 [129]. Pathologically, they are important to distinguish from variants of 
HGSOC such as HGSOC with clear cell change [175]. The majority of CCOC also arise from 
endometrioisis and display an IHC profile that is WT1 negative, p53 wild-type, and ER negative[173]. 
Napsin A is also a sensitive and specific marker for CCOC [176].  
Molecularly, CCOC are characterised by frequent ARID1A (50%) and PIK3CA (33%) mutations [177]. 
MET amplification occurs in 20% of cases and are associated with poor prognosis [178]. Other mutated 
genes include KRAS and PPP2I1A [177]. Clinically, they are distinct from HGSOC and most commonly 
present in younger women with early stage disease [179] Approximately 7% of tumours displaying loss 
of mismatch repair (MMR) proteins on IHC with a proportion of these related to Lynch Syndrome 
(discussed in section1.5.6.7) [180]. When adjusted for stage, CCOC have a poorer survival when 
compared to HGSOC particularly in advanced stage disease. It is considered an intrinsically platinum 
resistant subtype with response rates of between 11%-27%[181-183], as such the role of adjuvant 
chemotherapy, particularly in stage I disease, is less certain[182, 184]. Notably, the five year DFS for 
stage IA and stage IC (surgical rupture alone) CCOC have been found to be comparable and the 
omission of adjuvant chemotherapy is increasingly being discussed as an option with these patients 
[184]. Patterns of relapse also differ with pelvic recurrences being most common [185]. 
In early stage disease, exploratory analysis of the GOG157 trial suggests that only patients with serous 
tumours benefited from six versus three cycles of chemotherapy whereas there were no additional 
benefit for CCOC [186]. Given the propensity for pelvic recurrences, pelvic irradiation has also been 
evaluated as a local treatment following adjuvant chemotherapy which has shown a 20% five year 
disease free survival benefit in patients with stage IC (surface involvement and positive cytology) and 
stage II disease in a retrospective study by Hoskins et al [184]. Relapsed CCOC is challenging to treat 
due to low chemotherapy response rates and poor prognosis. It also shares biological features with 
renal clear cell carcinoma which include upregulation of anti-angiogenic pathways. As such, clinical 
trials of antiangiogenic tyrosine kinase inhibitors in CCOC are currently being performed [187-189]. A 
proportion of CCOC with microsatellite instability (MSI) display increased PD-1/PD-L1 expression which 
make this subtype attractive candidates for immune checkpoint inhibitors [190]. This is supported by 
data from early phase immunotherapy studies performed in EOC [191, 192]. In these studies, patients 
with CCOC sustained complete or partial responses to immune check point inhibitors. Several phase II 




1.4.4 Mucinous carcinoma 
MuOC are a rare subtype comprising 3% of EOC. They can be difficult to distinguish between primary 
MuOC and mucinous carcinomas which have metastasized to the ovary [194]. Colorectal, appendiceal, 
pancreatic, biliary tract, stomach and cervical cancers are the most common primary sites. Specific IHC 
patterns involving CK7, CK20, CEA, CA19.9, CA125, ER, CDX2, and PAX8 can assist with this 
differentiation [195]. Many previously diagnosed MuOC were in fact ovarian metastases which explains 
the decrease in the reported incidence over time.  MuOC associated with pseudomyxoma peritonei 
have been shown to arise from the appendix [196]. MuOC are categorised by their growth pattern which 
have prognostic implications. The expansile subtype has lower metastatic potential whereas the 
infiltrative subtype is more aggressive and associated with a poorer prognosis with higher rates of lymph 
node involvement in early stage disease [197]. 
Unlike HGSOC, MuOC do not contain BRCA mutations or defects in HRR genes and have distinct gene 
expression profiles [197]. KRAS mutations occur in up to 50% of tumours [198, 199], with c-MYC 
amplifications in up to 65% of tumours [197]. HER2 gene amplification has been shown to occur in 18% 
of MuOC with early phase evidence supporting the use of the monoclonal anti-HER2 antibody, 
trastuzumab, in these tumours [200, 201]. HER2 amplification has been found to be mutually exclusive 
to KRAS. Other alterations include TP53 mutations (50-75%), CDKN2A/B deletions (25%), 
PI3KCA mutations (13%), with low mutational frequencies (up to 5%) of PTEN, BRAF, FGFR, KIT and 
STK11 [197]. 15% to 20% of MuOC harbour MSI, a finding which may make these tumours attractive 
candidates for immune check point inhibition [197]. 
The vast majority of MuOC present with early stage disease [202]. An analysis of seven phase III 
randomised GCIG trials found that advanced stage MuOC had a worse survival compared to serous 
tumours of 14.6 months versus 40.6 months, respectively [203].  MuOC also exhibit lower platinum 
sensitivity with response rates of between 26% and 60% [204-206] when compared to HGSOC.  The 
mEOC trial/GOG241 compared adjuvant capecitabine and oxaliplatin versus conventional 
carboplatin/paclitaxel chemotherapy in stage II-IV or recurrent MuOC. This trial unfortunately closed 
prematurely due to poor accrual [207]. Following central pathology review, only half the patients were 
found to have true MuOC with the remaining tumours diagnosed as metastases to the ovary, borderline 
mucinous tumours and other EOC histological subtypes. Progress in the management of this rare EOC 
subtype has thus been hindered by its rarity, challenges in pathological diagnosis and need for a 








1.5 Endometrioid ovarian carcinoma  
EnOC make up 10% of all EOC. Compared to the majority of histological subtypes of EOC, EnOC has 
been generally under-investigated. A comprehensive overview of the clinical, pathological and 
molecular characteristics of this subtype is presented in the following sections.  
1.5.1 Histogenesis 
Like CCOC, endometrioisis is a pre-cursor of EnOC. It is a benign condition defined by the presence of 
extra-uterine endometrial tissue that occurs via retrograde menstruation, and shares some 
characteristics of malignancy such as loss of heterozygosity and monoclonality [208].  
20% to 40% of EnOC are associated with endometrioisis, either contiguous with or in relation to 
anatomical sites such as the contralateral ovary or pelvic peritoneum [209]. Most low grade EnOC arise 
from within endometriotic lesions or cysts and can occasionally co-occur with CCOC as mixed tumours 
in support of their shared pre-cursor lesion [174]. Malignant transformation can occur via the 
development of atypical endometriosis. Adenofibromas and borderline endometrioid tumours have also 
been found to co-exist with low grade EnOC suggesting an adenoma-carcinoma progression model 
[210]. Mutations in the tumour suppressor gene, PTEN, and ARID1A, in both EnOC (discussed in 
section 1.5.8) and adjacent endometriotic lesions also support this malignant genetic transition 
spectrum [7, 211, 212]. In-vivo studies have also found deletion of PTEN or activation of KRAS to induce 
endometriotic lesions, whereas a combination of these two mutations resulted in the development of 
metastatic EnOC in these mouse models [213]. Studies comparing the gene expression profiles of 
different histological subtypes of EOC with different gynaecological epithelia found that EnOC 
correlated with changes in normal endometrium, whereas serous tumours correlated with those in 
normal fallopian tube, further supporting the endometriotic origins of EnOC [214].  
There are however studies which postulate that not all EnOC are directly related to endometrioisis and 
that endometrioisis-independent EnOC may differ in terms of their clinico-pathological characteristics 
[215-219]. Stewart et al found KRAS mutations to be significantly greater in endometrioisis-associated 
low grade EnOC compared to those with no endometrioisis [220]. Catasus et al found a higher 
frequency of mutations in PTEN, CTNNB1 and MSI in endometrioisis associated EnOC compared to 
those with no endometrioisis [219]. Banz et al and Zhang et al found that endometrioisis-associated 
EnOC have a distinct molecular gene signature compared to EnOC without endometrioisis [216, 217]. 
Zhang et al also found a trend for higher stage disease in those without endometriosis [216]. 
Collectively, these studies suggest that EnOC may not be one disease, and that subtypes of EnOC may 







The grading of EnOC is performed according to the International Federation of Obstetrics and 
Gynecology (FIGO) grading system for endometrial endometrioid carcinomas (EnEC) as they both 
share morphological similarities [221]. This is a three-tier grading system based on the percentage of 
non-squamous solid component present (<5% grade 1, 6%-50% grade 2 and >50% grade 3). The 
presence of severe nuclear atypia increases the architectural grading by 1 [222]. It is generally accepted 
that grade 1 and grade 2 EnOC can be grouped as low grade and grade 3 EnOC as high grade [223].  
However, the prognostic value of the FIGO grading system in EnOC has been questioned by several 
retrospective studies. Parra-Herran et al compared FIGO grading to the Silverberg grading system 
which is based on architecture and nuclear atypia, mitotic activity in two high-power fields [221]. 72 
patients with EnOC defined by the WHO 2014 criteria were reviewed and independently graded 
according to the Silverberg and FIGO grading systems. The survival outcomes of Silverberg grade 1 
and 2 EnOC clustered together and were superior to Silverberg grade 3 EnOC even after five years. 
This is in contrast to FIGO grade 2 EnOC which had similar outcomes to FIGO grade 1 EnOC for the 
first five years and declined after five years approaching that of FIGO grade 3 tumours. Only the 
Silverberg grading system retained statistical significance for survival in a multivariate analysis when 
compared to FIGO grading although lost significance when accounting for stage. There was no 
association between the type of grading and survival in Stage I and II disease although the authors 
argue that the lack of association may have been limited by cohort-size and the lower number of events.   
The authors conclude that the Silverberg grading system is a better predictor for survival then the FIGO 
grading system and may favour a two tier grading classification in EnOC. This contrasts with the study 
by Assem et al which assessed clinical outcomes of 179 EnOC graded by the FIGO system following 
contemporary pathology review [224]. No differences in clinical pathological variables or survival were 
found between grade 2 and 3 EnOC and the authors argue that grade 2 and 3 EnOC should be grouped 
together instead. Together, these studies indicate that there is likely inter-observer variation in the FIGO 
grading system of EnOC, particular in determining grade 2. This is in keeping with similar observations 
made in the FIGO grading system used in EnEC [223]. For example, in the PORTEC clinical trial which 
compared surgery and post-operative radiotherapy to surgery alone in stage I endometrial carcinomas, 










Most EnOC are usually well differentiated and are of low grade (grade 1 and 2). As such, they are easily 
distinguishable from other subtypes of EOCs based on histo-pathologic features [226].  Low grade 
EnOC closely resemble EnEC at both the histological and molecular level [227, 228] (discussed in 
section 1.5.8). Morphological features of EnOC include back to back glandular architecture with stromal 
exclusion and villo-glandular patterns with up to 50% of cases exhibiting squamous differentiation in the 
form of morules. Confirmatory endometrioid features include the presence of squamous metaplasia, 
background endometriosis or borderline adenofibroma, and borderline endometrioid features [226]. 
Other rarer morphological features include focal or diffuse sex-cord like formation, spindle cell 
differentiation, secretory and oxyphillic variants [129]. More than 70% of EnOC are positive for ER and 
PR with the classical IHC profile of EnOC being negative for WT1 staining and p53 wild-type expression 
(variable intensity of nuclear p53 staining). High grade EnOC are increasingly rare, and are challenging 
to diagnose as they share morphological overlap with HGSOC [229]. The use of WT1 is a useful 
discriminator (discussed in section 1.5.4) [230]. 
Overall, 15-20% of EnOC are associated with synchronous EnEC [129, 231]. These synchronous EnEC 
are usually low grade and organ confined and are normally treated as independent primary tumours. 
The Young and Scully criteria are used to identify both tumours as separate primaries: i) both tumours 
must be histologically distinct; ii) no evidence of deep myometrial invasion of the endometrial tumours; 
iii) no evidence of lymphovascular space invasion of the endometrial tumour; iv) presence of atypical 
endometrial hyperplasia; v) no evidence of other endometrial metastases; vi) unilateral ovarian tumour; 
vii) parenchymal confinement of the ovarian tumour with no other evidence of metastatic spread; viii) 
presence of ovarian endometriosis; vi) different DNA ploidy if evidence of tumour aneuploidy; and vii) 
different molecular genetic or karyotype of both tumours [232]. In clinical practice, however, it can still 
be challenging to differentiate between two independent primaries or metastatic disease either from the 
ovary or uterus. Notably, patients with synchronous EnEC have been shown to have a similar prognosis 
when compared to those without concurrent endometrial carcinomas [231, 233-235].  Interestingly, 
recent studies have shown that EnOC and synchronous EnEC demonstrate a clonal relationship 









1.5.4 Diagnostic challenges in Endometrioid Ovarian Carcinomas 
The biggest diagnostic challenge in EnOC is differentiating high grade EnOC from HGSOC. Other 
pitfalls include differentiating de-differentiated carcinomas (low grade EnOC with an undifferentiated 
carcinoma (UC) component) from grade 2 or high grade EnOC, as well as the exclusion of colorectal 
metastases with pseudo-endometrioid appearances.  Rarely, EnOC can also mimic serous borderline 
tumours [238] and MuOC [239].The first three major areas are discussed below.  
1.5.4.1 Role of WT1 in differentiating high grade EnOC versus HGSOC 
High grade EnOC can be challenging to distinguish from HGSOC on the basis of morphology alone 
[224, 226, 229]. HGSOC is morphologically diverse and can include glandular differentiation with a 
papillary architecture. Solid variants of HGSOC, with minimal glandular or papillary differentiation, can 
mimic undifferentiated carcinomas, as well as display morphological overlap with high grade 
EnOC[240]. In particular, a proportion of HGSOC demonstrate solid, pseudo-endometrioid 
and/or transitional-cell-like growth patterns (SET pattern), which has been shown to be associated with 
BRCA1 mutations [241].   
Through the refinement of ovarian cancer diagnostic criteria [242] and increased use of IHC, several 
studies have shown that many high grade EnOC are in fact HGSOC [226, 243]. The use of WT1 IHC 
[230, 244, 245], is a critical tool in differentiating high grade EnOC (WT1 negative) from HGSOC (WT1 
positive), and has helped reduce inter-observer variation [129, 224, 229, 243].  
These findings are further supported by both gene expression profiling studies performed in EnOC 
diagnosed without the use of IHC [243, 246-248]. In Wu et al, 72 historically diagnosed EnOC, of which 
29% were grade 3, underwent mutational analysis and 37 underwent gene expression profiling [247]. 
A subgroup of EnOC, which tended to be of higher grade with TP53 mutations, had similar gene 
expression profiles to serous carcinomas. In Winterhoff et al, 276 HGSOC, CCOC and high grade EnOC 
were selected for gene expression profiling using Agilent microarrays [248]. Notably, 39% of the high 
grade EnOC cohort in this study were grade 2. Transcriptional profiling using TCGA signatures of 
HGSOC found that high grade EnOC of advanced stage clustered together with HGSOC, whereas early 
stage high grade EnOC and CCOC formed a distinct cluster of their own.  Schwartz et al found that the 
gene expression profiles of advanced stage high grade EnOC clustered together with serous 
carcinomas, whereas early stage low grade EnOC clustered separately [246]. Similar findings were 
reported in Tothill et al [249].  
The WT1 gene is a transcription factor involved in the development of genitourinary organs which acts 
as both an oncogene and tumour suppressor. It has been shown to be differentially expressed amongst 
gynaecological epithelia [250]. It is positive in the fallopian tube and ovarian surface epithelia but 
negative in the endometrium and cervix. As discussed in section 1.4.1 and 1.5.1, both HGSOC and 
EnOC differ in their gynaecological tissue of origin. As discussed in section 1.4.1, HGSOC have tubal 
origins whereas most EnOC arise from endometrioisis (ectopic endometrial tissue). As such, WT1 
expression is used to demonstrate cell lineage and is differentially expressed in the different histological 
subtypes of EOC [244, 251].  97% of HGSOC have been shown to be WT1 positive. An IHC profile of 
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WT1 positivity and p53 aberrant expression is highly specific for HGSOC (91.7%) [229, 251], whereas 
this combination is only observed in 1% of EnOC. Previously, 70% of EnOC were found to be WT1 
negative [245, 252]. However, large studies performed of contemporary subtyping of EOC now 
demonstrate that 90-96% of EnOC are indeed WT1 negative [229, 253].  
This is further supported by the study by Madore et al [243]. EnOC which expressed the WT1 gene 
clustered together with serous carcinomas, whereas EnOC which did not express the WT1 gene 
clustered separately.  It also found that high grade EnOC which were WT1 positive p53 aberrant 
expression on IHC were negative for β-catenin expression, supporting these to be HGSOC that had 
been misclassified [243].  However, this study also identified two WT1 negative EnOC of high grade 
and high stage with concurrent aberrant p53 and β‐catenin IHC staining. One of these tumours were 
immortalised in cell culture and gave rise to an aggressive well-characterised EnOC cell line, TOV112D. 
This study concluded that an IHC profile of WT1 negative p53 aberrant expression may identify a rare 
high grade variant of EnOC [243]. 
To date, studies which have applied contemporary ovarian sub-typing criteria have found that high 
grade EnOC is increasingly rare with reported frequencies of between 5-18.7% of all EnOC [224, 226, 
254, 255].  
1.5.4.2 De-differentiated carcinomas 
De-differentiated carcinomas of the ovary contain a mix of low grade EnOC and UC components. These 
tumours are recognised by the WHO 2014 [256] as a separate entity and was first described by Silva 
et al in 2006 [257]. Microscopically, they appear as medium to large sized monotonous cells that lack 
glandular papillary, squamous or neuroendocrine differentiation.  Most studies performed to date have 
largely comprised of de-differentiated endometrial carcinomas with only a few including those of ovarian 
origin reflecting its extreme rarity.  
Recent mutational analysis of de-differentiated carcinomas of both endometrial and ovarian origin have 
demonstrated a clonal relationship between both the low grade endometrioid and UC components [258]. 
In Kuhn et al, the same somatic mutations (PIK3CA, CTNNB1, TP53, FBXW7 and PPP2R1A) were 
found in both components in all cases [258]. In 42% of cases (n=5), additional exclusive somatic 
mutations were detected in UC but not found in the matched low grade endometrioid component. 
Subsequently, Karnezis et al found inactivating mutations of the SMARCA4 and SMARCB1 genes, 
which encode for core subunits of the switch/sucrose non-fermenting (SWI/SNF) chromatic remodelling 
complex, in half of the UC component, but with none in the matched low grade endometrioid component 
[259]. In a follow on study by Coatham et al, co-inactivation of ARID1A and ARID1B genes were 
identified as the other alternate mechanisms of de-differentiation [260]. The same mechanisms, 
including loss of BRG1 (encoded by SMARCA4), were also identified in the 3 ovarian de-differentiated 
carcinomas included in this study. Collectively, these studies support the hypothesis that the UC 
component develops as a result of tumour progression from the existing low grade endometrioid 
carcinoma, and that inactivation genes encoding the SWI/SNF complex subunits are a major 
mechanism of de-differentiation.   
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Clinically, de-differentiated ovarian and endometrial carcinomas are diagnostically challenging and can 
be mis-diagnosed as grade 2 or grade 3 endometrioid carcinomas. They are important to accurately 
diagnosis as they display aggressive clinical behaviour associated with poorer survival when compared 
to grade 3 endometrioid carcinomas [261, 262]. Furthermore, there is a reported association between 
dedifferentiated carcinomas of gynaecological origin and MMR deficiency, with loss of MMR proteins 
on IHC in over 50% of de-differentiated endometrial carcinomas [257, 261, 263, 264]. As such, it is 
likely that accurate diagnosis of de-differentiated ovarian carcinomas may also have implications in 
screening for Lynch syndrome.  
1.5.4.3 Pseudo-endometrioid colorectal metastases 
Ovarian metastases from colorectal carcinomas are a known mimic of primary ovarian carcinomas and 
can occur in 10-33% of cases [265, 266]. In particular, they can display pseudo-endometrioid 
appearances [265]. The coordinate use of CK7 and CK20 can help distinguish non-mucinous ovarian 
carcinomas (CK7 positive CK20 negative) from colorectal metastases (CK7 negative, CK20 positive) 



















1.5.5 Hormone receptor expression 
Most EnOC express ER and PR [81].The relative risks of developing EnOC following oestrogen 
replacement therapy have been found to be one of the highest amongst the histological subtypes of 
EOC [69, 269]. In keeping with this, the risk reducing effect of the oral contraceptive pill has been found 
to be one of the greatest for EnOC [70]. Furthermore, Kuhnel et al found the highest activity of 
aromatase in EnOC compared to serous and mucinous ovarian carcinomas, suggesting that in situ 
oestrogen production may be an important growth factor in EnOC, and as such may benefit from the 
use of aromatase inhibitors [270]. Like EnEC, these findings demonstrate that EnOC is an oestrogen 
dependent disease. 
The Ovarian Tumour Tissue Analysis Consortium Study was the largest study of over 3000 patients 
evaluating ER and PR expression between the histological sub-types [81]. As previously discussed in 
section 1.3.1, three categories were used to define hormone receptor expressions according to the 
proportion of nuclear staining (strong (≥50%), weak (1%-50%) and negative (0%)). 76.6% of EnOC 
(n=484) expressed ER with 60.2% displaying strong expression and 16.4% displaying weak expression. 
Similarly, 67.4% of EnOC expressed PR with 44.4% displaying strong expression and 23.0% weak 
expression. The majority of EnOC (81.6%) had co-expression of ER and PR. This study found that any 
ER and PR expression (defined as >1% nuclear staining) was associated with an improved disease-
specific survival (DSS) in EnOC. It also found that high grade EnOC were less likely to be ER or PR 
positive when compared to their lower grade counterparts. Co-expression of ER and PR were also 
evaluated in this study. The independent risk reduction on DSS of ER (positive or negative) and/or PR 
(positive or negative) expression was similar for all groups.  
EnOC in the Ovarian Tumour Tissue Analysis Consortium Study did not undergo contemporary 
pathology review [81]. In order to address the impact this may have had on the study results, WT1 IHC 
expression was examined in a subset of HGSOC. It found no differences in the frequencies of WT1 
expression in strong, weak and negative PR (P=0.61), thus concluding that the misclassification of 
EnOC as HGSOC was not more likely for PR positive tumours.  
Rambau et al performed independent validation of the Sieh et al study specifically in EnOC [255]. Here, 
contemporary pathology review utilising an eight marker IHC algorithm identified 182 EnOC of which 
19% were grade 3. Using the same scoring methodology as Sieh et al, frequencies of ER and PR 
expression were 87.3% and 86.7%, respectively. Co-expression occurred in 83.0%. There were no 
significant differences in DSS between focal (1-50% nuclear staining) and diffuse (>50% nuclear 
staining) staining and a binary approach for survival analyses was thus adopted. Any ER or PR 
expression was associated with superior DSS in EnOC independent of age, stage, grade, treating 
centre and residual disease, in keeping with those found by Sieh et al. However notably, the effect on 
DSS was diminished when restricted to stage I and II disease.  Only borderline significance was 
observed for ER positive (P=0.0452) and ER and PR co-expressed EnOC (P=0.0452), whilst no 
statistically significant differences were observed for PR (P=0.0932). 
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Very few studies have been performed evaluating the role of AR in EnOC as many of them grouped 
non-serous tumours together. The rate of AR expression in small cohorts vary between 20%-58% 
(Table 5). Like studies of ER and PR, variable thresholds of defining receptor positivity have been used.  
Furthermore, no study has assessed the prognostic role of AR specifically in EnOC due to the low 
numbers of EnOC present in each study. The only study that has come close to doing so was performed 
by Jonsson et al [83]. Here, 118 tumours of both serous (73.7%) and endometrioid histology (26.3%) 
were analysed and scored for ER, PR and AR expression. An IHC threshold of ≥ 10% was considered 
positive expression. In the whole cohort, both PR and AR expression, but not ER, were independently 
associated with improved prognosis. Co-expression of PR and AR was also found to provide a greater 
differential effect on survival compared to tumours with discordant or absent PR and AR expression. A 
trend was seen when the latter analysis was restricted to EnOC only (P=0.073). However, residual 
disease was not recorded in this study thus representing a major limitation to this study. The 
independent prognostic role of AR has thus not been established in EnOC. 
 
Table 5: Studies of AR expression in EnOC. 
Study IHC threshold N of EnOC included AR expression in EnOC 
Lee et al 2005a [87]     >10% 29 58% 
De Toledo et al 2014a[94] Allred score≥4 14 not recorded 
Van Kruchten et al 2015 a[95] ≥ 10% 21 not recorded 
Nodin et al 2010a[90] >10% 35 20% 
Jonsson et al 2015a[83] ≥ 10% 31 25% 
Gomora et al 2018a[105] Histoscore>30 29 Over 40%b 
Legend: IHC=immunohistochemistry; N=number; AR=androgen receptor. 
a performed in mixed population of epithelial ovarian carcinomas.  











1.5.6 Clinical characteristics  
EnOC are more commonly diagnosed in younger women compared to those with HGSOC [271, 272]. 
It usually presents as a large pelvic mass comprised of low grade carcinoma with the majority presenting 
as early stage disease [226]. Most EnOC are unilateral though 10-20% can develop as bilateral lesions 
[209, 210, 272]. As previously discussed, up to 40% of EnOC are associated with endometriosis [129, 
209] with 15-20% associated with synchronous EnEC [273].  
 
In general, EnOC is regarded as having a better prognosis then HGSOC [226, 229, 272, 274, 275]. It 
is however less certain whether this is solely due to earlier stage of presentation as most studies did 
not perform stage for stage comparisons [274, 276-278]. Furthermore, older studies of EnOC did not 
undergo contemporary pathology review [272, 279]. As discussed in section 1.5.4.1, many historically 
diagnosed high grade EnOC are in fact HGSOC and are likely to have confounded the clinical 
outcomes reported in these studies.  
A meta-analyses initiated by the GCIG investigated the prognostic relevance of histological subtype 
[203]. Here 8704 patients with stage III/IV EOC from seven randomised clinical trials (three of which 
underwent central pathological review) were included, of which 646 (7.4%) were EnOC. Patients with 
EnOC were more likely to have no gross residual disease compared to serous histology, independent 
of age and study. The median OS was 50.9 months for EnOC compared to 40.8 months in serous 
histologies, although this was not statistically significant [203].   
Storey et al performed evaluating a stage for stage comparison of serous carcinomas and 270 EnOC 
diagnosed between 1984 and 2004 [272]. EnOC had superior overall median PFS (24 months versus 
13 months; p<0.0001), and overall median OS (48 months versus 22 months, p<.0001), when 
compared to serous carcinomas. This held true for stage II and III disease, however there were no 
differences observed for stage I and IV disease. Histology, stage and residual disease were 
independently associated with survival following platinum based chemotherapy. However, this dataset 
did not undergo contemporary pathology review with 56% of EnOC in this study comprised of grade 3 
tumours. It is thus plausible that a significant proportion of these tumours were misdiagnosed HGSOC 
[280]. Furthermore, the distinction between HGSOC and LGSOC was also not made in this study with 
nearly a third of serous carcinomas comprised of grade 1(7%) and 2(22%) serous carcinomas. 
Together, these factors are likely to have confounded the results of this study. In another similar 
example, Bouchard Fortier et al compared 98 EnOC to 435 HGSOC [279]. No pathology review was 
performed. Five year OS was significantly higher at 80.6% in EnOC versus 35.0% in HGSOC although 
this lost significance on a multivariate analysis including stage.  
A few studies have compared contemporary defined EnOC to HGSOC. In Kobel et al, 185 EnOC were 
retrospectively diagnosed utilising WT1 IHC with 7.6% of patients diagnosed as G3 [281]. Ten year 
DSS was 96% for stage IA/IB EnOC compared to 68% for HGSOC, and 81% for stage IC-II EnOC 
compared to 57% for stage IC-II HGSOC. It is however worth noting that in this study, tumours were 
considered stage II if sharp dissection was required even in the absence of pathologically proven extra 
ovarian spread which is not standard practice worldwide. These patients, who would otherwise be 
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considered stage I, therefore received adjuvant therapy. Furthermore, over half of the study cohort also 
underwent abdominal pelvic radiation in addition to adjuvant chemotherapy. These practices, which 
are not considered standard of care worldwide, may pose some limitations on the interpretation of 
clinical outcomes reported in both studies. Nonetheless, this contributes to the growing body of data 
supporting the belief that EnOC demonstrate biologically superior outcomes compared to HGSOC.  
Lim et al performed contemporary pathology review on 109 historically diagnosed EnOC as per WHO 
2014 criteria [226]. Of these, 70% were classified as true EnOC. Only 31 tumours, excluding high grade 
EnOC, underwent WT1, p53 and p16 IHC on tissue microarrays. The rate of high grade EnOC was 
2.6% for Silverberg grading and 5.3% for FIGO grading. Compared to HGSOC also diagnosed through 
the same pathology review process, EnOC were found to present at an earlier age, stage, with low 
grade unilateral disease. They were also more likely to have no evidence of disease at last follow up. 
However, no stage for stage comparison was performed in this study.   
Some studies have tried to specifically compare contemporary defined high grade EnOC to HGSOC. 
In the study by Assem et al, 30 high grade EnOC diagnosed as per WHO 2014 utilising 10 IHC markers 
including WT1 and p53 IHC on TMAs were compared to HGSOC [224]. De-differentiated carcinomas 
were excluded. This study found the survival of high grade EnOC to be superior to that of HGSOC on 
univariate analysis, but not on multivariate analysis. It also found that grade 2 and grade 3 EnOC had 
similar outcomes and postulated that these 2 groups could be combined, in contrast to the convention 
of grouping grade 1 and 2 EnOC together.  In Soyama et al, WHO 2014 defined grade 3 EnOC 
comprising 13.8% (n=9) of EnOC were compared to HGSOC [282]. Notably, IHC performed at first 
diagnosis was used only if there were discrepancies between the two observers, with no specific details 
regarding this found in this paper. No differences in PFS or OS were found between the 2 groups.  In 
summary, the published evidence to date suggests that the clinical behaviour of high grade EnOC is 












1.5.7 Clinical Management 
As discussed in section 1.2, the principles of management of EOC largely reflect that of HGSOC due 
to its prevalence in prospective randomised trials. In general, the approach to the management of EnOC 
is similar to that of HGSOC. No established EnOC-specific management exist as no clinical trials have 
been performed specifically in this histological subtype. In particular, most modern day clinical trials 
often combine high grade EnOC with HGSOC. In this chapter, the treatment settings in which the 
management of EnOC may differ to that of HGSOC are discussed.  
1.5.7.1 Surgery in early stage EnOC 
In stage I disease, EnOC is one of the histological subtypes in which fertility sparing surgery can be 
considered. The European Society of Medical Oncology guidelines recommend that following 
appropriate counselling, this surgical procedure can be performed in younger pre-menopausal patients 
with stage IA or stage IC grade 1 and 2 EnOC, provided complete surgical staging, including 
lymphadenectomy, is performed to exclude more advanced disease [2].  
As discussed in section 1.2.1, the role of lymphadenectomy in early stage disease is uncertain as no 
OS benefit derived from a prospective randomised trial has been demonstrated [17]. Its practice is 
controversial and variable worldwide. Several large retrospective studies have evaluated the 
prevalence of lymph node metastases according to histological subtype, and the impact of lymph node 
sampling or lymphadenectomy on survival.  Heitz et al evaluated the role of lymphadanectomy in EOC 
with data extracted from a prospectively maintained database [283]. Of the 27 grade 1 EnOC in this 
cohort, no lymph node metastases were observed independent of stage. In contrast, the rate was 27.6% 
in grade 2 and 3 EnOC which was stage dependent, compared to 67.1% in HGSOC. Although there 
was a survival advantage of lymphadenectomy in non-serous tumours, there were no differences in 
survival specifically in EnOC. In Minig et al, the frequency of lymph node metastases following 
lymphadenectomy was also found to be similarly low at 1.5% of 68 historically diagnosed apparent 
stage I low grade EnOC [284]. Lymphadenectomy was not associated with survival. Similarly, in 
Melamed et al, the rate of lymph node metastases was 1.6% of 1120 historically diagnosed apparent 
stage I EnOC, compared to 34.5% in serous carcinomas [285]. In the study performed by Kobel at al 
which evaluated clinical outcomes of contemporary reviewed early stage EnOC, patients did not 
routinely undergo lymph node dissection. DSS was 96% in apparent stage IA and IB EnOC with no 
adjuvant therapy suggesting that radical staging surgery may be safely avoided in these patients. 
Conversely, other retrospective studies have concluded that lymphadenectomy remains an important 
determinant of survival even in EnOC. Nasioudis et al investigated the frequency of lymph node 
metastases and prognostic role of lymphadanectomy in apparent stage I EnOC and MuOC [286]. 17.8% 
of this historically diagnosed EnOC cohort were grade 3.Only 2.1% of 3354 EnOC had lymph node 
metastases. On multivariate analyses, lymph node sampling or lymphadanectomy was associated with 
DSS only in EnOC. In a large national Dutch retrospective study evaluating the role of 
lymphadenectomy in early stage EOC (stage I-IIA and IIIA1) of which 354 were EnOC, OS was superior 
in patients who underwent lymphadenectomy compared to those who did not, even after correcting for 
histology, grade and stage [287]. The proportion of grade 3 EnOC was however not reported in this 
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study. In a Chinese study of 78 stage I historically diagnosed EnOC of which 21.8% were grade 3, 
grade 3 disease and those who underwent lymphadenectomy were independent factors of prognosis 
[288]. In another large American study abstract of 3617 patients with historically diagnosed stage I 
EnOC, the removal of more than 10 lymph nodes was independently associated with improved DSS 
after adjusting for age, sub-stage, tumour grade and chemotherapy (P=0.01) [289]. No information was 
available on the proportion of patients with grade 3 disease or rates of lymph node metastases. In all 
four studies, no contemporary pathology review was conducted and there is thus some uncertainty 
regarding the proportion of misdiagnosed HGSOC included in these cohorts. 
Collectively, the data to date suggest that the rates of lymph nodes metastases in EnOC are low 
particularly in low grade tumours. The question as to whether a survival benefit exists for lymph node 
sampling or dissection specifically in EnOC is uncertain due to conflicting data. In particular, the possible 
inclusion of misdiagnosed HGSOC in these historically diagnosed cohorts may have influenced these 
results.   
1.5.7.2 Adjuvant chemotherapy in early stage EnOC 
Both the ICON1 and ACTION trials of adjuvant chemotherapy in EOC did not distinguish between each 
histological subtype and thus the survival benefit of adjuvant platinum-based chemotherapy specifically 
in EnOC is less well defined [27]. Only 24.1% (n=120) of patients in the ICON and ACTION trials were 
EnOC, Retrospective subgroup analysis of these two trials did not demonstrate a differential effect of 
chemotherapy for histological subtype. In a ten year update of the ACTION trial, the observed survival 
differences between the chemotherapy and observation arm were independent of histological sub-type 
[290].  
The majority of early stage EnOC are associated with good prognosis, in particular, five year DSS of 
stage I EnOC is over 90%. As such, retrospective studies have been performed evaluating the value 
of adjuvant chemotherapy in early stage disease [274, 281, 291]. In addition, attempts have been made 
to identify biomarkers which can define a subgroup of patients that can be spared adjuvant 
chemotherapy. 
The largest retrospective analysis performed by Nasioudis et al investigated the role of adjuvant 
chemotherapy in 4538 patients from the United States National Cancer Database with historically 
diagnosed stage 1 EnOC [292]. The use of lymphadenectomy was used as a surrogate marker of 
adequate surgical staging.  Here, a statistically significant OS advantage was observed in patients with 
grade 2 tumours with no lymph node dissection or who had limited lymphadenectomy who received 
adjuvant chemotherapy versus those who did not. A numerical but non statistical OS advantage was 
also observed in those with grade 3 disease with no lymphadenectomy who received adjuvant 
chemotherapy. The authors conclude that there is a survival benefit for patients with inadequately 
staged grade 2 EnOC and possibly those with grade 3 EnOC, however acknowledge the limitations of 
this study which include the lack of contemporary pathology review, as well as the use of OS rather 
than DSS as a survival endpoint. 
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 In Oseledchyk et al, the survival benefit of adjuvant chemotherapy was evaluated in 3552 historically 
diagnosed stage I EnOC diagnosed between 2000 and 2013 as part of the SEER database [291]. In 
this study, 75% of patients had at least one lymph node removed, and 17.6% were G3 EnOC. No 
differences in overall five year OS were found between patients who received adjuvant chemotherapy 
and those who did not (90% versus 89%, respectively; P=0.807). Only patients with stage IC G3 EnOC 
demonstrated a survival benefit from chemotherapy (five year OS of 81% versus 62%, P=0.003), 
whereas those with stage IA/IB any grade, and IC grade 1 or 2 EnOC did not derive benefit [291].  
Rambau et al evaluated the prognostic and predictive role of hormone receptor expression in a group 
of contemporary defined EnOC utilising IHC [255]. Five year DSS was excellent at 97.8% in stage IA/IB 
disease. In stage IC/II disease, no differences in five year DSS were found for tumours which 
expressed ER, PR or ER/PR co-expression versus those which did not. The authors conclude that for 
these patients, hormone receptor expression was of limited value in identifying those that could be 
spared adjuvant chemotherapy. For example, five year DSS was 89.0% and 89.9% in ER and PR 
positive tumours, respectively, which was lower than the 95% threshold defined in the study at which 
patients could avoid chemotherapy. Akin to the study by Oseledchyk et al, no differences in survival 
were observed in stage IC/II disease between those who received adjuvant chemotherapy versus those 
who did not (P=0.32), raising the hypothesis as to whether adjuvant chemotherapy could be omitted in 
these patients. Similarly, no differences were observed between these groups in ER positive (P=0.76) 
or negative disease (P=0.19).  
 Kumar et al evaluated clinical outcomes in 172 early stage EnOC [274]. No contemporary review was 
performed in this study and 12% were G3 EnOC. Five year DFS rates were 95% for stage IA-C (IC by 
tumour rupture only), 84% for stage IC (positive cytology and/or surface involvement), and 74% for 
stage II disease, respectively [274].The authors found 2 poor prognostic groups, patients older than 55 
years with stage IC (positive cytology and/or surface involvement) and any stage II patient. This study 
concluded that patients with stage IA/B and stage IC EnOC defined by tumour rupture alone could avoid 
adjuvant treatment. Like the study by Kobel et al [281], tumours requiring sharp dissection were 
considered stage II even with pathologically negative extra-ovarian spread, and a proportion of patients 
also underwent adjuvant radiotherapy in addition to chemotherapy. A trend in favour of DFS benefit for 
radiotherapy in early stage EnOC was observed, although the confidence intervals crossed 1 (RR 1.77 
(95% CI 0.74-4.24). 
Other studies have also evaluated the role of other molecular markers to identify patient cohorts who 
could be spared chemotherapy. Wang et al investigated the role of -catenin and CDX2 IHC staining in 
both a discovery (n=183) and validation cohort (n=174) [293]. Contemporary pathology review was 
performed using IHC. Both markers were individually associated with DSS on univariable analysis. In a 
multivariable analysis that only accounted for stage, double positivity of both markers identified patients 
with stage IC/II EnOC that could be spared chemotherapy in the discovery cohort (ten year DSS greater 
than 95%), however this lost significance in the validation cohort. Notably, this study did not have 
surgical procedures or residual disease recorded and the authors acknowledge the need to evaluate 
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other prognostic markers of EnOC as a multi-marker panel in order to establish the utility of both beta-
catenin and CDX2 as prognostic biomarkers.  
Soovares et al evaluated the role of L1CAM expression in 249 EnOC which underwent pathology review 
(though no details were outlined in the paper) [275]. On univariable analysis, higher levels of L1CAM 
expression were found in EnOC of advanced stage, high grade with residual disease following surgical 
cytoreduction compared to those of early stage, low grade disease with no residual disease. Although 
positive L1CAM expression was associated with poorer survival in EnOC upon univariable analysis, 
this lost significance upon multivariable analysis, limiting the clinical utility of this biomarker in identifying 
patient cohorts of EnOC which could be spared adjuvant chemotherapy. 
1.5.7.3 Management of advanced stage EnOC 
In general, the management of advanced stage and relapsed EnOC mirrors that of HGSOC. Following 
aggressive cytoreductive surgery and platinum based chemotherapy, maintenance PARP inhibition can 
be employed for germline BRCA mutated high grade EnOC as they were included in the original PARP 
inhibitor trials [294]. As discussed in section 1.4.5, EnOC is recognised to be a hormone sensitive 
cancer in particular due to high co-expression of both ER and PR. Endocrine therapy in EOC is 
unlicensed however phase II clinical trials and retrospective studies demonstrate that the degree of ER 
expression predicts for endocrine sensitivity [112, 113, 295]. The published evidence of use of 
endocrine therapy in EnOC is largely confined to case reports and sub-group analyses of retrospective 
studies. In Pan et al, two patients diagnosed with stage IIIC EnOC were treated with the aromatase 
inhibitor, letrozole, as maintenance treatment [296]. The first patient had treatment initiated following 
first line surgery and chemotherapy following the discovery of residual disease during a second-look 
laparoscopy. In the second patient, letrozole was initiated following secondary cytoreduction and 
chemotherapy following a third relapse after an 11 month remission. Both patients remained disease 
free for 30 months thereafter.  In George et al, retrospective analysis of endocrine sensitivity in EOC 
was performed [222]. Of the five high grade EnOC in this cohort, three had a partial response, and two 
demonstrated stable disease. Endocrine therapy, a low cost and well tolerated drug, could therefore be 
conceivably used for recurrent EnOC, or as maintenance therapy in high risk patients not fit for 
chemotherapy. In EnEC, in which EnOC is histologically and molecularly similar to, the use of endocrine 
therapy is commonly administrated for recurrent low grade disease despite the lack of prospective trial 









1.5.7.4 Platinum sensitivity of EnOC 
Finally, as discussed in sections 1.3, each histological subtype of EOC have differential platinum 
sensitivity, although this has been under-investigated specifically in EnOC. To date, only three studies 
have reported on platinum sensitivity specifically in EnOC. Storey et al clinically characterised 270 
historically diagnosed EnOC of which more than half were grade 3. According to WHO/UICC criteria, 
it  found EnOC to display similarly high objective response (59%) and CA125 response rates (66%) to 
platinum based chemotherapy when compared to serous carcinomas ( the majority of which were of 
high grade) [272]. There has only been one other study performed in 145 historically diagnosed EnOC 
in 1990 which reported a 72% platinum response rate in historically diagnosed EnOC, however this 
was not according to modern criteria [298]. In Soovares et al, 249 patients with EnOC which underwent 
pathology review were characterised [275]. Platinum response was evaluated after primary surgery 
and adjuvant chemotherapy based on gynaecological examination, vaginal ultrasonography, CA125 
measurement, and/or computed tomography imaging. Overall complete response was 79%. This 
methodology is highly flawed given the heterogeneous assessment of response. Furthermore, they did 
not restrict the response analysis to those with measurable residual disease post-operatively thus 
casting doubt on these high response rates observed. As such, the platinum sensitivity specifically in 
contemporarily defined EnOC is not well understood.  
1.5.8 Genetic profile of EnOC and comparisons with EnEC 
Mutations in the PI3K/AKT pathway and Wnt/β-catenin signalling pathway are prevalent in EnOC. 
Commonly mutated genes include PTEN (20%), ARID1A (30%), PIK3CA (20%), PPP2R1A and 
CTNNB1 (16-54%) [227, 247, 254]. Mutations in KRAS (20%) [299], a member of the MAP kinase 
pathway, as well as microsatellite instability (MSI) (7-14%)  [227, 300, 301], as a result of mutations in 
the MMR genes, are also associated with EnOC. TP53 mutations are rare in low grade EnOC and have 
been reported to occur in less than 10% [228]. In studies which evaluate TP53 mutation status by IHC, 
higher frequencies of up to 30% are observed when accounting for EnOC of all grades [224, 243, 254, 
302].   
In addition to similar morphology, EnOC and EnEC share common molecular alterations but with 
differing frequencies particularly in CTNNB1, PTEN and MSI in a number of studies [219, 227, 228]. 
Only two studies have carried out direct comparisons, each utilising different molecular detection 
techniques and cohorts for comparison. McConechy et al performed targeted exon capture on a panel 
of seven commonly mutated genes in both low grade EnOC and low grade EnEC [228].  It found low 
grade EnOC to have fewer PTEN mutations (16.6% versus 53.3%, p=0.0001) but a higher frequency 
of CTNNB1 mutations (53.3% versus 27.5%, p=0.020) when compared to low grade EnEC [228]. No 
differences in ARID1A, PIK3CA, KRAS, PPP2R1A or TP53 were observed. Only three high grade 
EnOC were identified in this study however all three had differing mutations in different genes. High 
grade EnEC shared similarly high frequencies of PTEN and low frequencies of CTNNB1 mutations 




Huang et al compared EnOC (27% G3) without synchronous endometrial carcinomas to EnEC (12% 
G3) without concurrent ovarian involvement [227]. They showed EnOC to have lower frequencies of 
the MSI-high phenotype (4% versus 29%, P=0.012), loss of PTEN IHC expression (38% versus 74%, 
P=0.004) and loss of ARID1A IHC expression (12% versus 33%, P=0.044). The frequency of MSI in 
EnOC when including those with concurrent EnEC rose to 11%. There were no differences in the 
frequency of KRAS or PIK3CA mutations as detected by PCR between both cohorts. However, unlike 
McConechy et al, there were also no differences in CTNNB1 mutations.  This study also found no 
relationship between grade of tumour and any of the molecular aberrations. In both the EnOC alone 
and EnEC alone cohorts, MSI-high tumours demonstrated significantly higher ARID1A loss compared 
to MSI-low tumours. Whereas in the EnOC alone cohort, loss of PTEN was also significantly higher in 
the MSI-high group.  
Both EnOC and EnEC share common pre-cursors. The development of EnEC most commonly occurs 
in post-menopausal women with high levels of unopposed oestrogen as a result of obesity leading to 
the proliferation of endometrial epithelial cells and tumorigenesis [303]. Conversely, most EnOC arise 
from endometriotic cysts which develop as a result of retrograde menstruation. Here, trapped 
menstruation blood within the confined space of a cyst leads to high iron concentrations causing 
oxidative stress resulting in DNA damage and an accumulation of mutations [304, 305]. This is in 
keeping with the studies that have shown higher levels of chromosomal abnormalities in ovarian 
endometriotic cysts compared to extra-ovarian endometriosis [306].  These different mechanisms of 
tumorigenesis and tumour microenvironment in both EnOC and EnEC may explain the differences in 
mutation profiles observed in both studies by Huang et al and McConechy et al.   














1.5.8.1 PTEN and PIK3CA 
Mutations in the PTEN-PI3K pathway occur in a wide range of malignancies. They are common in the 
endometrioisis-associated ovarian carcinomas, EnOC and CCOC. Phosphoinositide 3-kinases (PI3K) 
phosphorylates downstream signalling molecules including protein kinase B (AKT), which are pivotal to 
numerous cell functions including cell proliferation and migration[307]. PIK3CA is an oncogene which 
encodes for the p110alpha catalytic subunit of PI3K. Gain of function PIK3CA mutations result in 
increased PI3K activity promoting phosphatidylinositol (3, 4, 5)-triphosphate (PIP3) mediated AKT 
activation thus promoting cancer cell growth. Missense mutations in exon 9 and 20 are the most 
common in EOC [308].  
PTEN is a tumour suppressor gene on chromosome 10q23 which antagonizes the PI3K/AKT pathway 
through dephosphorylating PIP3, thus inhibiting cell proliferation and survival. Inactivation of PTEN 
through loss of heterozygosity (LOH), genetic and epigenetic mechanisms, results in AKT activation 
initiating cancer cell growth and altered metabolism [309]. Germline mutations in PTEN result in the 
PTEN hamartoma tumour syndrome, including Cowden’s disease. Two thirds of patients with Cowden’s 
disease harbour mutations in exon 5, 7 and 8 with nearly half occurring in exon 5. Somatic mutations 
are typically frameshift mutations that can occur throughout the whole gene [310]. Both splice site 
mutations, as well as epigenetic silencing of the gene through methylation of the PTEN promoter, can 
also occur. LOH at 10q23.3 has been reported in up to 42.1% and 60% of EnOC [311, 312]. 
Both inactivating mutations PTEN [228, 312, 313], and activating mutations of PIK3CA [307], have been 
shown to occur in up to 20% of EnOC. LOH and PTEN mutations have been found in both 
endometrioisis, EnOC and CCOC [311], postulating this to be an early event in the development of 














ARID1A is a large tumour suppressor gene comprising 20 exons, which codes for the protein, BAF250a, 
a subunit of the SWI/SNF chromatin remodelling complex [314]. This complex modifies the expression 
of several genes. It interacts directly with TP53, and regulates the expression of SMAD3, CDKN1A 
(p21), MLH1 and PIK3IP1 through downstream transcription modification. This controls cell proliferation 
through the PIK3/AKT pathway. 
Loss of ARID1A tumour suppressor function plays a pivotal role in the pathogenesis of endometriosis 
associated gynaecological malignancies [315]. In EOC, ARID1A mutations are mutually exclusive to 
CCOC and EnOC, with none in HGSOC [315]. The highest frequencies occur in CCOC between 46-
57% [177].  Up to 30% of EnOC have been reported to contain ARID1A mutations and have also been 
found in contiguous atypical endometrioisis suggesting ARID1A mutations to be an early mutagenic 
event [315, 316].   
Heterozygous truncating mutations (nonsense or frameshift (out of frame) mutations) and missense 
mutations [314, 317] of the ARID1A gene are most common whereas in-frame insertions and deletions 
are rarer (5%) but are also pathogenic [318]. Mutations in ARID1A occur across the gene with no 
hotspot mutation and occur as somatic but not germline mutations [177, 315]. Both heterozygous and 
homozygous ARID1A mutations correlate with loss of ARID1A protein expression on IHC suggesting 
either haplo-insufficiency or alternative mechanisms for loss of protein expression [315, 319].      
The prognostic role of ARID1A mutational status (mutations and IHC expression) has been evaluated 
across different cancers in several studies. The largest meta-analysis of more than 5000 patients with 
gynaecological, urological and gastrointestinal cancers found tumours which were ARID1A deficient, 
defined by mutational and IHC analysis, had an increased cancer-specific relapse (HR1.93) and 
mortality (HR 2.55) as compared to ARID1A proficient tumours [320]. In EOC, the prognostic role of 
ARID1A mutational status determined by IHC has been studied the most in CCOC. Yokoyama et al 
found that amongst EOC, loss of ARID1A IHC expression was highest in CCOC and was associated 
with platinum resistance and worse PFS compared to tumours with intact expression [321], a finding 
that was also replicated in Katagiri et al [322]. Itamochi et al found that loss of ARID1A expression was 
independently associated with inferior five year survival in early stage CCOC (91% versus 74%; 
P=0.0225), but not in advanced stage disease [323]. 
In other endometrioisis-associated carcinomas, the prognostic role of ARID1A mutational status is less 
well defined. Heckl et al found loss of ARID1A IHC expression, together with p53 and -catenin, to be 
independent variables of poor prognosis in a small cohort of historically diagnosed EnOC, CCOC, EnEC 
and clear cell endometrial carcinomas [324]. Mao et al correlated progressive loss of ARID1A 
expression to different stages of EnEC progression (0% complex atypical hyperplasia, 25% low grade 
endometrioid, and 44% high grade endometrioid)), highlighting its role in tumour progression [325].  In 
contrast, ARID1A mutations were not associated with OS in other studies of predominantly clear cell 
endometrial carcinomas [326-328]. Similarly, Lowery et al found no association between loss of ARID1A 
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IHC expression and survival in a cohort of 212 historically diagnosed CCOC and EnOC [329]. To date, 
no studies have evaluated the prognostic role of ARID1A mutation status solely in EnOC.  
1.5.8.3 CTNNB1 
The CTNNB1 gene encodes for β-catenin which is a membranous protein which regulates cell adhesion 
as part of the E-Cadherin:catenin adhesion complex [330]. It is a key downstream transcriptional factor 
in the canonical WNT signalling pathway and is a well-established cancer signalling pathway that occurs 
in a range of malignancies including colorectal and ovarian carcinomas. In a normal cell, the levels of 
β catenin are controlled by the adenomatous polyposis coli (APC) tumour suppressor protein complex 
which degrades free cytosolic β catenin through the ubiquitin-proteasome pathway [330]. Upon 
activation of the Wnt pathway, the breakdown of β-catenin is inhibited resulting in its accumulation and 
translocation into the nucleus where it activates target genes such as cyclooxygenase, cyclin D and c-
resulting in genomic instability [330].  Nuclear accumulation of the -catenin protein on IHC is thus a 
useful surrogate for CTNNB1 mutations and has been shown to be associated with squamous 
differentiation, lower grade and with endometrioid histology [293, 331, 332]. 
Activating mutations in the CTNNB1 gene has been reported in 16-54% of EnOC and are usually 
hotspot missense mutations of exon 3 [219, 227, 228, 254, 293, 301, 332, 333].  The wide range of 
mutation frequencies have been attributed to various methods of detection which included IHC and 
different sequencing methods. The most recent study by McConechy et al 2014 performed both exon 
capture sequencing (n=33) and Sanger sequencing of hotspot exon 3 (n=20) of CTNNB1 in low grade 
EnOC [228]. 50% of these samples had CTNNB1 mutations all of which were missense mutations.  
CTNNB1 mutational status (mutations and IHC expression) in EnOC have also been shown to be 
associated with good prognosis in a small number of studies [254, 293, 334, 335]. The largest study 
ever performed was by Wang et al 2018 who examined the prognostic role of nuclear -catenin and 
CDX2 expression on IHC in 357 patients with EnOC, 183 were in the discovery set and 174 were in the 
validation set [293]. Contemporary pathology review was applied. In keeping with the literature, nuclear 
-catenin expression was higher in grade 1 EnOC (81.2%) compared to 11.8% in grade 3 EnOC 
(P=0.003). It was also associated with squamous differentiation (P<0.001). No differences in expression 
were observed for stage. Nuclear -catenin expression was associated with longer DSS upon 
univariable analysis in both the discovery and validation set. In the multivariable analysis which only 
accounted for stage but not residual disease, nuclear -catenin expression together with CDX2 positivity 
was independently associated with DSS in the discovery cohort but not the validation cohort.  
In contrast, CTNNB1 mutations are associated with poor prognosis in EnEC. In Liu et al 2014, 
comparison of two transcriptomic clusters characterised by the endometrial TCGA (The Cancer 
Genome Atlas) was performed [336]. Both clusters were comprised of low stage, low grade disease 
without TP53 mutations. Cluster II, made up of younger obese patients, demonstrated a significantly 
higher proportion of CTNNB1 exon 3 activating mutations with poorer survival as compared to Cluster 
I (87.0% versus 17.4%; P<0.001) which had higher levels of MSI-high tumours and expression of 
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hormone receptors. Cluster II was found to have the lowest mutation rate amongst the four clusters of 
the endometrial TCGA, suggesting that the aggressive biology of this cluster was driven by CTNNB1 
mutations.  Similarly in Kurnit et al, CTNNB1 mutations, together with TP53 mutations and age, were 
independently associated with worse RFS in early stage (I and II) and low grade (I and II) EnEC [337]. 
Furthermore, Myers et al also demonstrated an association between CTNNB1 mutations and risk of 
relapse in stage IA, grade 1 EnEC which is typically regarded as having an excellent prognosis with a 
cure rate of above 95% [338].  
1.5.8.4 KRAS 
The RAS family of oncogenes comprise KRAS, HRAS and NRAS, all of which have been associated 
with the promotion of malignancies. The KRAS gene resides on chromosome 12p12 and encodes the 
GTPase transductor protein, KRAS. It is involved in the MAP-kinase signal transduction pathway and 
is responsible for a vast range of cellular processes. In normal cells, KRAS migrates between an active 
(GTP-bound) and inactive (GDP bound) state. Activating point mutations in KRAS most commonly 
occur in exon 1 at position 12 and 13 near the GTP binding site [339]. This results in the cells inability 
to hydrolyse GTP and are thus locked in a permanent active state. This causes downstream activation 
of the MAP-kinase pathway, driving carcinogenesis. 
12% to 33% of EnOC are reported to have KRAS mutations [220, 227, 228, 254, 340]. Notably, studies 
have also found that KRAS mutations are mainly associated with endometrioisis [340, 341].  In Stewart 
et al, 29% of low grade EnOC with endometrioisis had KRAS mutations, compared to 3% without 
endometrioisis. Higher frequencies were also observed in endometrioisis identified in the ovarian 
tumour compared to extra-ovarian sites (32% versus 13%). In this study, the rate of BRAF mutations 
was extremely low at 1.4%, a finding similar to the low frequencies found in EnEC and unlike that of 
LGSOC [342]. Similarly in a follow on study also by Stewart et al performed in all grades of EnOC, the 
frequency of KRAS mutations was 25.7% in endometrioisis associated EnOC, compared to 6.3% in 
endometrioisis negative EnOC [340]. It is however worth noting that 12% of this cohort were WT1 
positive, and nearly 10% had p53 mutant expression on IHC, thus raising the possibility that 
misdiagnosed HGSOC may have been included in the cohort [340]. Nonetheless, the association of 
KRAS mutations with endometrioisis is further supported by in vivo work performed by Dinulescu et al 
in 2005 [213]. Here, activation of KRAS induced both peritoneal endometrioisis and benign ovarian 
epithelial lesions with glandular endometrioid morphology. A further loss of PTEN resulted in the 
development of invasive EnOC. Together, these data support KRAS mutations to be an early event in 
the pathogenesis of EnOC. 
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1.5.8.5 Mismatch repair deficiency and microsatellite instability 
The MMR system is important in maintaining genomic fidelity [343]. It recognises and repairs small 
base-base insertion/deletion mutations that occur frequently during DNA replication due to errors made 
by DNA polymerase. It also repairs mis-paired bases caused by exogenous chemicals (e.g. cigarette 
smoke, asbestos), environmental factors (e.g. ultraviolet light) as well as endogenous reactive oxygen 
and nitrogen species [344]. The MMR system therefore prevents the accumulation of DNA errors and 
thus fixed mutations during cell proliferation by 100-1000 fold [343]. 
 
There are 7 major genes which encode for enzymes involved in MMR.  They include the MutS-homologs 
(MSH2, MSH3 and MSH6) and the MutL homologs (MLH1, MLH3, PMS1 and PMS2).  Microsatellites 
are multiple tandem repeats of 1-6 nucleotides distributed within the genome. These are vulnerable to 
insertion/deletion mutations and defects in any one of the MMR genes causes an abnormal 
accumulation of microsatellites repeats resulting in MSI. MSI in oncogenes or tumour suppressor genes 
increase susceptibility to damaging frameshift mutations resulting in a truncated, non-functional protein 
or loss of protein, both which drive tumorigenesis [343]. 
 
Deficiency in MMR (dMMR) can be caused by both genetic and epigenetic defects in any one of the 
MMR genes. In germline dMMR, the wild-type allele can be inactivated via somatic nonsense mutations, 
LOH or by methylation, resulting in the second ‘hit’ in hereditary cancers. In sporadic cancers due to 
somatic dMMR, the most common mechanism is via MLH1 promoter hypermethylation, and less 
commonly, biallelic inactivation of MMR genes. In colorectal cancers, MLH1 promoter methylation 
correlates with BRAF V600E mutations and negatively predicts for germline MMR mutation status [345].   
 
Lynch syndrome (LS) is an autosomal dominant disease caused by germline MMR gene mutations 
which cause several malignancies associated with younger age of onset [346]. 90% of LS are due to 
germline mutations in MLH1 and MSH2, whilst MSH6 and PMS2 are much rarer, occurring in 7-10% 
and <5% of cases, respectively [346]. Germline mutations in PMS1, MSH3 and MLH3, are very rare 
[347]. Colorectal and gynaecological cancers are the two most common LS associated cancers [348]. 
In LS, the cumulative lifetime risk of colorectal cancers is 50-70% [348], 40-60% for endometrial cancer, 
and 12%-17% risk for EOC [346, 348]. Other associated malignancies include upper gastrointestinal, 
urothelial, prostate and brain tumours. The age of onset and cumulative lifetime risk of these cancers 
also differs according to each germline MMR gene mutation [349]. In the largest prospective 
observational study published of 3119 women, the cumulative incidence at 75 years for LS associated 
gynaecological cancers was 10.1%, 16.9%, 13.1% and 0% for ovarian cancers, and 42.0%, 56.7%, 
46.2% and 26.4% for endometrial cancers, in MLH1, MSH2, MSH6 and PMS2 carriers, respectively 
[348]. The age of onset was more likely to be under 40 years of age for MLH1 and MSH2 mutations, 
and over 40 years in those with MSH6 and PMS2 mutations.  Similar findings were demonstrated in 
another large retrospective study of 1063 patients [350]. Furthermore, women with truncating MLH1 
mutations developed endometrial cancer at an older age than those with non-truncating mutations 
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(P=0.002) in this study [350]. Together, these studies conclude that cancer surveillance for patients with 
LS could potentially be tailored according to type of mutation.  
Both MMR IHC and MSI testing are useful surrogate screening tools for dMMR tumours. The biological 
rationale and interpretation of MMR IHC is discussed in detail in section 2.5.1.2.  MSI is evaluated from 
a panel of five validated microsatellites [351]. They include two mononucleotides BAT25 and BAT26, 
as well as three dinucleotides, D2S123, D5S346 and D17S250. MSI status is then classified as MSI-
high (at least two unstable markers), MSI-low (one unstable marker), and microsatellite stable (MSS) 
(no unstable markers). In colorectal cancer, MSI testing and MMR IHC demonstrate good concordance 
and has an overall reported sensitivity and specificity of more than 90% [351].  
Approximately 30% of endometrial carcinomas and 18% of colorectal carcinomas are dMMR. Most are 
somatically acquired although 6% and 3% are due to LS, respectively [352]. In colorectal cancers, the 
Amsterdam II and revised Bethesda guidelines based on age, personal and family history were 
developed to help identify patients with LS [353]. However, universal MMR testing in colorectal 
carcinomas is now recommended due to the prognostic and predictive significance of detecting dMMR 
[354].  This practice is similarly starting to emerge for endometrial carcinomas in North American centres 
but has not been established worldwide [355]. In both colorectal and endometrial carcinomas, dMMR 
is associated with improved prognosis over MMR proficient (pMMR) tumours [353, 356].  In colorectal 
cancers, dMMR predicts for chemotherapy resistance to 5-flurouracil [357], although this association is 
less established in endometrial carcinomas. Furthermore, there is now emerging data suggesting that 
MSI-high tumours have better responses to immune checkpoint inhibitors [358]. On this basis, the 
United States Federation of Food and Drug Administration recently granted accelerated approval for 
pembrolizumab, an immune check point PD1 inhibitor, for all MSI-high or dMMR tumours. Tumour 
mutation burden (TMB) is also associated with MSI status. MSI-high tumours are usually hyper-mutated 
due to dMMR, ranging from 10 to 100 mutations per Mb, whereas MSS tumours exhibit lower mutation 
frequencies between 1 to 10 mutations per Mb. TMB correlates with the level of neo-antigens thus 
increasing the immunogenicity of tumours [359]. High TMB (approximately above 10 mutations per Mb) 
is increasingly recognised as a predictive biomarker for immune checkpoint inhibitors, although the 
exact thresholds for different malignancies has not been formally established [359]. Emerging work is 









1.5.8.5.1 Mismatch repair deficiency in EnOC  
Whilst dMMR in colorectal and endometrial carcinomas has been extensively investigated, data on 
dMMR in EOC is relatively sparse. Overall, 2%- 29% of EOC display dMMR by loss of IHC expression, 
and 5-15% display MSI [343]. Meta-analyses performed by Pal et al and Murphy et al finds the pooled 
proportion of MSH-high EOC to be 10-12% [347, 360]. Germline dMMR is rare and only accounts for 
1-2% in EOC [343, 361].Some studies performed to date have found dMMR EOC correlates with the 
MSI-high phenotype [362-364], whereas others have demonstrated poor concordance [365, 366]. 
dMMR occurs most commonly in non-HGSOC tumours, with highest frequencies observed in EnOC 
followed by CCOC [361, 367, 368]. In contrast, very low frequencies of one percent or less have been 
observed in HGSOC [352, 369, 370]. LS associated EOC tends to occur in younger women (median 
45 years) of non-serous histology with early stage disease and good prognosis. Amongst patients with 
LS, the highest frequencies of EOC are observed in EnOC (19%-35%) followed by CCOC (12%-17%) 
[346, 367, 371].  In line with this, the most recent College of American Pathologists guidance now 
recommends universal MMR screen for EnOC and CCOC. This practice is however not established 
worldwide.  
In contrast to endometrial carcinomas, the frequency of dMMR (by IHC) in EnOC is lower at 7-14% 
[255, 302, 352, 361, 372]. The prognostic role of dMMR in EnOC is less certain. Rambau et al evaluated 
MMR status in 104 pathology reviewed EnOC. In this study, the prevalence of dMMR was 13.8% [352]. 
Cases with loss of MSH2/MSH6 were more likely to present at a younger age compared to those who 
were MMR proficient (44.4 years versus 54.8 years; P=0.0024), whereas no differences were observed 
in age of onset for patients with loss of MLH1/PMS2. Cases with MSH2/MSH6 loss had higher CA125 
levels at diagnosis, whereas MLH1/PMS2 loss cases were more likely to present with higher grade 
disease and synchronous EnEC. Overall, no differences between DSS and RFS was observed between 
dMMR and MMR proficient tumours in EnOC of all grades and stages. In contrast, Parra Herran et al 
found in a cohort of 97 pathological reviewed EnOC, tumours with dMMR had superior outcomes 
independent of grade and stage [302].  
A few studies have also evaluated the association between dMMR EnOC and histo-pathological 
features in order to guide MMR testing. In Aysal et al, they found the lack of an adenofibromatous 
background was predictive of MMR loss, however peritumoral lymphocytes and tumour infiltrating 
lymphocytes were rare in 71 EnOC [373]. This low frequency was also confirmed by Chui et al in 20 LS 
associated ovarian carcinomas, of which 14 were EnOC [374]. This finding contrasts with those of 
Rambau et al which found that at least 20 CD8 positive TILs per high powered field (HPF) was 
independently associated with dMMR although reported poor sensitivity and specificity of this test [352]. 
Bennet et al found TILs to average 47/10 high powered fields with no association of clinico-pathological 
features with dMMR [372]. These studies conclude that universal reflex MMR testing of EnOC may be 
warranted.  The immunogenicity of EnOC was explored in the study by Wang et al which performed 
whole genome sequencing of 29 EnOC. Here, of the third of tumours which displayed MSI, higher 
number of immunogenic epitopes were observed compared to MSS cases (P=0.0023) [375]. This 
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suggested greater neo-antigen generation in these cases, and the authors conclude that EnOC may be 
candidates for immune checkpoint inhibitors.  
1.5.8.6 Molecular stratification of endometrial carcinomas and EnOC 
The landmark endometrial carcinoma TCGA study performed multi-platform analysis incorporating 
somatic copy number alterations (CNA), single nucleotide variants and TMB. It identified 4 molecular 
groups which were: i) POLE-mutant, ii) MSI-high (MSI-H), iii) copy number low (CN-low) and iv) copy 
number high (CN-high; serous like) [356].  Each molecular group demonstrated distinct genomic 
aberrations and differing survival outcomes. The POLE-mutant group displayed the best PFS of the 
four groups. This ultra-mutated copy number stable group had recurrent mutations in the exonuclease 
domain of DNA polymerase episilon (POLE) and was characterised by an extremely high somatic 
mutation burden of greater than 100 mutations per megabase. Notably, tumours in the POLE-mutant 
group also demonstrated diverse morphologies. The MSI-H group was a hyper-mutated group with 
mutations in MMR genes and high mutational frequencies of greater than 10 mutations per Mb. This 
group comprised predominantly endometrioid histologies. The CN-low group was MMR proficient and 
characterised by genomic stability with mutations in the PI3K/AKT and Wnt signalling pathways. This 
group was exclusively made up of EnEC with high expression of ER and PR. The CN-high group 
demonstrated high somatic CNA with frequent TP53 mutations and displayed the worst PFS (Figure 2) 
[356].  
The PROMISE algorithm was developed and proposed as a more pragmatic algorithm stratifying 
endometrial carcinomas into the four prognostic groups, outcomes which mirror that of the pivotal TCGA 
study (Figure 3) [376]. When it was applied to the intermediate and intermediate-high risk early stage 
patients as part of the PORTEC 1 and 2 clinical trials, integrated use of the PROMISE algorithm with 
traditional clinico-pathological factors resulted in improved risk stratification [377, 378]. Those with 
POLE mutant endometrial carcinomas had no loco-regional recurrences whereas those with p53 mutant 
IHC expression had a 6 fold increase in loco-regional recurrences when compared to those with p53 
wild-type IHC expression [378].  
Figure 2: Progression free survival of molecular groups identified from the endometrial TCGA. 





Figure 3: PROMISE algorithm reflecting the molecular groups identified in the endometrial TCGA. The first 
step utilised mismatch repair (MMR) immunohistochemistry (IHC) to identify MMR deficient tumours, this is followed 
by testing for POLE exonuclease domain mutations (EDM), and finally for aberrant p53 expression on IHC. Figure 

















The findings of the endometrial TCGA study prompted a similar analysis in EnOC. Parra-Herran et al 
applied the PROMISE algorithm to 72 contemporary pathology reviewed ovarian EnOC [302]. In this 
study, only WT1 negative samples with at least one confirmatory endometrioid feature were included. 
The five year RFS of the three main prognostic groups in this cohort were 100% in the POLE mutated 
(n=7; 10%) and dMMR tumours (n=6; 8%), 82% and 42% in the p53 wild-type (n=42; 58%) and p53 
mutant expression groups (n=17; 24%), respectively. The molecular classifier was found to be an 
independent prognostic factor on multivariable analysis which accounted for stage and grade, but not 
residual disease [302].  
Three studies have performed whole exome and whole genome sequencing of EnOC. In Teer et al, a 
cohort of non-serous tumours underwent WES and target gene sequencing of 1321 genes [379]. These 
included six pathology reviewed stage I EnOC (three grade 1 and three grade 2) for WES, and 14 EnOC 
(grade not reported) for targeted sequencing. The frequencies of common EnOC mutations were similar 
to that described earlier (Figure 4).  Notably, TP53 mutations were in six of the 14 EnOC which 
underwent target gene sequencing but none in the WES cohort. Across both sequenced cohorts, 
BRCA2 mutations were identified in 5 EnOC (two truncating mutations, three missense mutations). All 
five of these tumours also had concurrent mutations in at least one classical EnOC genes (ARID1A, 
PIK3CA, PTEN, CTNNB1). The authors suggest that the findings of mutations in HRR genes may 





Figure 4: (A) Mutation profiles of six stage I grade 1 and 2 EnOC identified through whole exome 
sequencing analysis of paired tumour and normal samples. (B) Mutation profiles of 14 EnOC (unknown 
grade) identified through target gene sequencing. Asterixes indicate POLE proofreading domain mutations. 
Figure from Teer et al, Scientific Reports 2017 [379]. 
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In Wang et al, 133 ovarian tumours, which included 29 EnOC and matched normal samples, underwent 
whole genome sequencing and copy number analysis [375]. Information on grade or whether pathology 
review of these samples were performed were not available. Seven molecular groups were identified 
between and within each histological subtype. These groups were: i) G-BC (granulosa cell tumours with 
a mutation signature associated with breast cancer and medulloblastoma), ii) E-MSI (EnOC with a 
mutation signature of dMMR), iii) Mixture (HGSOC, CCOC and EnOC with no discriminant features), 
iv) C-APOBEC (CCOC with a mutation signature defined by activity of the AID/APOBEC family of 
cytodine deaminase), v) C-AGE (CCOC with a mutation signature associated with age of diagnosis); 
vi) H-FBI (HGSOC with a high frequency of fold-back inversions structural variants); and vii) H-HRD 
(HGSOC with frequent duplications or deletion rearrangements and characterised by a mutation 
signature of HRD). Within EnOC, three main molecular groups were identified (Figure 5). The first was 
the ultra-mutated group, characterised by a POLE mutation signature. The E-MSI group, in which a 
third of tumours clustered within, contained no focal CNAs with RPL22 mutations in 50% of the group. 
The MSS group, in which 40% contained TP53 mutations, lacked a strong genomic signature and 
clustered across the 6 molecular groups. Notably, 14% of EnOC in this study clustered in the H-HRD 
group, a finding similar to that of Teer at al. The MSS group also contained the highest proportion of 
CTNNB1 and KRAS mutations (Figure 6) [375, 379]. Interestingly, the number of immunogenic epitopes 
were higher in the E-MSI group compared to those in the MSS group (P=0.0023), suggesting that these 
tumours may derive benefit from immune checkpoint inhibitors [375, 380].  
 
Cybulska et al investigated the mutational landscape of EnOC without concurrent synchronous 
endometrial carcinomas and compared this to EnOC with synchronous endometrial carcinomas, 
HGSOC, and EnEC [381]. Eight tumours (all grades of EnOC) underwent massively parallel sequencing 
targeting 341-468 cancer related genes and the remaining 28 EnOC (unknown grade) underwent WGS 
(derived from the study performed by Wang et al [375]) (Figure 7). Here, the most commonly mutated 
genes were KRAS (42%), PIK3CA (39%), PTEN (33%), CTNNB1 (25%) and ARID1A (19%). 17% of 
tumours harboured TP53 mutations, whilst 19% were MSI-high. POLE mutations were infrequent (3%). 
Similar to Teer et al [379], 11% of EnOC harboured BRCA2 non-synonymous mutations (three 
missense and one truncating mutation) [381]. 
A formal comparison of 341 cancer-related genes was performed between pure EnOC with MSI-high 
and POLE exonuclease domain mutated EnOC removed, and HGSOC from TCGA [131, 381]. Here, 
KRAS, PIK3CA, PTEN and PIK3R1 were significantly more frequent in non-hyper-mutated pure EnOC 
compared to HGSOC, whereas TP53 was more significantly more frequent in HGSOC. When compared 
to EnEC from TCGA, similar genes were mutated albeit at different frequencies. PTEN, PIK3R1, 
ARID1A, KMT2D and CTCF were more commonly mutated in EnEC than pure EnOC, whereas KRAS 
and PIK3CA mutations were present at similar frequencies [381]. These differences held true when 
comparing pure EnOC to EnOC with synchronous endometrial carcinomas, consistent with the 
emerging data suggesting that EnOC with synchronous endometrial carcinomas are clonally related 
[236, 382]. Due to a higher proportion of grade 2 and grade 3 EnEC in the TCGA cohort, a matched 
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analysis with grade 1 and 2 EnEC was performed. Here only PTEN mutations were significantly lower 
in EnOC compared to EnEC [381].   
The PROMISE algorithm was subsequently applied to this cohort of tumours and all four molecular 
subtypes were identified. The POLE mutant (3% versus 11%) and MSI-high cohorts (19% versus 34%) 
in EnOC were numerically less frequent, whilst the p53 wild-type expression (copy-number low) (61% 
versus 47%), and p53 aberrant expression (copy-number high) (17% versus 9%) cohorts were more 
frequent, when compared to the corresponding surrogate cohorts in the endometrial TCGA. These 
differences were however not statistically significant. Furthermore, no significant differences in clinical 
outcome between the PROMISE cohorts in pure EnOC were observed.  
 
Figure 5: Molecular subgroups of EnOC. 
Figure from Wang et al, Nature 2017 [375]. S.POLE= POLE mutations signature; E-MSI= microsatellite unstable 
tumours with a mismatch repair deficient mutation signature; MSS= microsatellite stable tumours.  
Figure 6: Oncoplot displaying frequent mutations in EnOC in MSI-high versus MSS tumours. 






Figure 7: Oncoplot displaying non-synonymous mutations identified following whole genome sequencing 
(n=28; black box) and massively targeted parallel sequencing (n=8; grey box) identified in EnOC.  
Figure from Cybulska et al, Gynecologic Oncology 2019 [381]. 
 
These three studies investigating the molecular landscape of EnOC demonstrates that it is a molecularly 
heterogeneous disease. However, all of these studies have analysed small patient cohorts which have 
lacked the statistical power to correlate molecular events to patient outcome. Furthermore, whether 
high grade EnOC constitutes a unique entity both clinically, pathologically and at the molecular level, or 
simply a pathological variant of HGSOC, continues to remain elusive.  
1.5.9 Aims and hypothesis 
The hypothesis of this study is that there are pathological and molecular subgroups of endometrioid 
ovarian carcinoma that correlate with clinical outcome.   
The objective of this study is to answer the following clinical and scientific questions:  
 How do WT1 negative EnOC behave as a clinical entity? 
 What are the predominant genetic mutations that occur in EnOC? 
 Are there any mutationally defined molecular subgroups within low and high grade EnOC and 
how do they correlate with clinical outcome? 
 What is the prognostic and predictive value of ER, PR and AR expression in EnOC? 
 Are low and high grade EnOC different diseases at the clinical and genomic level, and should 
a two-tier grading system be used instead? 
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2.1 Ethical approval 
Pathology samples obtained before 1st September 2006 are automatically covered by the Human 
Tissues Act Scotland 2006. All subsequent human tissue specimens used for research have ethical 
approval obtained from South East Scotland Scottish Academic Health Sciences Collaboration 
(SAHSC) BioResource (reference: 15/ES/0094-S494). Correlation of molecular data to clinical outcome 
and clinico-pathological variables in ovarian cancer was approved by NHS Lothian Research and 
Development (reference 2007/W/ON/29).  
2.2 Pathology review  
Between August 1968 and May 2014, 505 patients were identified through the Edinburgh ovarian 
cancer database with a diagnosis of EnOC or mixed tumours with an endometrioid component.  234 of 
these cases were not evaluable, with the majority (n=216) due to irretrievable tumour blocks.  Of the 
remaining 271 cases, the most representative sample from the primary tumour site from corresponding 
pathology reports and pre-existing haematoxylin and eosin (H&E) slide series (n=89) were identified. 
Only baseline chemotherapy naïve samples were included due to the recognised effect of 
chemotherapy on morphology [383]. Six tumours were identified as endometrial cancer metastases 
(n=6) and excluded. Of the remaining 265 tumours, six 5μm sections were taken from the selected 
archival formalin fixed paraffin embedded (FFPE) tumour block and stained for H&E WT1 (DAKO, clone 
6F-H2; 1:1000 dilution) and p53 (DAKO, clone DO-7; 1:50 dilution) (details in section 2.3).  
Pathology review was conducted as per WHO 2014 classification by an expert gynaecological 
pathologist (CSH). The presence of endometriosis (Figure 9B) or synchronous endometrial carcinomas 
were recorded either from the reviewed slide/s or if mentioned in the pathology report. Following WT1 
and p53 immunohistochemistry (IHC), tumours excluded were: 1) WT1 positive HGSOC (n=109), 2) 
WT1 positive mixed grade 1 and 3 EnOC (n=1), 3) tumours of other histology (n=19), and 4) tumours 
with non-evaluable clinical outcome data (n=2) (Figure 8). Six WT1 positive p53 wild-type expression 





Figure 8: Consort diagram of the pathology review process. 
Legend: NE=not evaluable; IHC=immunohistochemistry; +ve=positive; -ve=negative; HGS=high grade serous 
morphology; EnOC=endometrioid; LGSOC=low grade serous; CrC=colorectal carcinoma; mut=mutant; 





CK7 (Leica, Clone RN7, 1:100 dilution) and CK20 immunostaining (Leica, clone KS20.8, 1:50 dilution) 
was performed on the remaining 128 WT1 negative tumours and the six WT1 positive low grade EnOC 
to exclude colorectal metastases (n=1 identified) (details in section 2.3.2). The remaining 127 WT1 
negative tumours were assigned to three IHC cohorts based on p53 expression pattern and tumour 
grade:  
o Group 1: WT1 negative, p53 wild-type expression, low grade EnOC (n= 87) (grade 1 
(Figure 9C), grade 2 (Figure 10A)) 
o Group 2: WT1 negative, p53 mutant expression carcinomas (low grade EnOC and 
high grade carcinomas) (n=28) 
o Group 3: WT1 negative, p53 wild-type expression high grade carcinomas (n=12).  
WT1 negative high grade carcinomas in this study included those with the histological appearances of 
grade 3 EnOC (Figure 10B), HGSOC (Figure 11A), and undifferentiated carcinomas (Figure 11B), due 
to the recognised morphological overlap displayed by these tumours. As discussed extensively in 
chapter 1, WT1 negativity is a useful and validated marker in distinguishing HGSOC from grade 3 EnOC 
[229]. Undifferentiated carcinomas were also included due to the association with low grade EnOC as 
distinct de-differentiated carcinomas with emerging data to support a clonal relationship between each 

















Figure 9: H&E stain of grade 1 EnOC (A) arising from adjacent endometrioisis (B). H&E stain of grade 1 
EnOC (C). 
 
Figure 10: H&E stain of grade 2 (A) and grade 3 (B) EnOC. 
 
Figure 11: H&E stain of WT1 negative carcinoma with high grade serous morphology (A), and WT1 negative 







2.3.1 WT1 and p53 IHC staining  
Both IHC staining for WT1 and p53 were performed on the Leica Bond III machine as per protocol F. 
WT1 staining was performed using a 1:1000 dilution of the monoclonal mouse anti-human WT1 
antibody clone 6F-H2 (DAKO) (antigen retrieval Bond solution 2: 20 minutes). Tumours with any WT1 
nuclear positivity were considered WT1 positive (Figure 12(i)), while complete absence of nuclear WT1 
with internal control vascular positivity was considered WT1 negative (Figure 12(ii)). p53 IHC staining 
was performed using a 1:50 dilution of the monoclonal mouse anti-human p53 antibody cloneDO-7 
(DAKO) (antigen retrieval Bond solution 1: 20 minutes). A tissue section of HGSOC showing both WT1 
positivity and aberrant diffuse (mutant) p53 positivity served as a control for both IHC stains.  
P53 IHC staining was evaluated according to three staining patterns. Two patterns have been shown 
to correlate with a TP53 mutation [384, 385]. The first is a strong and diffuse nuclear stain pattern 
indicative of missense mutations; this was recorded as ‘aberrant diffuse’ (Figure 13(i)). The second 
pattern is complete lack of nuclear staining which is associated with nonsense mutations; this was 
recorded as ‘null’ (Figure 13(ii)). Both aberrant diffuse and null patterns were termed p53 mutant 
expression. The third pattern is variable nuclear expression of the p53 immunostain due to the relative 
instability of the protein due to its short half-life in p53 wild-type samples [385].  This was recorded as 
‘p53 wild-type’ (Figure 14). Positive nuclear staining of stromal cells served as internal controls and was 
an absolute requirement for identification of the ‘null’ pattern. Tumours which exhibited cytoplasmic 













Figure 12(i): Diffusely strong nuclear positive WT1 immunohistochemistry stain (A) with negative non-
vascular stroma (B). Figure 12(ii): Negative WT1 immunohistochemistry stain (A) with positive vascular 
endothelial cells as an internal control (B). 
 
Figure 13(i): Aberrant diffuse p53 immunohistochemistry stain. Figure 13(ii): Null p53 
immunohistochemistry stain (A) with positive stroma (B) as an internal control.  
 




2.3.2 CK7 and CK20 immuno-staining 
All samples in the WT1 negative primary cohort and the WT1 positive low grade EnOC cohort 
underwent CK7 (Figure 15A) and CK20 immunostaining (Figure 15B). Samples which were CK7 
negative and CK20 positive were diagnosed as likely colorectal metastases and excluded. Antibody 
staining was performed using the Leica Bond III autostainer using Protocol F.  
 
Figure 15: CK7 positive immunohistochemistry (A), CK20 negative immunohistochemistry (B). 
CK7 staining was performed using a 1:100 dilution of the monoclonal mouse CK7 antibody (Leica, 
Clone RN7, Hier1 – 20 minutes). A WT1 positive p53 aberrant expression HGSOC tissue section was 
used as a control. CK7 staining was considered positive with any positive nuclear staining of tumour 
cells.  
CK20 staining was performed using a 1:50 dilution of the monoclonal mouse CK20 antibody (Leica, 
clone KS20.8, Hier1-20 minutes). Normal stomach tissue was used as a control. CK20 staining was 












2.4 Clinical data extraction 
Clinico-pathological variables and outcome data were prospectively entered into a database for each 
patient as part of routine care. Baseline characteristics including age, date of diagnosis, date and cause 
of death, stage at diagnosis, residual disease following surgery and details of surgical staging were 
extracted from the Edinburgh Ovarian Cancer database. Due to the variable definitions used to record 
data over time, I manually reviewed all patient case notes to ensure a consistent approach was used. 
In particular, all patients with a residual disease recorded as <2cm were specifically reviewed. Cases 
with a clinical annotation or surgical note stating complete cytoreduction was achieved were recorded 
as 0cm. Full surgical staging was defined in my study as total abdominal hysterectomy, bilateral 
salpingo-oophorectomy, omental biopsy or omentectomy, and washings. Patients who underwent 
systematic lymph node sampling or lymphadenectomy were recorded. Patterns of first relapse for stage 
I and II disease and sites of disease at presentation for stage IV patients were also recorded.  
Data capture was censored as of 4th September 2017. DSS was recorded as the duration between the 
date of diagnosis and date of death from ovarian cancer. RFS was recorded as the duration between 
the date of diagnosis and the date of first radiological progression or recurrence, or death from EnOC.  
Treatment characteristics including type, line of treatment, indication, duration of therapy, and reasons 
for treatment cessation were recorded. Patients were evaluable for radiological responses if baseline 
radiological imaging was performed within six weeks of the start of therapy with measurable disease, 
and had follow up radiological imaging during their treatment following at least 3 cycles of platinum 
based chemotherapy. As many patients did not have measurements on their radiology reports, best 
radiological response was documented as per the reporting radiologist across the duration of therapy. 
In order to prevent overestimation of radiological response rates, only patients with at least a 30% 
decrease in the sum of measurements provided on the report were considered to have a partial 
response (PR). Patients with complete response (CR) or progressive disease (PD) were recorded as 
per the reporting radiologist. If the radiologist reported a response with no measurements provided, 
they were recorded as stable disease (SD). Patients who had complete macroscopic cytoreduction with 
no baseline imaging who then developed new metastases after at least 3 cycles of platinum based 
chemotherapy were considered to have PD. 
The best CA125 response to platinum based chemotherapy across the duration of therapy was also 
recorded. Due to the variable frequency of CA125 measurements, a modified GCIG criteria was 
adopted [386]. Patients were evaluable for CA125 response if they had an evaluable CA125 (>70U/ml) 
within four weeks of starting therapy, and had at least a further 2 CA125 responses recorded, with the 
last value within 4 weeks of completion of treatment. A second CA125 value at least 4 weeks after a 
CA125 CR or PR was required as confirmatory evidence. Patients who received post-operative platinum 
based chemotherapy following complete macroscopic cytoreduction were not considered evaluable for 
CA125 response due to the effect of surgical cytoreduction on CA125. Patients with residual disease 




In patients who received endocrine therapy, CA125 was most commonly used by clinicians as a marker 
of response. Radiology was only performed when there was evidence of a significant rise in CA125 or 
symptomatic deterioration. As such, radiological PFS could not be accurately defined in this study. 
Endocrine therapy was continued until there was symptomatic disease progression prompting further 
chemotherapy. Thus, the duration of therapy was recorded as an objective end-point and surrogate of 
endocrine sensitivity. 
 
 In addition to the CA125 evaluability criteria for those receiving platinum based chemotherapy as 
outlined above, patients were evaluable for CA125 response if they received endocrine therapy as 
treatment for at least four weeks duration, and if they had at least three CA125 values if they received 
endocrine therapy for greater than 12 weeks. If endocrine therapy was received for 12 weeks or less, 
two CA125 values were required with the second CA125 within 4 weeks of therapy cessation. Patients 
treated for less than 12 weeks but with clear CA125 progression were also considered evaluable. 
Patients with one CA125 measure, or if they received endocrine therapy for 12 weeks or less with no 
CA125 progression were not evaluable. The 12 week threshold was used as this has been shown to 
be the median time to a CA125 response to endocrine therapy [112]. 
 
The definitions of CA125 response were as per GCIG criteria. SD was defined if maintained for at least 
12 weeks from treatment initiation. Progressive disease (PD) was defined as doubling of the baseline 
CA125 value. Response rates were calculated and recorded as follows: 
 CA125 overall response rate (ORR)=CR+PR 
 CA125 clinical benefit rate (CBR)= CR+PR+SD 
 
The change in rate of rise of CA125 can demonstrate activity of cytostatic agents such as tamoxifen 
[387]. Stanley et al (Appendix C) described a group of patients whose CA125 rose (PD in 12 weeks or 
less by GCIG criteria) than stabilised (<50% rise in CA125) for at least another 12 weeks [295]. This 
delayed SD cohort was found to remain on endocrine therapy for a significantly longer duration than 
those who had disease progression by CA125 GCIG criteria but without the subsequent period of 
stabilisation (196 days versus 84 days, P<0.0001) [295]. Patients who demonstrated delayed CA125 













2.5 Tissue Microarray construction 
Tissue microarrays (TMA) were constructed from the WT1 negative primary cohort (n=125) and the 
WT1 positive low grade EnOC cohort (n=6) using a Mini Core machine.  Six 0.8mm tissue cores were 
obtained from areas enriched for tumour using the marked H&E slide as reference. TMA triplicates were 
created for each patient sample and stained for 9 antibodies with appropriate controls. All IHC staining 
was performed on the Leica Bond III autostainer using protocol F. 
2.5.1 TMA immunohistochemistry 
All TMA IHC stain evaluation was performed initially by two independent observers (BS, YI) following a 
training session with CSH on each antibody. Cores with discordant scores were then reviewed together 
with a third observer (CSH) and a consensus score was obtained. All observers were blinded to the 
clinical outcome of each case. 
2.5.1.1 Hormone receptors (ER, PR and AR) 
ERα (referred to as ER from henceforth) staining was performed using a 1:50 dilution of the monoclonal 
rabbit anti-human ER antibody clone M3643 (DAKO, Clone EP1, antigen retrieval tris EDTA ph9, 
epitope retrieval solution (ERS 2) - 20 minutes). PR staining was performed using a 1:50 dilution of the 
monoclonal mouse anti-human PR antibody clone M3569 (DAKO, clone PgR 636, antigen retrieval Tris 
EDTA ph9, ERS2- 20 minutes). AR staining was performed used a 1:50 dilution of the monoclonal 
mouse anti-human AR antibody M3562 (DAKO, clone AR441, antigen retrieval Tris EDTA ph9, ERS2- 
20 minutes). Normal breast tissue was used as the control for ER and PR, and normal prostate tissue 
for AR. 
Hormone receptor stain interpretation 
TMA cores were scored based on positive nuclear staining.  The area of each core occupied by tumour 
was recorded as a percentage and the stain intensity was recorded as 1+ (weak positivity), 2+ 
(moderate positivity) or 3+ (strong positivity) as compared to a validated breast carcinoma control. 
Areas of squamous differentiation which are usually ER negative were also included. Cores which were 
missing or with less than 10% tumour were excluded. A weighted histoscore accounting for the 
percentage of tumour (% tumour) and stain intensity (1+, 2+ or 3+) was recorded for each core as 
follows: (% 1+ tumour x1) + (% 2+ tumour x 2) + (% 3+ tumour x 3) (Figure 16). If the difference between 
histoscores between BS and YI was less than 50 points, the histoscore was averaged. If the difference 
was 50 points or greater, the core was reviewed together with CSH, who scored it independently; the 
middle score was recorded. At least two cores had to have an evaluable weighted histoscore for the 









The final histoscore for each case was calculated as follows:  
(core 1 Histoscore x A)  +  (core 2 Histoscore x B) +  (core 3 Histoscore x C)





Figure 16: Examples of IHC stain interpretation for ER, PR and AR: A: histoscore 300, B: histoscore 150, 

























2.5.1.2 Mismatch repair proteins  
The MMR antibodies used were MLH1, MSH2, MSH6 and PMS2. These antibodies were chosen as 
they are used by the National Health Service and are thus clinically validated. Normal small bowel was 
used as a control for all four antibodies. MLH1 staining was performed using a 1:25 dilution of the 
monoclonal mouse anti-human MLH1 antibody M364001-2 (Agilent, clone ES05, ERS2 - 60mins). 
MSH2 staining was performed using a 1:75 dilution of the monoclonal mouse anti-human MSH2 
antibody M363901-2 (Agilent, clone FE11, ERS2- 40 minutes). MSH6 staining was performed using a 
1:25 dilution of the monoclonal mouse anti-human MSH6 antibody M364601-2 (Agilent, clone EP49, 
ERS1-30 minutes). PMS2 staining was performed using a 1:40 dilution of the monoclonal mouse anti-
human PMS2 antibody M364701-2 (Agilent, clone EP51, ERS2-60 minutes).  
MMR stain interpretation 
For each core, any positive nuclear staining of tumour cells was recorded as ‘1’ for that antibody. 
Complete loss of nuclear staining of tumour cells with positive stromal cells as an internal control was 
recorded as ‘0’. Cores which were missing or had absence of staining for both tumour and stromal cells 
were not evaluable. For each antibody, the case was considered ‘intact’ if at least 1 core was recorded 
as ‘1’, and considered as ‘loss’ if all cores were recorded as ‘0’ (Figure 17). Cases with at least one 
evaluable core were included in the analysis. 
 
The four main genes involved in DNA mismatch repair are MLH1, MSH2, MSH6 and PMS2 [388]. In a 
normal cell, MLH1 forms a heterodimer with PMS2 and MSH2 with MSH6. Both MLH1 and MSH2 are 
obligatory partners whereas PMS2 and MSH6 are secondary partners. Mutations in the MLH1 or MSH2 
genes disrupt the heterodimer resulting in degradation of PMS2 and MSH6, respectively. Conversely, 
mutations in PMS2 and MSH6 may not result in degradation of their obligatory partners as both MLH2 
and MSH2 are able to dimerise with secondary proteins such as PMS1 and MSH3 which compensate 
for the loss of the secondary protein [388]. In this study, MMR status was considered evaluable if at 
least PMS 2 and MSH 6 immunostains were evaluable. MMR was considered ‘not intact’ if the following 





Figure 17: Example of MMR IHC staining of all four antibodies in the same tumour: Intact MLH1 and PMS2 














Betacatenin staining was performed using a 1:100 dilution of the monoclonal mouse anti-human beta-
catenin antibody M353901-2 (Agilent, clone b-catenin-, ERS2- 20 minutes). Normal tonsil tissue was 
used as the control. 
Beta-catenin stain interpretation 
IHC can provide a surrogate measure of CTNNB1 mutations and has been shown to have 93-100% 
specificity and 80-85% sensitivity in EnEC [293]. Normal beta-catenin staining (i.e. wild-type CTNNB1) 
is expressed as membranous staining whereas CTNNB1 mutations are expressed as abnormal nuclear 
accumulation of the beta-catenin protein (Figure 18). 
For each core, beta-catenin staining was recorded as ‘0’ (i.e. no mutation) if all tumour cells exhibited 
membranous staining [293]. Membranous staining of stromal cells acted as an internal control. Any 
nuclear staining of tumour cells was recorded as ‘1’ (i.e. mutation present). Cores which were missing, 
or had less than 10% tumour cells were not evaluable. Cases with at least 2 evaluable cores were 
analysed. Cases were recorded as having an IHC staining pattern consistent with a beta-catenin 
mutation if at least one core was recorded as ‘1’.  
 
Figure 18: Example of beta-catenin IHC stain patterns: A: normal membranous staining of beta-catenin. B: 













PTEN staining was performed using a 1:100 dilution of the monoclonal mouse anti-human PTEN 
antibody (Sigma Aldrich, clone 6H2.1, ERS1 -20 minutes). Normal tonsil tissue was used as the control.  
PTEN stain interpretation 
Normal PTEN IHC expression occurs in both the nucleus and cytoplasm [389]. No ‘hotspot’ mutations 
exist. In general, loss of PTEN expression is associated with PTEN mutations, therefore a binary 
approach was adopted for this study [389, 390].  
For each core, PTEN staining on tumour cells was evaluated as ‘1’ if there was any nuclear and/or 
cytoplasmic staining, or ‘0’ if there was complete loss of staining with positive stromal cells as an internal 
control (Figure 19). Cores which were missing or had an absence of staining of both tumour and stroma 
were not evaluable. Cases with at least two evaluable cores were analysed.  Cases in which all cores 
were ‘1’ were recorded as ‘intact’. Cases in which all cores were ‘0’ were recorded as loss. Cases with 
discordant cores were recorded as ‘heterogeneous’.  
 
Figure 19: Example of PTEN IHC stain patterns. A: normal nuclear and membranous staining of PTEN. B: 











ARID1A staining was performed using a 1:100 dilution of the polyclonal mouse anti-human ARID1A 
antibody HPA005456 (Sigma Aldrich, ERS1- 20minutes). Normal endometrial tissue was used as the 
control.  
 
ARID1A stain interpretation 
ARID1A mutations result in truncated mRNA that degrades readily which results in the loss of protein 
expression [315]. Loss of ARID1A on IHC has been shown to have good concordance between IHC 
and its mutation status [391].  
For each core, ARID1A staining on tumour cells was evaluated as ‘1’ if there was any positive nuclear 
stain, or ‘0’ if there was complete loss of staining with positive stromal cell as an internal control (Figure 
20). Core which were missing or had an absence of staining of both tumour and stroma were not 
evaluable. Cases with at least one evaluable core were evaluable. Cases with at least one core with ‘1’ 
were recorded as ‘intact’. Case in which all cores were ‘0’ were recorded as loss.  
 
Figure 20: Example of ARID1A IHC stain patterns. A: normal nuclear staining. B: loss of nuclear staining 
with positive stromal cells as internal control. 
 
2.5.1.6 PIK3CA 
Staining for the PIK3CA antibody was not carried out due to discontinuation of the validated antibody 









2.6 Tumour FFPE macro-dissection and DNA extraction 
In section 2.2, the primary tumour cohort was assigned three IHC defined groups. The rationale for 
these groups were based on the following hypotheses: 
Group 1: The WT1 negative p53 wild-type IHC expression low grade EnOC tumours (n=23) were 
pathologically homogenous and as such were hypothesised to be so at the molecular level. 
Group 2 and 3: The WT1 negative p53 mutated expression IHC group which contained an admix of 
low grade EnOC and high grade carcinomas (n=28), and the WT1 negative p53 wild-type expression 
high grade carcinoma group (n=12) are likely to contain a mixture of molecular subtypes of EnOC 
including a subset of true high grade EnOC that could be defined genomically through whole exome 
sequencing (WES).  
As such, DNA extraction and whole exome sequencing on all of group 2 and 3, and a randomly selected 
cohort of group 1 was performed. During the pathology review process, tumours which were WT1 
positive but were histologically grade 1 or 2 (low grade) EnOC (n=6) were also identified. This group 
formed a distinct cohort of interest to the WT1 negative group and also underwent DNA extraction and 
subsequent WES. 
A total of 69 tumours underwent macro-dissection. Ten 10μm FFPE sections were obtained from the 
original selected tumour block. Each H&E slide was scanned onto the Nanozoom image viewer and the 
area of tumour was digitally marked out and verified by CSH. Tumour cellularity was also recorded. A 
minimum of four 10μm FFPE sections per sample were manually macro-dissected to enrich for tumour 
over stroma using the marked H&E slide as a guide. Sections with a low proportion of tumour had up 
to eight slides macro-dissected. 
 
DNA extraction was carried out using the QIAamp DNA FFPE Tissue Kit and Deparaffinization Solution 
according to the manufacturer’s instructions. DNA samples extracted from FFPE tissue were quantified 
using the Qubit 2.0 Fluorimeter (Thermo Fisher Scientific Inc) and the Qubit DNA BR assay kit. An 
aliquot of each sample was then sent for WES (Appendix A). Two WT1 negative p53 mutant IHC 
expression tumours failed DNA extraction and were thus excluded, leaving 61 samples in the main 











2.7 Whole exome sequencing 
Whole Exome Sequencing was performed by the Wellcome Trust Clinical Research Facility in 
Edinburgh. Exome capture was performed using the Illumina TruSeq Exome Library Prep kit. Libraries 
were prepared from each DNA sample using the Illumina TruSeq Exome Library Prep kit (#FC-150-
1002 - Illumina) according to the provided protocol using modifications for working with FFPE sourced 
material.  
200ng of DNA was end-repaired to remove 3’ and 5’ overhangs, and fragment length was optimised 
using sample purification beads. A single 'A' nucleotide was added to the 3' ends of the blunt fragments 
to prevent them from ligating to another during the subsequent adapter ligation reaction, and a 
corresponding single 'T' nucleotide on the 3' end of the adapter provided a complementary overhang 
for ligating the adapter to the fragment. Multiple indexing adapters were then ligated to the ends of the 
ds cDNA to prepare them for hybridisation onto a flow cell, before 12 cycles of PCR were used to 
selectively enrich those DNA fragments that had adapter molecules on both ends and amplify the 
amount of DNA in the library suitable for sequencing. Libraries were quantified using the Qubit 2.0 
Fluorometer and the Qubit DNA HS assay (#Q32854 - ThermoFisher) and the size distribution of 
fragments was assessed using the Agilent Bioanalyser with the DNA HS Kit (#5067-4626 - Agilent).  
DNA libraries containing unique indexes were combined in pools of six, and then target regions of the 
DNA were bound with capture probes. Streptavidin Magnetic Beads were then used to capture probes 
hybridised to the targeted regions of interest and a series of washes removed nonspecific binding from 
the beads. This process was repeated to ensure high specificity of the captured regions. Captured 
enriched library was then purified before eight cycles of PCR amplification and a final purification step 
to remove unwanted products.  
Exome-captured sequencing library pools were quantified using the Qubit 2.0 Fluorometer and the 
Qubit DNA HS assay (#Q32854 - ThermoFisher) and the size distribution of fragments was assessed 
using the Agilent Bioanalyser with the DNA HS Kit (#5067-4626 - Agilent). Fragment size and quantity 
measurements were used to calculate molarity for each library pool. 
WES was performed using the NextSeq 500/550 High-Output v2 (150 cycle) Kit (# FC-404-2002) on 
the Illumina NextSeq 550 (Illumina, Inc., San Diego, CA, USA), achieving a median per-sample mean 
target coverage of 148X (range 50X-327X). Three samples achieved <60M reads. Data was aligned to 
the human reference genome using bwa bwa-0.7.17 [392], duplicates marked and base quality scores 









2.8 Variant calling and classification 
The bioinformatics analysis pipeline was performed and analysed by Dr John Thompson, Dr Robert 
Hollis and the MRC Human Genetics Unit, University of Edinburgh. Variant calling was performed using 
a majority vote from three variant caller algorithms; VarDict [394], Mutect2 [395], Freebayes [396]. 
Filtering for C>T (FFPE artifacts) and G>T (oxidation artifacts) was applied using GATK 
(CollectSequencingArtifactMetrics and FilterByOrientationBias). Resulting VCF files were then 
analysed in R using the maftools package 
(https://bioconductor.org/packages/release/bioc/html/maftools.html.  
Datasets were filtered for common population variants using the 1000 genomes (1000 genomes phase 
1 snp and indel dataset; http://www.internationalgenome.org/ ) and the Exome Aggregation consortium 
(ExAC) reference datasets(ExAC.0.3.GRCh38 : http://exac.broadinstitute.org/ ). Using the 
Polymorphism Phenotyping (PolyPhen) [397] and/or Sorting Intolerant from Tolerant (SIFT) [398] 
prediction tools as well as the NCBI clinVar database (https://www.ncbi.nlm.nih.gov/clinvar/) which 
aggregates pathogenicity reports  associated with genomic variants, variants predicted not to affect 
protein function were discarded as likely non-functional events. Filtering was then applied to define high 
impact mutations where the variant allele frequency of a given mutation was > 10% across regions with 


















2.9 Analysis of mutational status 
Mutational and copy number analysis in sections 2.9, 2.10 and 2.11 was performed by Dr John 
Thompson. Supervised mutational analysis of the 61 WT1 negative samples was carried out by 
investigating the mutational landscape across 75 commonly mutated genes previously reported in either 
endometrial, ovarian or pan cancer studies (Appendix B) [131, 356]. This list of genes were curated by 
Dr John Thompson. The mutational status of these genes was visualised using the R package maftools. 
The same analysis was applied to the six WT1 positive low grade EnOC identified during the pathology 
review process.  
2.10 Unsupervised clustering analysis 
Unsupervised clustering analysis was performed across the top 100 differentially mutated genes within 
the dataset. Samples were clustered by Euclidian and Ward methods based on the overall Pearson 
correlation score of these binary signatures. Heat maps were drawn in R using the ggplot package 
[399]. 
2.11 Copy number variation (CNV) detection 
Copy number analysis was performed by using GeneCN pipelines using Bio-DB-HTS version 2.10 
(https://github.com/wwcrc/geneCN). Copy number (CN) analysis for the 75 gene panel described above 
was performed using GeneCN pipelines using Bio-DB-HTS version 2.10 
(https://github.com/wwcrc/geneCN) to identify significant CN gain or loss (CN score >3 standard 
deviations from reference, P<0.05) using the pooled WT1 negative TP53 wild-type (TP53wt) samples 
as a reference. Heat maps of CN gain and loss were drawn in R using the “heatmap2” function in the 
“gplots” package.  
2.12 Statistical Analysis 
All statistical analyses were performed using R version 3.5.1 by Dr Robert Hollis. Comparisons of 
continuous data were made with the Mann Whitney-U test or T-test, as appropriate. Survival analysis 
was performed using the Survival package in R using cox proportional hazards regression analysis 
[400]. Owing to the established concordance between TP53 mutations and p53 IHC [384], TP53 
mutation status was inferred as wild-type in p53 IHC wild-type samples to supplement multivariable 
analysis of this marker in the WES cohort (referred to as TP53 mutation status in the multivariable 
analysis). Multivariable analyses accounted for disease stage, patient age at diagnosis, decade of 
patient diagnosis and extent of residual disease following surgical cytoreduction. Comparisons of 
frequency as well as mutation status with IHC were performed using the Chi-squared test or Fisher’s 








































EnOC usually present as early stage, low grade disease and are associated with endometrioisis [209, 
220] and synchronous EnEC [129, 231]. Low grade EnOC are morphologically distinct with a classical 
IHC profile which is WT1 negative, p53 wild type expression, and strong ER expression [129, 226]. Due 
to refinement in pathological definitions over time, it is now recognised that many high grade EnOC are 
in fact misclassified HGSOC, a finding that is supported by several transcriptomic studies [243, 246-
248]. True high grade EnOC are increasingly rare and are challenging to diagnose. They share 
morphological overlap with both HGSOC, as well as the rare and aggressive de-differentiated 
carcinomas which are a mix of low grade EnOC and undifferentiated carcinoma [257]. As discussed in 
chapter 1, WT1 IHC is a useful and validated marker which can assist in discriminating between these 
sub-types (high grade EnOC; WT1 negative, HGSOC; WT1 positive), and can help reduce inter-
observer diagnostic variation  [224, 229, 230, 243].  
 
 In general, EnOC is regarded as having a better prognosis compared to HGSOC [226, 229, 272, 274], 
however it is less certain whether this is mostly due to the majority of EnOC presenting at an earlier 
stage. Moreover, most studies did not perform stage for stage comparison [274, 276-278] or 
contemporary pathology review according to WHO 2014 criteria on their cohorts [272, 279]. As such, 
these studies are likely to have included a proportion of misclassified HGSOC which would have 
influenced clinical outcomes. In those studies that did perform contemporary pathology review, most 
did not utilise IHC to confirm the diagnosis of high grade EnOC with a reliance on histology for 
pathological diagnosis [224, 226, 282]. This once again raises doubt as to the clinical outcomes reported 
in those studies as differentiation between HGSOC and high grade EnOC is a notorious area of poor 
reproducibility based on histology alone [229]. The clinical behaviour of high grade EnOC compared to 
HGSOC in terms of treatment responses and clinical outcomes have also been under-investigated 
[224]. 
 
The management of EnOC largely mirrors that of HGSOC. In Europe, the standard of care for surgery 
includes total abdominal hysterectomy, bilateral salpingo-oophorectomy, infracolic omentectomy, and 
lymph node sampling [2]. Systematic aortic and pelvic lymphadenectomy is however controversial [17]. 
In early stage EnOC, the rates of lymph node involvement are reported to be approximately 2% [284-
286], with some studies reporting higher rates for high grade EnOC [234]. Some retrospective studies 
performed have not found a survival benefit with lymphadenectomy [284-286], whereas other studies 
of historically diagnosed EnOC have found lymphadenectomy to be an independent factor of prognosis 
[286-289]. However, it is plausible that the presence of undiagnosed HGSOC in these cohorts may 




As discussed in chapter 1.5.7.2, the survival benefit of adjuvant chemotherapy in early stage EnOC is 
difficult to quantify as the early adjuvant trials performed included all histological subtypes of EOC [27]. 
Retrospective studies have been performed to identify prognostic factors in order to define a cohort of 
patients with EnOC who can be spared the toxicity of adjuvant chemotherapy. These have included 
grade [291], sub-staging of IC disease [274], ER and PR receptor status [255],-catenin and CDX2 
[293], and L1CAM [275]. However, these biomarkers were not investigated as a multi-marker panel in 
a comprehensive multivariable analysis. As such, it remains standard of care to consider adjuvant 
chemotherapy for all patients with stage 1C and above EnOC of any grade, and stage 1B grade 3 EnOC 
[41]. The management of advanced stage and relapsed EnOC is in line with that of HGSOC with 
platinum based chemotherapy forming the main stay of treatment. Maintenance PARP inhibitors are 
used for platinum sensitive relapsed high grade EnOC following a response to platinum based 
chemotherapy [149] or as first line maintenance treatment in germline BRCA mutated high grade EnOC 
[294]. As these tumours mostly display strong ER expression, endocrine therapy is often used as the 
preferred option at first relapse. The platinum sensitivity of EnOC is however not well understood and 
has been largely extrapolated from that of HGSOC. 
 
As described in chapter 2, pathology review performed in this study identified 125 WT1 negative 
carcinomas stratified by p53 IHC and grade. These three IHC defined cohorts were classical low grade 
EnOC (WT1 negative, p53 wild-type expression), low grade EnOC and high grade carcinomas with 
WT1 negative p53 aberrant IHC expression, and WT1 negative p53 wild-type expression high grade 
carcinomas. The WT1 negative high grade carcinomas included for review had high grade serous, high 
grade endometrioid and undifferentiated histology due to the well described morphological overlap 
between these tumours.  
In this chapter, it is hypothesised that the defined WT1 negative cohort in this study display favourable 
prognosis and platinum sensitivity lower than that reported in studies of platinum naïve or sensitive 
relapsed HGSOC. Although one of the objectives of this study was to clinically compare low grade 
EnOC with high grade EnOC, the pathological definitions used to define high grade disease included 
tumours with serous and undifferentiated morphology. Furthermore, there were insufficient numbers of 
tumours with histologically defined high grade EnOC. As such, this clinical comparison was not 
performed in this chapter. Instead, this chapter is purely descriptive, and presents the clinical 
characteristics, survival and platinum sensitivity of the WT1 negative cohort. It was also hypothesised 
that the presence of high grade carcinomas and that of low grade EnOC with aberrant p53 expression 
on IHC would impact on survival outcomes, as such the same clinical characteristics were reported 






3.2 Clinical characteristics  
WT1 negative cohort: 
In the WT1 negative cohort, 22 (17.6%), 48 (38.4%), 33 (26.4%), and 22 (17.6%) were diagnosed in 
the 1980s, 1990s, 2000s and 2010s, respectively. The median age of diagnosis was 58 years (range 
28 years to 88 years). Median body mass index of patients was 25.3 (range 18-44). Median size of the 
ovarian mass was 13.0cm (range 1.4cm to 30.0cm) of which 17.5% were bilateral. 20 (16.0%) had 
synchronous endometrial cancers, and 42 (33.6%) had endometrioisis. The majority of patients 
presented with stage I (40.0%) and stage II (37.6%) disease. Of these, the majority of stage I patients 
had IC disease (28 of 50; 56.0%) and stage II patients had IIC disease (30 of 47; 63.8%). Notably, 7 
(77.8%) stage IV patients had visceral metastases at presentation with liver metastases as the most 
common site (Figure 21).  
102 (81.6%) patients were surgically cyto-reduced to less than 2cm, of which 65 (52.0%) were recorded 
as 0 cm. 5 (4.0%) had unknown residual disease.  
Of the 97 patients with early stage (stage I and II disease), 74 (76.3%) underwent full surgical staging 
(defined as total abdominal hysterectomy, bilateral salpingo-oopherectomy, omental biopsy or 
omentectomy, and washings). Two patients underwent lymph node sampling whilst no patients 
underwent lymphadenectomy. One patient with stage IA disease underwent adjuvant chemotherapy 
due to the absence of lymph node sampling. 18 (18.6%) were under-staged, with the majority (12; 
66.7%) due to the omission of an omentectomy.   
Classical low grade EnOC: 
87 tumours were diagnosed as classical low grade EnOC (87.4% G1, 12.6% G2). Clinical 
characteristics are summarised in Table 6.  The majority of patients (75; 86.2%) presented with early 
stage disease with only 2.3% as stage IV. Most patients were surgically cyto-reduced to less than 2cm 
































Table 6: Clinical characteristics of the WT1 negative cohort (A) and classical low grade EnOC (B). 
    A: (n=125) B: (n=87) 
Variables   n % n % 
Age   58(28-88) - 57 (28-88)  - 
BMI (A: n=68; B: n=44)   25.3 (range 18-44) - 25(18-44)  - 
Endometrial cancer   20 16.0 17 19.5 
Endometrioisis   42 33.6 34 39.1 
Histology G1 EnOC 80 64.0 76 87.4 
  G2 EnOC 19 15.2 11 12.6 
  G3 EnOC 8 6.4 0 0.0 
  HGS 15 12.0 0 0.0 
  Undifferentiated 3 2.4 0 0.0 
Year of Diagnosis 1980s 22 17.6 17 19.5 
  1990s 48 38.4 30 34.5 
  2000s 33 26.4 26 29.9 
  2010s 22 17.6 14 16.1 
Stage I all 50 40.0 38 43.7 
  IA 20 16.0 14 16.1 
  IB 2 1.6 1 1.1 
  IC 28 22.4 23 26.4 
Stage II all 47 37.6 37 42.5 
  IIA 4 3.2 3 3.4 
  IIB 11 8.8 9 10.3 
  IIC 30 24.0 24 27.6 
  UK sub-staging 2 1.6 1 1.1 
Stage III all 17 13.6 8 9.2 
  IIIA 2 1.6 1 1.1 
  IIIB 2 1.6 1 1.1 
  IIIC 9 7.2 4 4.6 
  UK sub-staging 4 3.2 2 2.3 
Stage IV all 9 7.2 2 2.3 
  IVA 0 0.0 0 0.0 
  IVB 9 7.2 2 2.3 
UK stage   2 1.6 2 2.3 
Residual diseasea  <2cm
b 102 81.6 78 89.7 
 ≥ 2cm
C 18 14.4 6 6.9 
  UK 5 4.0 3 3.4 
Surgical staging (I+II) Fully staged 74 76.3 57 76.0 
(A: n=97; B: n=75) Under staged 18 18.6 13 17.3 
  UK 5 5.2 5 6.7 
Legend: G=grade; EnOC=endometrioid ovarian carcinoma; HGS=high grade serous morphology; BMI=body mass index; 
UK=unknown.aClassification of optimal surgical cytoreduction changed over time; some of the patients were diagnosed 
at a time when resection to <2cm was considered optimal. b65 (52%) patients were cyto-reduced to 0cm in the whole 
cohort. C 2 patients were inoperable.  
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3.2.1 Therapy received (WT1 negative cohort)  
67 (53.6%), 14 (11.2%), 10 (8.0%) received one, two and three lines of chemotherapy, respectively. 33 
(26.4%) received no chemotherapy. A total of 128 courses of chemotherapy were delivered, of which 
102 (79.7%) were platinum based. 84(82.4%) were delivered in the platinum naïve setting, 15 (14.7%) 
in the platinum sensitive setting, 1 (1.0%) in the partially platinum sensitive setting and 2 (2.0%) in the 
platinum resistant setting (Table 7).  
 In early stage disease (n=97), 66 (68.0%) patients received adjuvant chemotherapy, of which 57 
(86.4%) were platinum-based (Table 7). The median number of cycles received of adjuvant platinum 
chemotherapy was six (range 3-6), and 44 (77.2%) received all six cycles. In advanced stage disease 
(n=26), 19 (73.1%) patients received platinum based chemotherapy as their first line of treatment. The 
median number of platinum cycles received was six (range1-6), and 63.2% received all 6 cycles. 
Eight (6.4%) patients, of which five were classical low grade EnOC, underwent an attempt at secondary 
cytoreductive surgery as second line treatment. The median time to relapse was 2.8 years (1.4-6.1 
years). All 8 patients recurred as solitary masses (six pelvic, two nodal).  Six (75.0%) achieved complete 
macroscopic cytoreduction. Of these, only two patients died from ovarian cancer after a median follow 
up time of 11.5 years (4.0-24.2 years). 11 (8.8%) patients received endocrine therapy of which eight 


















Table 7: Treatment received by the WT1 negative cohort (A) and classical low grade EnOC (B). 
    A: (n=125) B: (n=87) 
Variables n % n % 
Chemotherapy none 33 26.4 26 29.9 
  1 line 67 53.6 48 55.2 
  2 lines 14 11.2 10 11.5 
  3 or more lines 10 8.0 2 2.3 
  UK 1 0.8 1 1.1 
No. of chemotherapy courses 
received 
Platinum 102 79.7 65 86.7 
(A:n=128; B:n=75) non-platinum 26 20.3 10 13.3 
Line of treatment platinum 
received in 
1 80 78.4 54 83.1 
(A:n=102; B:n=65) 2 17 16.7 9 13.8 
  3 3 2.9 2 3.1 
  4 2 2.0 1 1.5 
Platinum setting Naïve  84 82.4 56 86.2 




1 1.0 0 0.0 
  Platinum resistant 2 2.0 0 0.0 







Endocrine therapy none  112 89.6 78 89.7 
  1 line 9 7.2 7 8.0 
  2 lines 2 1.6 1 1.1 
  UK 2 1.6 1 1.1 
Adjuvant treatment stage I/II platinum only 33 34.0 23 30.7 
(A:n=97; B:n=75) platinum-taxane 21 21.6 17 22.7 
  platinum-other 3 3.1 3 4.0 
  chlorambucil 9 9.3 5 6.7 
  None 30 30.9 27 36.0 
  UK 1 1.0 1 1.3 
Adjuvant platinum stage I/II Median no. of cycles 6 (3-6) NA 6(4-6) NA 
(A:n=57; B:n=43) 6 cycles received 44 77.2 33 76.7 
First treatment Stage III/IV  platinum only 13 50.0 5 50.0 
(A:n=26; B:n=10) platinum-taxane 2 7.7 1 10.0 
  platinum-other 4 15.4 2 20.0 
  endocrine therapy 1 3.8 1 10.0 
  None 6 23.1 1 10.0 
platinum chemotherapy 
 (A;n=19; B:n=8) 
Median no. of cycles 6(1-6) NA 6(4-6) NA 





3.2.2 Overall Survival 
The median duration of follow up was 7.5 years (range 0.1-29.7 years). 61 (48.8%) deaths occurred, of 
which 38 (30.4%) were ovarian cancer related with the remaining 23 (18.4%) due to other causes. The 
overall median DSS and RFS was not reached at ten years. For the WT1 negative cohort, overall five 
year RFS and DSS was 69.1% and 73.2%, and ten year RFS and DSS was 63.6% and 67.0%, 
respectively (Table 8, Figure 22).  For the classical low grade EnOC cohort, overall five and ten year 
RFS was 83.0% and 76.7%, and DSS was 86.4% and 79.7%, respectively (Table 9, Figure 23). 
3.2.3 Survival by stage 
For the WT1 negative cohort, five and ten year DSS was 93.7% and 87.6% for stage I, 81.6% and 
71.1% for stage II, 29.4% for both in stage III and 0% for both in stage IV (Table 8, Figure 24). Median 
DSS for stage III and IV disease was 2.9 years and 0.7 years, respectively. In the classical low grade 
EnOC cohort, five and ten year DSS was 94.3% and 90.5% for stage I, and 88.5% and 75.4% for stage 
II disease, respectively. Five and ten year DSS for advanced stage disease (n=10) was 50.0% with a 
median of 7.8 years (Table 9, Figure 25). Similar patterns were observed for five and ten year RFS in 
both cohorts. Median RFS and DFS was not reached for early stage disease.  
3.2.4 Other clinical variables of prognosis 
Upon univariable analysis, only age, grade and residual disease was significant for RFS and DSS, 
whereas no differences were observed for decade of diagnosis (Table 10). Multivariable analysis was 
















Table 8: Survival by stage in the WT1 negative cohort (n=125).   
























Overall N/R 73.2 67.0 - N/R 69.1 63.6 - 
Stage I 
(n=50) 











































Legend: N/R=not reached. 2 patients had unknown stage. 
 
Table 10: Univariable analysis of clinical prognostic variables.      
Variable   Disease specific survival Relapse free survival  
    HR (95% CI) P HR (95% CI) P 
Decade of diagnosis 1980s ref   ref   
  1990s 1.03(0.47-2.29) 0.935 0.84 (0.39-1.81) 0.667 
  2000s 0.63 (0.24-1.62) 0.335 0.58 (0.23-1.42) 0.233 
  2010s 0.26 (0.06-1.21) 0.085 0.37 (0.12-1.19) 0.095 
Residual diseasea <2cm 0.03 (0.01-0.07) <0.001 0.04 (0.01-0.09) <0.001 
  2-5cm 0.3 (0.10-0.83) 0.021 0.31 (0.11-0.86) 0.025 
  >5cm ref   ref   
Age years 1.05 (1.01-1.08) 0.006 1.03 (1.00-1.06) 0.031 
Grade 1 0.19 (0.09-0.40) <0.001 0.23 (0.12-0.46) <0.001 
  2 0.61 (0.26-1.42) 0.248 0.87 (0.40-1.93) 0.74 
  3 ref   ref   
Legend: aClassification of optimal surgical cytoreduction changed over time; some of the patients were diagnosed at 
a time when resection to <2cm was considered optimal. 
 
Table 9: Survival by stage in classical low grade EnOC (n=87).   
























Overall N/R 86.4 79.7 - - N/R 83.0 76.7 - -  
Stage I 
(n=38) 











    N/R 88.5 75.4 
0.27  
(0.09-0.81) 







7.8 50.0 50.0  ref ref  2.0 40.0 40.0 ref   ref 
Legend: NR=not reached. 2 patients had unknown stage. 
93 
 
Figure 22: Overall disease specific survival (A) and relapse free survival (B) in the WT1 negative cohort. 





Figure 24: Disease specific survival (A) and relapse free survival (B) by stage in the WT1 negative cohort. 
 
Figure 25: Disease specific survival (A) and relapse free survival (B) by stage in the classical low grade 







3.3 Characteristics and survival of stage I disease 
22 patients were diagnosed with stage IA/IB disease (Table 11). Ten year RFS and DSS was 82.5% 
and 80.6%, respectively. 14(63.6%) underwent full surgical staging and 5 (22.7%) received adjuvant 
platinum chemotherapy. The three patients who died of their disease had G1 EnOC, G3 EnOC and 
undifferentiated carcinoma, and recurred at 6.3 years, 7.4 years and 0.1 years, respectively.  
Of the 28 patients diagnosed with stage IC disease, 71.4% underwent full surgical staging. Overall ten 
year RFS and DSS was 89.3% and 92.5%, respectively. No differences in RFS (P=0.67) or DSS 
(P=0.89) were observed between those who received adjuvant chemotherapy versus those who did 
(Table 12).   
Table 11: Characteristics of stage IA/IB disease (n=22).   
    N % 
Stage IA 20 90.9 
  IB 2 9.1 
Ten year RFS NA 82.5 
  DSS NA 80.6 
Histology G1 EnOC 14 63.6 
  G2 EnOC 3 13.6 
  G3 EnOC 2 9.1 
  HGS 1 4.5 
  Undiff 1 4.5 
Full surgical staging Yes 14 63.6 
  No 6 27.3 
  UK 2 9.1 
Platinum chemotherapy Yes 5 22.7 
  No 17 77.3 
Legend: RFS=relapse free survival; DSS=disease specific survival; EnOC=endometrioid histology; HGS=high 
grade serous morphology; Undiff=undifferentiated histology;UK=unknown.  
 
Table 12: Characteristics of stage IC disease (n=28).   




No chemotherapy/       
non-platinum (n=15) 
    
Overall 
  
    N % N % P-value N % 
ten year RFS - 92.3 - 86.7 0.67 - 89.3 
  DSS - 92.3 - 92.9 0.89 - 92.5 
Histology G1 EnOC 10 76.9 12 80.0 NC 22 78.6 
  G2 EnOC 0 0.0 3 20.0 NC 3 10.7 






Yes 8 61.5 12 80.0 NC 20 71.4 
No 4 30.8 3 20.0 NC 7 25.0 
UK 1 7.7 0 0.0 NC 1 3.6 
Legend: RFS=relapse free survival; DSS=disease specific survival; EnOC=endometrioid histology; NA=not 
applicable; NC=not calculated due to low numbers; UK=unknown. 
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3.4 Patterns of relapse in early stage disease 
Of 97 patients with early stage disease, 22 (22.7%) relapsed. 20 patients had radiological or 
intraoperative evidence of disease recurrence (Table 13). Of these, ten (45.5%) recurred as a solitary 
pelvic mass, with lower frequencies in other sites (13.6% nodal, 13.6% visceral, 2% peritoneal, 9.1% 
other). All ten cases which recurred as a solitary pelvic mass had low grade EnOC (six G1, four G2) at 
diagnosis. 13 (59.1%) recurrences were confirmed pathologically as recurrent ovarian carcinoma. 
Pathology review of recurrent samples was not performed in this study and details of the post biopsy 
pathology report are detailed in Table 14. Of the four samples which had grade of the tumour recurrence 
reported, three were higher grade than the initial diagnosis of grade 1 EnOC ( one high grade EnOC, 























Table 13: Patterns of relapse in early stage disease (n=22). 
    N % 
Method of detection CT 14 63.6 
  US 3 13.6 
  Laparotomy 2 9.1 
  MRI  1 4.5 
  CA125 only relapse 1 4.5 
  UK 1 4.5 
Site Nodal only 3 13.6 
  Viscerala 3 13.6 
  Solitary pelvic mass 10 45.5 
  Peritoneal 2 9.1 
  Otherb 2 9.1 
  NA 1 4.5 
  UK 1 4.5 
Relapse Biopsy confirmed 13 59.1 
  Not biopsied 7 31.8 
  No diseasec 1 4.5 
  UK 1 4.5 
aLung or liver metastases and peritoneal/pelvic disease. 
b1 patient had pelvic mass and paraaortic lymphadenopathy,1 patient had chest/abdominal wall metastases   
  and paraaortic lymphadenopathy 
c no radiologically detectable disease (CA125 only relapse) 
Legend: UK=unknown. 
 
Table 14: Pathology of recurrent disease (n=13). 
Pathology at diagnosis Pathology at relapsea 
G1 EnOC Consistent with ovarian cancer 
G1 EnOC Consistent with ovarian cancer 
G1 EnOC Endometrioid no grade 
G1 EnOC Endometrioid no grade 
G1 EnOC G2 EnOC 
G1 EnOC G3 EnOC 
G1 EnOC Mixed grade 3 serous/endometrioid 
G2 EnOC G1 EnOC 
G2 EnOC Consistent with ovarian cancer 
G2 EnOC Endometrioid no grade 
G3 EnOC Papillary serous 
HGS Consistent with ovarian cancer 
a As per the pathology report. 






3.5 Platinum responses 
99 patients received platinum chemotherapy in the platinum naïve or platinum sensitive (≥12 month 
from last platinum) setting. Of these, 18 (18.2%) and 13 (13.1%) patients were evaluable for radiological 
and CA125 responses, respectively, in the WT1 negative cohort (Table 15). Most patients received 
single agent platinum only (83.3% of radiology evaluable cohort, 84.6% CA125 evaluable cohort). 
Overall radiological response rate was 44.5% (5.6% CR, 38.9% PR), 11.1% SD, and 44.4% PD. Overall 
CA125 response rate was 69.3 %( 38.5% CR, 30.8% PR), 23.1% SD and 7.7% PD. The median number 
of CA125s recorded was 7 (range 3-10).   
65 classical low grade EnOC patients received platinum-based chemotherapy in the platinum naïve and 
platinum sensitive setting. Of 10 evaluable radiological responses, 50.0% demonstrated PR, 20.0% SD 
and 30.0% PD. All five evaluable CA125 responses demonstrated response or stabilisation of CA125 
(20.0% CR, 40.0% PR, 40.0% SD).  
Table 15: Radiological and CA125 response to platinum chemotherapy.  
  WT1 negative cohort Classical low grade EnOC 
Variable  Radiology (n=18) CA125 (n=13)  Radiology (n=10) 
CA125 
(n=5) 
   n % n % n % n % 
Setting Platinum Naïve 9 50 6 46.2 5 50.0 2 40.0 
 Platinum sensitive 9 50 7 53.8 5 50.0 3 60.0 
Chemo Platinum only 15 83.3 11 84.6 10 100.0 5 100.0 
 Platinum/taxane 2 11.1 1 7.7 0 0.0 0 0.0 
 Platinum/other 1 5.6 1 7.7 0 0.0 0 0.0 
Response CR 1 5.6 5 38.5 0 0.0 1 20.0 
 PR 7 38.9 4 30.8 5 50.0 2 40.0 
 SD 2 11.1 3 23.1 2 20.0 2 40.0 
 PD 8 44.4 1 7.7 3 30.0 0 0.0 
Legend: EnOC=endometrioid ovarian carcinoma; CR=complete response; PR=partial response; SD=stable 
disease; PD=progressive disease.  
 
3.5.1 Stage IV disease 
Due to the poor survival demonstrated in stage IV disease, the clinical characteristics and response to 
platinum chemotherapy specifically in this cohort were investigated. Six (66.7%) of nine stage IV 
patients received first line platinum chemotherapy. Three were G2 EnOC, and three were high grade 
carcinomas.  Of these, five (83.3%) patients were platinum refractory, and one patient had radiological 
PR. Of these five patients, two died rapidly after one cycle (37 days and 69 days), three experienced 
disease progression after at least five cycles. All three evaluable patients had a CA125 response (two 





Herein, the clinical characteristics of the WT1 negative study cohort comprising all low grade EnOC and 
high grade carcinomas stratified by p53 IHC expression are described. All high grade carcinomas had 
either endometrioid, high grade serous or undifferentiated histology as they display significant 
morphological overlap with poor diagnostic inter-observer variation when diagnosed based on histology 
alone [229]. Due to the presence of this heterogeneous group of high grade carcinomas and its likely 
impact on survival, data from both the whole WT1 negative cohort as well as from classical low grade 
EnOC were reported separately. 
 
Overall, the rates of endometrioisis [209, 271] and synchronous endometrial carcinomas were 
consistent with the literature [129, 231]. The presence of endometrioisis and endometrial carcinomas 
were largely based on pathology reports and as such this data was not collected in a systematic way, 
posing a limitation in evaluating their prognostic value. In line with the published data [226, 274, 281], 
the majority of patients in our cohort presented with early stage disease with favourable five year DSS 
of over 90% in stage I disease for both cohorts. Interestingly, DSS for stage II disease in the classical 
EnOC cohort was similarly favourable, approaching nearly 90% at five years. Notably, a fifth of early 
stage patients did not undergo full surgical staging with the majority due to the omission of an 
omentectomy. Furthermore, most patients did not undergo systemic lymph node sampling and none 
underwent lymphadenectomy. This may suggest that particularly in stage I disease, less radical surgery 
may be appropriate and that second surgeries for comprehensive staging could potentially be avoided. 
This finding is in keeping with Kobel et al in which the ten year DSS for ‘apparent’ stage IA and IB EnOC 
was 96% despite no patients undergoing an omentectomy or lymph node sampling [281]. This is also 
in line with several large studies demonstrating the extremely low rate of lymph node metastases in 2% 
or less in early stage EnOC [284-286]. 
In stage 1 disease, ten year RFS and DSS were lower than reported in the literature for stage IA/IB 
disease at just over 80% however this is likely due to the presence of high grade carcinomas in nearly 
20% of this cohort. In the stage IC cohort which were comprised of mostly low grade EnOC, ten year 
DSS was favourable at just over 90%. When those who received adjuvant platinum chemotherapy were 
compared to those who did not in stage IC disease, there were no significant differences in RFS or 
DSS. Whilst the numbers were small in each cohort thus limiting the statistical power of this comparison, 
these results are consistent with the large study of 3552 stage I EnOC performed by Oseledchyk et al 
which found no survival benefit with adjuvant chemotherapy in stage IA/IB disease of any grade, and 
stage IC low grade (grade 1 and 2) disease [291].  
In this study, ten year RFS and DSS rates were lower than that observed at five years in early stage 
disease, but not in advanced stage. This was particularly evident in stage II disease with approximately 
10% of ovarian cancer recurrences and deaths occurring beyond five years. This same pattern was 
also observed in classical low grade EnOC tumours. This is akin to the study by Parra-Herran et al of 
EnOC where the separation of DSS curves between FIGO grade 1 and 2 EnOC only occurred at five 
years illustrating late relapses in grade 2 EnOC [221]. Similarly, this is mirrored by a retrospective study 
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of 2233 patients with endometrial carcinoma performed by Takahashi et al [401]. In this study, late 
recurrences (beyond five years from initial diagnosis) were associated with endometrioid carcinomas of 
low or intermediate grade with no lymphovascular invasion [401]. EnOC frequently express ER, and 
this clinical behaviour observed in early stage disease is akin to that of ER positive breast cancers 
which, unlike its ER negative counterpart, also demonstrate late recurrences [402].  To my knowledge, 
these findings have never been reported in EnOC, and have implications for the duration of clinical 
follow up as these patients are usually discharged after five years. Clinical trials performed in EnOC 
may need to consider extended follow up as late events are more likely to occur in this subtype which 
contrasts with HGSOC where the vast majority of relapses occur in the first 2 years [31].  
Patterns of relapse in EnOC were also evaluated in this study. Nearly half of recurrences from early 
stage EnOC presented as a solitary pelvic mass, and all of these patients had low grade EnOC at 
diagnosis. This is very similar to CCOC, a histological subtype which shares common histogenic 
precursors with EnOC. In Macrie et al, 25% of 56 CCOC experienced pelvic relapse at first recurrence 
[185].  In those with early stage disease, this frequency rose to 62%. There has also been published 
retrospective studies exploring the role of adjuvant radiotherapy in early stage CCOC. In a study by 
Hoskins et al of 241 patients with CCOC, half the cohort received 3 cycles of adjuvant carboplatin and 
paclitaxel, followed by abdominopelvic irradiation (22.5Gy in 10 fractions over 2 weeks to the pelvis, 
followed by 22.5Gy to the whole abdomen and pelvic in 22 fractions over 4.5 weeks), whilst the other 
half received 6 cycles of conventional carboplatin and paclitaxel [184]. No disease free survival benefit 
for radiotherapy was observed in stage IA and IC (rupture only) disease. In the remaining stage IC/II 
cohort (positive cytology, surface involvement or unknown status), radiotherapy resulted in a 20% 
improvement in five year disease free survival (RR 0.52 (95% CI 0.33-0.95; P=0.02). It also showed 
that pelvic relapses were more common in patients who did not undergo radiotherapy compared to 
those who did (76% versus 62%). Prospective clinical trials of adjuvant radiotherapy in CCOC are now 
being proposed to validate these findings. Notably, this is also similar to endometrial carcinomas in 
which EnOC bears close histological and molecular semblance to. The vast majority of relapsed 
endometrial carcinomas are vaginal or pelvic recurrences. Adjuvant external beam radiotherapy has 
been shown to reduce the risk of local relapse in high intermediate risk endometrial carcinoma (two out 
of three risk factors: grade 3; age 60 years or older and deep myometrial invasion) [403].  
Only one retrospective study has explored the role of adjuvant radiotherapy in EnOC [274].  As a follow 
up study performed in the same Canadian centre as Hoskins et al, Kumar et al performed the same 
comparison (chemotherapy versus chemotherapy/radiation) in 172 early stage EnOC. Here, the authors 
conclude that a non-statistically significant trend in disease free survival benefit from radiotherapy was 
observed in patients older than 55 with stage IC based on positive cytology, surface involvement or any 
stage II disease (n=32) (RR 1.77(95% CI 0.74-4.24). These findings reported by Kumar et al may be 
explained by the high propensity for isolated pelvic recurrences in early stage low grade EnOC observed 
in this study. This raises the hypothesis that a subset of early stage low grade EnOC may also benefit 
from adjuvant radiotherapy akin to CCOC.  
101 
 
In this study, the platinum sensitivity of platinum naïve tumours or of those which relapsed 12 months 
or more from the dose of last platinum was reported.  The majority of this cohort received single agent 
platinum and the radiological response rate was nearly 50% and CA125 response rate of just over 70%. 
This is numerically lower than that reported in HGSOC although a matched comparison would be 
required to formally determine this [42]. This data is somewhat comparable to the three studies 
performed to date evaluating platinum sensitivity specifically in EnOC. Dawn et al found radiological 
responses rates of 60% in EnOC and CA125 response rates of 66% [272]. However, this study 
contained 56% of grade 3 carcinomas and did not undergo contemporary pathology review, as such it 
is likely that a good proportion of these poorly differentiated tumours were misdiagnosed HGSOC which 
limit the interpretation of this study. Similarly, Kline et al reported a 72% platinum response rate in 145 
historically diagnosed EnOC in 1990 [298], although the proportion of grade 3 EnOC was not known. 
In Soovares et al, 249 patients with pathology reviewed EnOC had platinum response evaluated after 
primary surgery and adjuvant chemotherapy based on gynaecological examination, vaginal 
ultrasonography, CA125 measurement, and/or computed tomography imaging [275]. Overall complete 
response was 79% although this methodology is highly flawed given the heterogeneous assessment of 
response. Furthermore, they did not restrict the response analysis to those with measurable residual 
disease post-operatively thus casting some doubt on these high response rates observed.  
The radiological response rate of platinum based chemotherapy in classical low grade EnOC was 50% 
with a similar CA125 response rate of 60%. Although the numbers in our cohort were small, this does 
suggest that classical low grade EnOC demonstrates moderate platinum sensitivity which is in contrast 
to LGSOC with low response rates of 5-10% [160].  
When the survival analysis was restricted to patients with advanced stage classical low grade EnOC 
(the majority of which presented with stage III disease), the median DSS was over seven years with a 
five year and ten year DSS of 50%. This is superior to reported outcomes of advanced stage HGSOC 
with ten year DSS of 15% [404]. In keeping with this, Rambau et al reported a five year DSS of 59.6% 
for pathology reviewed stage III EnOC, the majority of which were low grade EnOC. Similarly, this is 
akin to the large GCIG study of seven randomised clinical trials which found stage III/IV EnOC (n=646) 
to have a median OS of 50.9 months [203]. Similarly, it also mirrors the indolent clinical behaviour of 
LGSOC with a reported medial survival of 82 months [84] 
However, when accounting for the whole WT1 negative cohort, patients with stage III and IV disease 
were found to have a poor prognosis, particularly in stage IV disease with median RFS and DSS of less 
than 1 year with no survivors at five years. This may be accounted for by a quarter of patients not 
receiving any chemotherapy. Although the number of patients were small, it is worth noting that the 
majority of patients with stage IV disease who received platinum chemotherapy were platinum 
refractory, a finding which contrasts with first line platinum response rates of 80% in HGSOC [31]. 
It is also observed in this small dataset that more than 70% of stage IV patients had visceral metastases 
at diagnosis as well as two patients with unusual sites of disease (one had bone metastases and the 
other had splenic, renal and thyroid metastases diagnosed at post mortem shortly after diagnosis). 
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These findings are notable as both bone and thyroid metastases in EOC are extremely rare [405].  This 
disease distribution, together with the predominantly platinum refractory nature of this cohort, may 
suggest that stage IV EnOC, in particular those of high grade and p53 mutant IHC expression, is 
biologically distinct from HGSOC, and warrants alternative therapeutic strategies. 
Eight patients with late isolated pelvic or nodal relapse in this study underwent an attempt at secondary 
surgery with most undergoing successful complete macroscopic cytoreduction. Interestingly, more than 
half these patients did not experience further recurrences after a median follow up time of over ten 
years which suggests that secondary surgery may have been a curative procedure. These results are 
in line with the DESKTOP III trial which demonstrated a PFS benefit of surgery over chemotherapy for 
platinum sensitive relapsed disease although OS data remains immature [66]. This data supports the 
use of surgical resections for late solitary relapses should be favoured over the use of chemotherapy in 
EnOC.  
There are a few limitations of this clinical characterisation study. Firstly, over 200 samples were unable 
to be retrieved for pathology review which may have contributed to selection bias. The inclusion of WT1 
negative tumours with high grade serous and undifferentiated carcinoma morphology are likely to have 
contributed to poorer outcomes. In view of this, the classical low grade EnOC cohort was characterised 
separately and the overall clinical profile was in keeping with that reported in the literature on EnOC.   
The assessment of platinum sensitivity in this cohort was challenging with only a small proportion 
evaluable for radiological and CA125 response. This was due to low relapse rates and infrequent use 
of radiological monitoring in this cohort. RECIST criteria was unable to be employed due to variable 
reporting methods used and relied on the interpretation of the reporting radiologist to determine 
response. However, radiological response was only recorded if a 30% or more reduction in tumour 
diameter was reported, otherwise this was recorded as stable disease in the absence of reported 
disease progression. It is therefore unlikely that the rates of radiological responses to platinum 
chemotherapy in this study are overestimated. It is also worth noting that half these responses were 
evaluated in relapsed disease. At least two patients who initially presented with low grade EnOC 
recurred as high grade carcinomas. Whilst recurrent tumours did not undergo pathology review, it is 
plausible that a proportion of tumours underwent malignant high grade transformation, an extremely 
rare phenomenon that has been observed in LGSOC [406, 407]. As such, it is hypothesised that 









In this study, the clinical characteristics of classical low grade EnOC as well as the whole WT1 negative 
cohort including high grade carcinomas following comprehensive pathology review are described. The 
key messages are as follows:  
 EnOC is associated with a good prognosis in early stage disease.  
 Late relapses beyond five years are frequent particularly in stage II disease and may thus 
influence follow up time in these patients.  
 An isolated pelvic mass is the most common pattern of relapse and as such there may be an 
argument for designing clinical trials to investigate the role of adjuvant radiotherapy in EnOC 
akin to CCOC.  
 The use of secondary cytoreductive surgery is associated with prolonged disease free survival 
when employed in EnOC with late solitary recurrences. 
 Stage IV EnOC are biologically aggressive tumours which may be platinum refractory and are 
associated with very poor prognosis. Whole exome sequencing data of these tumours may 
help inform whether these tumours have actionable mutations which may be suitable for the 
development of novel therapeutic strategies. 
In conclusion, I have presented data on EnOC which may have relevance to clinical management and 







4. Hormone receptor expression 

















As discussed in section 1.4.5, the majority of EnOC express ER and PR as demonstrated by the large 
Ovarian Cancer Tissue Consortium study performed by Sieh et al [81]. These findings were confirmed 
in an independent study by Rambau et al of contemporarily defined EnOC utilising IHC [255]. In both 
studies, any expression of ER and PR, as determined by the percentage of tumour nuclei stained, was 
found to be prognostic in EnOC. Notably in Rambau et al, the prognostic effect of ER and ER/PR co-
expression was diminished when restricted to early stage disease, with PR losing significance. In 
contrast, the frequency of AR expression in EnOC has only been evaluated in small studies and is 
variable depending on the IHC expression threshold used [83, 87, 90, 94].  Furthermore, its prognostic 
role in EnOC is unknown.  
 In view of its high frequencies of ER expression, EnOC is considered an endocrine sensitive disease. 
Endocrine therapy is not licensed for use in EOC due to conflicting data derived from more than 50 
phase II clinical trials. These heterogeneous trials were mostly performed in heavily pre-treated patients 
of all histological subtypes of EOC, comprising both ER positive and negative disease [295] (Appendix 
C). Furthermore, different thresholds and methods of measuring ER expression were also used. The 
only phase III clinical trial performed comparing tamoxifen against conventional chemotherapy in a 
platinum resistant ovarian cancer population, failed to demonstrate a survival advantage [110]. As a 
result, the use of endocrine therapy varies worldwide and is not considered standard of care.  
There is however good prospective [112, 113] and retrospective data [295] show that the degree of ER 
expression predicts for endocrine sensitivity in EOC. These studies utilised the histoscore, a weighted 
scoring method which accounts for stain intensity and percentage of tumour nuclei stained, as the 
preferred method of determining ER expression. An ER histoscore of 150 or greater was found to be 
the threshold at which patients derived benefit from endocrine therapy in the prospective trials [112, 
113]. In the large retrospective study performed by Stanley et al of endocrine therapy in recurrent 
HGSOC, patients with a treatment free interval of ≥180 days and a tumour ER histoscore of >200 
derived the greatest benefit [295] (Appendix C).  
As previously discussed, the five main histological subtypes of EOC are recognised to be biologically 
and clinically distinct. Apart from EnOC, the Ovarian Cancer Tissue Consortium study found LGSOC 
and HGSOC to have the highest levels of ER expression [81]. There is emerging retrospective data 
supporting the use of maintenance endocrine therapy in LGSOC in both the relapsed [118] and first line 
settings [119]. In addition, a small retrospective study performed by Heinzelmann-Schwarz et al 
demonstrated improved recurrence free survival in patients with HGSOC who received maintenance 
letrozole compared to those who did not. [120]. Together, these studies support the evaluation of 
endocrine therapy in EOC in a histological subtype- specific manner. As discussed in section 1.4.9.3, 
there is minimal published data describing the endocrine sensitivity of EnOC which is in contrast to 
HGSOC and LGSOC [222, 296]. 
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In this chapter, the hormone receptor expression of ER, PR and AR are described as weighted 
histoscores, and correlated to RFS and DSS, in both the earlier defined WT1 negative cohort as well 
as in the classical low grade EnOC group. The endocrine sensitivity of EnOC is also evaluated.    
4.2 Results  
4.2.1 Hormone receptor expression in  EnOC 
Overall, 103 (82.4%), 103 (82.4%) and 107 (85.6%) of cases were evaluable for ER, PR and AR, 
respectively. 77.7%, 74.8% and 70.1% expressed any ER, PR and AR, respectively. The spread of ER, 
PR and AR expression was similar for both the WT1 negative and classical low grade EnOC cohorts 
(Figure 26). All hormone receptors were non-normally distributed and PR expression demonstrated a 
bimodal distribution (Hartigan’s dip test; P<0.0001). There was some evidence of multimodality for AR 
expression (Hartigan’s dip test; P=0.0374) in the classical low grade EnOC cohort. The majority of 
tumours had low AR expression (histoscore 0-50) (76.6% WT1 negative cohort, 77.0% classical low 
grade EnOC).  
In ER and PR, histoscores were grouped according to strong (histoscore>150) or weak 
(histoscore≤150) expression. There were significant associations between ER and PR (rho=0.68, 
P<0.0001), ER and AR (rho=0.46, p<0.0001), with weaker but significant associations between PR and 
AR (rho=0.38; P<0.0001). The frequency of strong ER was higher in the strong PR group compared to 
the weak PR group (59.6% vs 20.8%, p<0.0002). 
Figure 27 illustrates the distribution of strong and weak ER and PR. In both the WT1 negative and 
classical low grade EnOC cohorts, the highest frequencies were that of strong ER/strong PR and weak 
ER/weak PR (WT1 negative cohort: 28.0% and 42.0%, respectively, classical low grade EnOC: 36.8% 






Figure 26: Spread of ER, PR and AR immunohistochemical expression in the WT1 negative cohort (A, B 




Figure 27: Distribution of strong (histoscore>150) and weak (histoscore≤150) ER and PR in the WT1 




4.2.2 Hormone receptor expression and survival 
WT1 negative cohort 
Strong PR was significant for both RFS (univariable HR 0.24 (95%CI 0.10-0.55); P<0.001) and DSS 
(univariable HR 0.14 (95%CI 0.05-0.39); P<0.001) when compared to weak PR. Strong ER was 
significant for DSS (univariable HR 0.37 (95%CI 0.15-0.91); P=0.03) and approached significance for 
RFS (univariable P=0.07) when compared to weak ER.  
Strong PR expression remained an independent predictor of DSS (multivariable HR 0.23 (95%CI 0.08-
0.72); P=0.011) and approached significance for RFS (multivariable P=0.092), but strong ER lost 
significance for both RFS (P=0.712) and DSS (P=0.299) upon multivariable analysis (Table 16, Figure 
28). Ten year RFS and DSS for strong PR was 82.6% and 91.4% compared to 47.8% and 50.7% for 
weak PR, respectively. The differential impact of PR on DSS was most marked in stage II disease 
(HR0.10 (95%CI 0.13-0.82); P=0.031) (Figure 29). AR expression was not associated with RFS or DSS 
on univariable or multivariable analysis.  
When compared with weak PR, tumours with strong PR were more likely to be diagnosed with low 
grade disease (P<0.001), early stage disease (P=0.018), and were more likely to be surgically cyto-
reduced to <2cm (P=0.042) (Table 17). No differences in age, BMI, year of diagnosis, and proportion 
of patients receiving at least three cycles of platinum chemotherapy were observed between the two 
cohorts.   
Classical low grade EnOC cohort 
In the classical low grade EnOC cohort, only strong PR was independently significant for DSS 
(multivariable HR 0.13 (95%CI 0.02-0.64); P=0.013) and approached significance for RFS 
(multivariable HR 0.34 (95%CI 0.09-1.22); P=0.097) (Table 16). Ten year RFS and DSS for strong PR 
was 82.9% and 93.1% compared to 58.7% and 60.2% for weak PR, respectively.  No significant 
















Table 16: Univariable and multivariable analysis of hormone receptor expression and survival in the WT1 negative cohort and classical low grade EnOC cohort.  
WT1 negative cohort (n=125) 
       Univariable Multivariablea 
      RFS  DSS RFS DSS 
    N % HR (95% CI) P HR (95% CI) P HR (95% CI) P HR (95% CI) P 
ER >150 41 39.8 0.50 (0.23-1.07) 0.072 0.37 (0.15-0.91) 0.03 0.84 (0.34-2.08) 0.712 0.57 (0.2-1.64) 0.299 
  ≤150 62 60.2 ref   ref   ref   ref   
PR >150 47 45.6 0.24 (0.10-0.55) 
<0.00
1 
0.14 (0.05-0.39) <0.001 0.45 (0.18-1.14) 0.092 0.23 (0.08-0.72) 0.011 
  ≤150 56 54.4 ref   ref   ref   ref   
AR 0-100 94 87.9 ref   ref   ref   ref   
  101-200 10 9.3 0.83 (0.26-2.72) 0.764 0.61 (0.15-2.58) 0.506 1.01 (0.28-3.65) 0.988 0.46 (0.09-2.28) 0.341 
  201-300 3 2.8 1.41 (0.19-10.35) 0.737 2.07 (0.28-15.39) 0.479 2.88 (0.28-29.96) 0.376 3.35 (0.28-40.39) 0.341 
classical low grade EnOC (n=87) 
    
  
HR P HR P HR P HR P 
ER >150 33 47.1 0.63 (0.21-1.88) 0.407 0.45 (0.12-1.69) 0.236 0.41 (0.1-1.68) 0.215 0.26 (0.05-1.44) 0.122 
  ≤150 37 52.9 ref   ref   ref   ref   
PR >150 42 60 0.39 (0.14-1.10) 0.076 0.18 (0.05-0.66) 0.01 0.34 (0.09-1.22) 0.097 0.13 (0.02-0.64) 0.013 
  ≤150 28 40 ref   ref   ref   ref   
AR 0-100 63 85.1 ref   ref  ref   ref   
  101-200 9 12.2 1.76 (0.50-6.19) 0.378 1.38 (0.3-6.23) 0.678 NE NE NE NE 
  201-300 2 2.7 NE NE NE NE NE NE NE NE 
aadjusted for stage, residual disease, decade of diagnosis and age.  
Legend: RFS=relapse free survival; DSS=disease specific survival; ER=oestrogen receptor; PR=progesterone receptor; AR=androgen receptor; EnOC=endometrioid 






Table 17: Clinical characteristics of strong (histoscore>150) and weak (histoscore≤150) PR expression. 
  PR>150 (n=47)   PR≤150 (n=56)   P-value 
  N % N %   
median age 56(28-88) NA 60(32-79) NA 0.105 
BMIa 24.9 NA 24.8 NA 0.545 
Endometrial cancer 6 12.8 9 16.1 0.847 
Endometrioisis 17 36.2 15 26.8 0.417 
Grade           
1 39 83.0 26 46.4 <0.001 
2 4 8.5 20 35.7   
3 4 8.5 10 17.9   
Year of Diagnosis   0.0       
1980s 7 14.9 8 14.3 0.509 
1990s 16 34.0 27 48.2   
2000s 14 29.8 12 21.4   
2010s 10 21.3 9 16.1   
Stage           
I 21 46.7 21 37.5 0.018 
II 21 46.7 20 35.7   
III 3 6.7 9 16.1   
IV 0 0.0 6 10.7   
UK 2 NA 0 NA   
Surgical Cytoreduction           
<2cmb 43 95.6 43 79.6 0.042  
≥2cm 2 4.4 11 20.4  
UK 2 NA 2 NA   
At least 3 cycles platinum           
Yes 30 63.8 39 69.6 0.679 
No 17 36.2 17 30.4   
aEvaluable in 25 cases for PR>150 and 34 cases for PR≤150. b32 cases were surgically cyto-reduced to 0cm. Classification of 
optimal surgical cytoreduction changed over time; some of the patients were diagnosed at a time when resection to <2cm was 
considered optimal. 




Figure 28: Disease specific survival (A) and relapse free survival (B) by strong (histoscore >150) and 
weak (histoscore ≤150) PR expression. 
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Figure 29: Kaplan Meier survival curves for disease specific survival (A, C, E) and relapse free survival 






4.2.3 Endocrine sensitivity in EnOC 
Of the 125 WT1 negative tumours, 11 (8.8%) patients received endocrine therapy (Table 18). Of these, 
eight (72.7%) patients had classical low grade EnOC at diagnosis. A total of 13 courses of endocrine 
therapy courses were delivered (letrozole (n=7), megesterol acetate (n=3), medroxyprogesterone 
(n=2), tamoxifen (n=1)). 11 were used as treatment following disease progression (one CA125 only 
relapse), one as maintenance treatment due to chemotherapy toxicity, and one as adjuvant treatment 
following surgical cytoreduction to <2cm for stage III disease. Nine (81.8%) of 11 evaluable courses 
had an ER histoscore of 150 or greater, whilst seven (77.8%) of nine evaluable courses had PR 
histoscores less than 100.  
 Of the eight evaluable courses of endocrine therapy with a duration of least four weeks started as 
treatment for relapsed disease, the median duration of therapy was 317 days (range 35-615 days). Of 
these eight courses of endocrine therapy, the median interval from last platinum chemotherapy received 
to endocrine therapy initiation was 322 days (range 9-2233 days). Of the five evaluable CA125 
responses, three had PR, one had SD, and   one displayed delayed stabilisation of CA125. Two patients 
had evaluable radiological responses (1 PR, 1 SD).  Notably, one patient whose tumour was negative 
for both ER and PR expression, received megesterol acetate for CA125 only relapse for 594 days, 
followed by sequential tamoxifen due to CA125 progression for another 385 days.  Best CA125 


















Table 18: Treatment summary for endocrine therapy received. 




















































































































Death 1 NE NE 
21899a Let HGS mut 225 0 120 77 
PD on 
platinum  
PD 2 SD PD 




UK 3 NE NE 
a duplicate patient. 
bhistoscore 
Legend: Pat=patient; ET=endocrine therapy; prov=provera (medroxyprogesterone acetate); let=letrozole; meg=megesterol 
acetate; tam=tamoxifen; G=grade; EnOC=endometrioid ovarian carcinoma; HGS=high grade serous morphology; wt=wild-
type expression; mut=mutant expression; chemo=chemotherapy; path=pathology; IHC=immunohistochemistry; 
ER=oestrogen receptor; PR=progesterone receptor; DOT=duration of therapy; TFI=treatment free interval (from last 







4.3 Discussion  
In this study, the majority of EnOC display ER and PR expression which is in keeping with the literature 
[81, 255]. In particular, PR expression displays a bimodal distribution unlike the expression of ER.  In 
order to ascertain if this effect was in part due to the inclusion of high grade carcinomas and low grade 
EnOC with p53 mutated expression on IHC, both factors which may influence hormone receptor 
expression patterns, the analyses was restricted to the pathologically homogenous cohort of classical 
low grade EnOC which demonstrate the same findings. This contrasts with ER positive breast 
carcinomas which demonstrate a bimodal distribution of ER but uniform distribution of PR [408]. The 
bimodal distribution of PR in EnOC may also suggest bimodal gene expression akin to that of ER in 
breast cancer [409, 410].  To my knowledge, the distribution of ER and PR expression as weighted 
histoscores has never been formally described in EnOC or EOC before. When compared to the study 
performed by Rambau et al of 182 pathology reviewed EnOC, frequencies for ER staining were 12.7%, 
14.3%, and 73% and that of PR were 13.3%, 12.7%, and 74% for negative (0% nuclear stain), weak 
(1-50% nuclear stain) and strong expression (>50% nuclear stain), respectively [255]. When compared 
to the classical low grade EnOC cohort, the rates of ER and PR negativity were similar, whereas the 
rates of strong ER and strong PR in our study were numerically lower at 47.1% and 60.0%, respectively. 
These observed differences may be in part due to our use of a weighted histoscore, which in addition 
to percentage nuclei stained, also incorporates nuclear stain intensity.  
In the WT1 negative cohort, strong PR expression, when compared to weak PR, is associated with DSS 
independent of stage, residual disease, decade of diagnosis and age. A trend for significance was 
observed for RFS. In contrast, strong ER was significant on univariable analysis but was not an 
independent variable of prognosis. When this analysis was restricted to the classical low grade EnOC, 
strong PR remained an independent predictor of prognosis whereas no correlation was observed 
between strong or weak ER in the univariable or multivariable analysis for RFS or DFS. These findings 
parallel that of HGSOC in which strong PR (>50% nuclei staining), but not weak PR (1-50% nuclei 
staining), expression was found to be an independent predictor of prognosis in HGSOC [81]. 
Sieh et al and Rambau et al were the two largest studies performed evaluating the prognostic role of 
hormone receptor expression in EnOC [81, 255]. In Rambau et al, EnOC underwent contemporary 
pathology review utilising IHC.  Both studies found that any ER or PR expression were independently 
associated with DSS. No survival differences were observed between the weak (1-50%) and strong 
(>50% nuclear stain) expression cohorts. These differences to our study may be explained by our 
scoring methodology, as well as the use of weak expression rather than negative expression as a 
comparison cohort. The histoscore threshold of 150 was chosen due to the spread of PR and ER 
expression in our study. Furthermore, the prospective studies performed by Bowman and Smyth et al 
established an ER histoscore of 150 as a treatment threshold for the use of endocrine therapy [112, 
113]. In Stanley et al, patients with HGSOC and ER histoscores of 250-300 received endocrine therapy 
for a longer duration then compared to those with ER histoscores of 0-150, further demonstrating that 
the degree of ER expression predicts for endocrine sensitivity [295]. As such, it is hypothesised that the 
histoscore may provide greater granularity at higher expression levels in determining prognosis. A 
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formal comparison of scoring methods utilising receiver operating characteristics analyses would be 
required to confirm this.  
In the overall WT1 negative cohort, the independent impact on DSS of strong PR was most marked in 
stage II disease with DSS of over 90% in this cohort. Although most patients with stage II disease 
received platinum chemotherapy, no significant differences were observed in the proportion of patients 
who received at least three cycles of platinum chemotherapy between the strong PR and weak PR 
cohorts. It thus raises the hypothesis as to whether patients diagnosed with early stage EnOC and 
strong PR expression, could afford to have adjuvant chemotherapy omitted even in stage II disease.  
This finding contrasts with the study performed by Rambau et al where PR lost significance and ER 
was of only borderline prognostic significance when restricted to early stage disease [255]. It is possible 
that the use of the histoscore in determining the degree of hormone receptor expression and the greater 
power of this study explain these differences. Together with the bimodal distribution of PR, this data 
supports the use of a PR histoscore>150 as a reproducible biomarker which can be used to identify a 
cohort of patients with superior prognoses. This finding, together with the significant association of 
strong ER and PR, is also in keeping with the role of PR as surrogate for a functionally intact ER pathway 
and its role in inhibiting cell proliferation [80].    
AR expression was also evaluated in both cohorts. Overall, AR expression was low with the majority of 
cases negative or with very weak expression (histoscore1-50) for AR. The degree of AR expression 
was not associated with survival which contrasts with HGSOC however, the numbers with higher 
expression of AR were very small which limit the interpretation of these findings. Nonetheless, no other 
studies have evaluated the prognostic significance of AR specifically in EnOC and the overall weak AR 
expression displayed in EnOC thus makes it an unreliable biomarker. Jonsson et al found a trend for 
OS with co-expression of PR and AR in a sub-group analysis of 31 EnOC, however notably post-
operative residual disease was not recorded in this study [83]. In contrast, AR expression has been 
shown to have independent prognostic significance in retrospective studies of HGSOC [96, 104]. 
In the largest series reported to date, the endocrine sensitivity of EnOC, most of which were low grade, 
was evaluated. Patients who received endocrine therapy for relapsed disease had a median duration 
of therapy of nearly a year. This contrasts with HGSOC where median duration of endocrine therapy 
has been shown to be approximately four months [295] (Appendix C). All five courses of endocrine 
therapy evaluable for CA125 response demonstrated response, stabilisation or delayed stabilisation of 
CA125. Similarly, radiological response and stabilisation was observed in both evaluable patients. The 
majority of cases had an ER histoscore of 150 or greater with most cases displaying low PR expression 
in keeping with ER expression as the main predictor of endocrine response as outlined in the literature 
[112, 113, 295].  The size of this cohort illustrates the rarity of relapsed cases of EnOC and the 
challenges in performing clinical trials in assessing the efficacy of endocrine therapy in EnOC. As such, 




In this study, both histoscores as determined by BS and YI were averaged in order to minimise inter-
observer variability. A third scorer, SH, was introduced if the difference between the histoscores were 
greater than 50 points, thus reducing any observer bias that may have occurred. TMAs, rather than 
whole tissue sections, were used for scoring as good concordance between the two have been 
demonstrated in the literature [411]. Less than 10% of patients received endocrine therapy and is 
therefore unlikely to have influenced the reported survival outcomes. Furthermore, no differences in 
platinum chemotherapy received were observed between the strong and weak PR cohorts, and 
multivariable analysis also corrected for decade of diagnosis to account for variations in management 
over time.  
Further to this work, hierarchical clustering of PR and ER histoscores across 107 WT1 negative EnOC 
of all grades, excluding those with undifferentiated and high grade serous histology (Appendix D) [412]. 
Here, four subgroups of EnOC defined by hormone receptor expression patterns were identified 
(PRhigh/ERhigh, PRhigh/ERlow, PRlow/ERhigh, PRlow/ERlow). Similar to this study, both PRhigh cohorts were 
independently associated with superior prognosis. Based on the unsupervised clustering algorithm, the 
histoscore threshold identified was around 150 to define the PRhigh and PRlow groups, thus supporting 
the threshold used in this study. 
4.4 Conclusion 
This is the largest study performed to date evaluating the prognostic role of ER, PR and AR expression 
as weighted histoscores in contemporary defined EnOC. The use of PR histoscore>150 can define a 
group of patients with good prognosis, thus generating the hypothesis that these patients with early 
stage EnOC could potentially be spared adjuvant chemotherapy. To my knowledge, this is the largest 
series to date illustrating the endocrine sensitivity of EnOC, and that these patients can derive prolonged 
benefit from endocrine therapy. Given the prevalence of ER expression and the indolent nature of EnOC 
particularly in low grade disease as illustrated in section 3, there may be an argument for considering 
maintenance or adjuvant endocrine therapy particularly in advanced stage disease in order to improve 
patient outcomes. This will be comparable to the management of ER positive breast cancer, and 
supported by the emerging retrospective data of maintenance endocrine therapy in LGSOC and 









5. Single nucleotide variant and 






























As described in chapter 1, the majority of EnOC arise from endometriosis, and most grade 1 and 2 (low 
grade) EnOC display a classical IHC profile  comprising WT1 negativity, wild-type p53 expression, and 
ER positivity [226]. These tumours bear close histological and molecular resemblance to EnEC [413]. 
Commonly mutated genes in EnOC include PTEN, ARID1A, PIK3CA and CTNNB1 [227, 247, 254]. 
Mutations in KRAS, encoding a member of the MAP kinase pathway, and MSI resulting from mutations 
in the MMR genes, are also associated with EnOC [227]. TP53 mutations (TP53mut) are rare in low 
grade EnOC and have been reported to occur in less than 10% of cases [228], with higher frequencies 
of up to 32% in all grades of EnOC [243, 254, 302].   
In chapter 1, the diagnostic challenges in differentiating high grade EnOC from HGSOC on the basis of 
morphology alone [226, 413] are discussed.  In particular, a proportion of HGSOC demonstrate solid, 
pseudo-endometrioid and/or transitional-cell-like growth patterns (SET pattern), which may be 
associated with BRCA1 mutations [241].  De-differentiated carcinomas are rare, aggressive tumours 
consisting of undifferentiated carcinomas with a low grade EnOC component. They often lack defining 
morphologic features and can also be misdiagnosed as high grade EnOC [257, 261]. Through the 
refinement of EOC diagnostic criteria [242], several studies have now demonstrated that many 
previously diagnosed high grade ECs are in fact HGSOC [226, 243]. This is supported by gene 
expression profiling studies demonstrating that a proportion of high grade EnOC cluster together with 
HGSOC [243, 246-248].  As such, true high grade EnOC are increasingly rare, representing around 5-
19% of EnOC cases [224, 226, 254]. Reports of high grade EnOC have suggested poor clinical 
outcomes in this subset, in contrast to their low grade counterparts [272, 282] 
To date, several studies have attempted to define the molecular landscape of EnOC. The study cohorts 
and molecular tools used across the studies have been heterogeneous. For example, some studies 
were performed only in low grade EnOC [228] whereas others accounted for all grades of EnOC [227, 
375]. Some studies did not describe the diagnostic criteria used [249, 254, 375, 381], and others relied 
on historical pathological subtyping [227, 228, 243, 246-248, 375, 414, 415]. It is thus plausible that a 
proportion of these cohorts comprised misdiagnosed HGSOC. More in-depth molecular analysis 
utilising WES and WGS comprised very small cohorts of EnOC [375, 379]. For example Teer et al 
performed WES in only six grade 1 and 2 stage I EnOC, and targeted sequencing in 14 EnOC of 
unknown grade [379]. In Wang et al, whole genome sequencing was applied to 29 EnOC once again 
of unknown grade [375]. As such, the molecular landscape of EnOC, in particular high grade EnOC, is 
not well defined.   
Currently, management of EnOC follows the historic ‘one size fits all’ approach, with aggressive 
cytoreductive surgery and platinum based chemotherapy forming the mainstay of treatment. This 
contrasts with routine molecular stratification of HGSOC with the advent of PARP inhibitors for 
BRCA1/2-mutant cases [150, 294] and the emergence of histotype-specific management in other EOC 
subtypes. These include the use of MEK inhibitors in LGSOC [416] and immune check point inhibitors 
in CCOC [193]. 
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WT1 IHC is a useful tool to discriminate high grade EnOC (WT1 negative) from HGSOC (WT1 positive) 
[229, 230, 244, 245], reducing inter-observer variation [129, 224, 229, 243].  
Here, whole exome sequencing (WES) was performed to investigate the molecular landscape of WT1 
negative EnOC, including high grade carcinomas of endometrioid, high grade serous and 
undifferentiated histology. The hypothesis of this chapter is that there are molecular subgroups with 
differential clinical outcomes within EnOC, and molecular biomarkers which provide greater prognostic 
granularity over grade. The six WT1 positive low grade EnOC, which formed a separate cohort of 
interest in this study, also underwent WES and it is hypothesised that these tumours are also true EnOC 
at the molecular level.  
5.2 Results 
5.3 Molecular landscape 
As described in section 2.6, the WT1 negative cohort was categorised by p53 IHC expression and 
grade. Three cohorts were identified: group 1) WT1 negative p53 wild-type expression low grade EnOC 
(classical low grade EnOC), group 2) WT1 negative p53 mutated expression carcinomas (comprising 
both low grade EnOC and high grade carcinomas), and group 3) WT1 negative p53 wild-type 
expression high grade carcinomas. I chose to perform WES in all tumours of group 2 and 3, as well as 
a select cohort of group 1 as this group was deemed to be pathologically homogenous.  
In total, 61 cases were characterised by WES. 25,067 variants were identified with a median of 214 
variants per sample (range 198-3852).  Six tumours were considered ‘hyper-mutated’ (>500 mutations 
per sample) and one tumour was considered ‘ultra-mutated’ (>3500 mutations). Five genes were 
mutated at high frequency (>20%) across the cohort: TP53 (45.9%); ARID1A (41.0%), CTNNB1 
(31.1%), PTEN (24.6%) and PIK3CA (23.0%) [356]. The type and location of mutations were in keeping 
with the literature (Figure 30). Overall, 36 (59.0%) cases had one or more mutations in PTEN, CTNNB1, 
ARID1A, or PIK3CA (EnOClike profile) [229, 356], and 25 (41.0%) tumours had no mutations in any of 
these genes (EnOCwt profile). Other commonly mutated genes included FBXW7 (13.1%), KRAS 
(13.1%), APC (11.5%), BRCA2 (11.5%), MTOR (9.8%) and PIK3R1 (9.8%).  
Molecular group Definition  
EnOClike profile 
One or more mutations in PTEN, CTNNB1, 
ARID1A, or PIK3CA 
EnOCwt profile 
No mutations in PTEN, CTNNB1, ARID1A, or 
PIK3CA 
Legend: EnOCwt  = Endometrioid ovarian carcinoma wild type  
 
The majority of TP53 mutations were missense mutations (16/28; 57.1%). The remainder were 
nonsense mutations (n=4), in-frame deletions (n=4), frame shift deletions (n=3), and multi-hit (frame 
shift insertion + missense mutation) mutations (n=1). Of 25 tumours with ARID1A mutations, most were 
nonsense (n=7) and frameshift mutations (n=10, 4 insertions, 6 deletions), two were missense 
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mutations and six had multiple hits. Of 15 PTEN mutations, nine were missense mutations, three were 
frameshift deletions, two were nonsense mutations, and one was a splice site deletion. Of 19 CTNNB1 
mutations, 18 were missense mutations, and one was an in-frame deletion. 17 tumours had CTNNB1 
mutations in exon 3 in line with the literature. Of 14 PIK3CA mutations, 13 were missense mutations.  
 
Figure 30: Lollipop plot of the 5 most commonly mutated genes in EnOC. Figure by Dr John Thompson. 
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5.3.1 Mutational and Immunohistochemical correlation 
Correlation between mutational status and TMA IHC for MMR, beta-catenin, ARID1A and PTEN was 
performed (Table 19, Figure 31). For MMR, the mutation rate was 40.0% in the IHC loss group, whereas 
this was 8.2% in the IHC intact group (P=0.089). For beta-catenin, the mutation rate was 85.7% in the 
tumours which demonstrated aberrant nuclear staining, and 14.3% in normal membranous staining 
(P<0.001). For ARID1A, the mutation rate 85.7% in the IHC loss group, and 27.9% in the IHC intact 
group (P<0.001). For PTEN, the mutation rate was 71.4% in the loss group, and 5.4% in the IHC intact 
group (P<0.001). During the scoring process, a cohort of tumours which demonstrated heterogeneous 
PTEN staining (one core intact, one core loss) were identified. The mutation rate was higher at 40.0% 






















Table 19: Correlation of tissue microarray immunohistochemistry and mutation status.  
IHC Stain Mut WT NE Evaluable Mutation (%) 
MMR intact 4 45 52 49 8.2 
  loss 2 3 3 5 40.0 
  NE 1 6 9 7 14.3 
beta-catenin nuclear 12 2 30 14 85.7 
  membranous 6 36 27 42 14.3 
  NE 1 4 7 5 20.0 
ARID1A intact 12 31 48 43 27.9 
  loss 12 2 10 14 85.7 
  NE 1 3 6 4 25.0 
PTEN intact 2 35 31 37 5.4 
  loss 5 2 10 7 71.4 
  het 2 3 9 5 40.0 
  NE 6 6 14 12 50.0 
Legend: Mut=mutated, WT=wild-type, het=heterozygous (1 core intact, 1 core loss); NE=not evaluable.  
 
 
Figure 31: Mutational and immunohistochemical correlation of mismatch repair (MMR), beta-catenin, 
ARID1A and PTEN proteins. Figure by Dr Robert Hollis. 
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5.3.1 POLE mutations 
Four (6.6%) tumours contained POLE mutations (1 hyper-mutated, 1 ultra-mutated) (Table 20; Figure 
32). Three were missense mutations and one was a frameshift deletion. Only one pathogenic mutation 
occurred in the exonuclease domain. Two were novel variants not reported in the literature 
(p.R1675Lfs*69; p.E1062G) (Table 20). POLE mutations clustered solely in the TP53wt group with none 
in the TP53mut group. All four tumours had mutations in EnOClike genes (100% PTEN and CTNNB1, 
75% ARID1A, 25% PIK3CA), and demonstrated differences in histology and grade (Table 20). Two of 
these patients with POLE mutated tumours relapsed. One had grade 1 EnOC and was still alive 13.1 
years after diagnosis, and the other with undifferentiated carcinoma died rapidly within 2 months of 
diagnosis. Neither of these patients’ tumours were hyper- or ultra-mutated. 



















Unknown Undiff 3 52, IA Deceased - 
8462 Missense 33 c.4156C>T/ 
p.R1386W 
VUS EnOC 3 49, IA Alive Ultra 
 
9241 Missense 9b c.857C>G/ 
p.P286R 
 
Path EnOC 2 49, IIC Alive Hyper 
9332 Missense 26 c.3185A>G/ 
p.E1062G 
 
Unknown EnOC 1 62, IIC Relapsed 
and Alive 
- 
aClinical significance as annotated on ClinVar as of July 2019.b Within the exonuclease domain. 
Legend: VUS=variant of unknown significant; path=pathogenic; hist=histology; TMB=tumour mutation burden, hyper=hyper-
mutated (>500 mutations); ultra=ultra-mutated (>3500 mutations). 
Figure 32: POLE mutations and mutational load. Figure by Dr John Thompson. 
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5.3.2 Mutations in Mismatch repair genes and BRCA mutations 
Seven (11.5%) tumours of all grades displayed mutational inactivation in at least one of the MMR genes 
(Table 21). Four were low grade EnOC, and three were high grade carcinomas (Three HGS 
morphology, one G3 EnOC). Of nine mutations (two tumours with co-occurring MLH1 and MSH6 
mutations), four were missense, whilst the rest were truncating mutations (frameshift (n=2), nonsense 
(n=2), splice site (n=1)). Only two mutations had their clinical significance recorded as pathogenic or 
likely pathogenic on ClinVar, whilst the rest were either novel (n=5) or variants of uncertain clinical 
significance (n=2). Four tumours had concurrent TP53 mutations with no mutations in EnOClike genes, 
and three were TP53wt with EnOClike mutations. The mutation rates for MSH6, MLH1, PMS2 and MSH2 
were 6.6%, 3.3%, 3.3% and 1.6%, respectively.  
Across the 125 WT1 negative tumours cohort, eight (7.3%) of 109 evaluable tumours had loss of MMR 
on IHC (MLH1/PMS2 (n=5), MSH2/MSH6 (n=2), MSH6 (n=1)). All occurred in tumours which were 
TP53wt or displayed p53 wild-type expression on IHC. Six of these eight tumours were G1 EnOC, with 
the remainder occurring in high grade carcinomas (one G3 EnOC, one HGS morphology). Only two of 
the six evaluable tumours with mutations in the MMR genes demonstrated corresponding loss of MMR 
on IHC. An additional three tumours demonstrated loss of MMR protein on IHC with no mutations in 
MMR genes detected (MLH1/PMS2 loss (n=2), MSH6 loss (n=1)). Correlation between MMR mutational 
status and IHC protein expression was poor (P=0.089). Of the ten sequenced tumours which had either 
MMR mutations and/or loss of MMR on IHC, five (50.0%) tumours had high tumour mutation burden 
(hyper-mutated (n=4), ultra-mutated (n=1)), two of which were high grade carcinomas (1 G3 EnOC, 1 
HGS morphology) (Table 21).  
12 tumours contained BRCA mutations (BRCA1 (n=5), BRCA2 (n=7)). Nine were truncating mutations 
(frameshift (n=6), nonsense (n=2), splice site (n=1)), two were missense, and one had multiple hits 
(nonsense (n=2), missense (n=2)). The BRCA mutation variant allele frequency was greater than 0.5 
for seven tumours and manually determined tumour cellularity was 50% or greater in nine tumours. 
Concurrent mutations were found in either EnOClike genes (ARID1A, PTEN, CTNNB1, PIK3CA), and/or 
MMR genes in eight tumours (66.7%) (Table 22).  Of these eight tumours, six were low grade EnOC 
(containing both TP53wt and TP53mut), and two high grade carcinomas (1 G3 EnOC, 1 HGS 
morphology). Four BRCA mutated tumours did not contain mutations in EnOClike or MMR genes, and 
displayed classical HGS or undifferentiated morphology.  
Interestingly, the only ultra-mutated tumour was diagnosed as grade 3 EnOC, and contained concurrent 
pathogenic MSH2 and pathogenic BRCA2 mutation as well as mutations in POLE, PTEN, CTNNB1 and 







Table 21: Tumours with inactivation of mismatch repair (MMR) genes and/or loss of MMR on immunohistochemistry.         
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HGS III Hyper 











  wt mut MSH6 Missense c.2511C>G p.His837Gln  VUS Intact  




Unknown Intact HGS IB - 
















































ap53 wild-type expression on IHC, EnOClike based on loss of protein IHC expression for either PTEN or ARID1A, or nuclear staining of beta-catenin. The rest of the EnOClike samples are 
mutational loss of either PTEN, ARID1A, CTNNB1 or PIK3CA mutations. 
bClinical significance as annotated on ClinVar as of July 2019. 
Legend: MMR=mismatch repair; mut= mutation; IHC=immunohistochemistry; Hist=histology; G=grade; TMB=tumour mutation burden; wt=wild-type; mut=mutated FS del=frameshift deletion; 
path=pathogenic; VUS=variant uncertain significance; EnOC=endometrioid; HGS=high grade serous morphology; Ultra=ultra-mutated (>3500 mutations); Hyper=hyper-mutated (>500 mutations); 





Table 22: Clinical pathological and genomic characteristics of tumours with BRCA mutations.  





















Path wt wt no - Undiff IIB No 
7523 2 FS insert c.6129dup p.Gly2044ArgfsTer5 0.34 
80 




7920 1 Missense c.1897C>T p.Pro633Ser 0.45 
60 




21776 2 Nonsense c.2409T>G p.Tyr803Ter 0.31 
60 













4006 2 Nonsense c.37G>T p.Glu13Ter 0.62 
 
 




8462 2 Missense c.2585A>T p.Lys862Ile 0.19 
30 




 8462 2 Nonsense c.2659G>T p.Glu887Ter 0.16 
30 




 8462 2 Nonsense c.5782G>T p.Glu1928Ter 0.23 
 




 8462 2 Missense c.9428T>G p.Phe3143Cys 0.21 
30 


















Path wt mut yes Unknown HGS IB No 
9231 1 FS del c.1961del p.Lys654SerfsTer47 0.72 >80 Path wt mut no - HGS IIIC Yes 
9759 2 Missense c.4436G>T p.Ser1479Ile 0.39 20 Unknown wt mut no - HGS IIIC Yes 
9759 2 Missense c.8587G>C p.Glu2863Gln 0.12 20 Unknown wt mut no - HGS IIIC Yes 
21562 1 Splice site c.80+1G>T p.X27_splice 0.89 
 
80 Path wt mut no  - Undiff IV Yes 
 
aClinical significance as annotated on ClinVar as of July 2019. bManual quantification of tumour cellularity. 
Legend: MMR=mismatch repair; mut= mutation; Hist=histology; G=grade; FS del=frameshift deletion; path=pathogenic; VAF= variant allele frequency; Var. Sig.= variant significance; VUS=variant 
uncertain significance; EnOC=endometrioid; HGS=high grade serous morphology; EnOClike profile=one or more mutations in PTEN, ARID1A, CTNNB1 or PIK3CA. HGS-profile=TP53 mutations with 




5.3.1 Prognostic impact of TP53, ARID1A and CTNNB1 mutation status 
Upon univariable analysis, TP53mut was associated with inferior DSS versus TP53wt cases (HR for 
TP53wt=0.29[0.13-0.48], P=0.004), while ARID1A and CTNNB1 mutations (ARID1Amut and CTNNB1mut) 
were significantly associated with prolonged DSS (HR for ARID1Amut=0.32[0.12-0.85] P=0.022; HR for 
CTNNB1mut=0.23[0.07-0.78]; P=0.018). Collectively, EnOClike cases (PTEN, CTNNB1, ARID1A, or 
PIK3CA mutation) had prolonged DSS versus the EnOCwt group (HR for EnOClike =0.32[0.14-0.73]; 
P=0.007). Similarly, these events were associated with significantly differential RFS (Table 23). 
Compared to TP53mut cases, TP53wt cases were more likely to be of low grade (71.8% versus 46.4%; 
P=0.0323), present with earlier stage disease (84.4% versus 53.6%; P=0.0206), and were more likely 
to undergo surgical cytoreduction to <2cm residual disease (90.3% versus 63.0%; P=0.0351) (Table 
24). TP53 mutation status was independently associated with inferior DSS and RFS upon multivariable 
analysis (P=0.040 and P=0.003) (Table 23, Figure 33), and this differential effect was most marked in 
stage II cases (DSS: HR=0.17, P=0.006, RFS: HR=0.13, P<0.001) (Figure 34). 
Table 23: Univariable and multivariable survival analysis of mutations in EnOC. 
    Univariable Multivariablea 
Variable   RFS   DSS   RFS   DSS   















mut ref   ref   ref   ref   




























































  EnOCwt ref   ref   ref   ref   
aaccounting for stage, residual disease, decade of diagnosis, disease grade and age. 
bsequenced tumours only. 
Legend: HR=hazard ratio. CI=95% confidence intervals; TP53 mutant (mut) status= tumours with a TP53 mutation; TP53 
wild-type (wt) status= sequenced tumours which are TP53 wild-type and non-sequenced low grade EnoC with p53 wild-type 
expression on IHC; NA=not applicable. 
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Figure 33: Disease specific survival (A) and relapse free survival(B) for TP53 wild-type status versus TP53 





Figure 34: Disease specific survival and relapse free survival by stage in TP53 wild-type versus TP53 
mutant status tumours.  
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5.4 A molecular taxonomy for classifying EnOC 
A molecular taxonomy for classifying EnOClike and EnOCwt tumours by TP53 and ARID1A mutation 
status, as the most common events across the cohort, was proposed. This yielded 5 subgroups: 
EnOClike:TP53mut (n=8; 13.1%), EnOClike:ARID1Awt (n=6; 9.8%), EnOClike:ARID1Amut (n=22; 36.1%), 
EnOCwt: TP53mut (n=20; 32.8%), and EnOCwt:TP53wt (n=5; 8.2%) (Figure 35). Clinical characteristics of 
these groups are outlined in Table 24. Molecular heterogeneity was displayed in both low grade EnOC 
and high grade carcinomas (Figure 35). In the 23 classical low grade EnOC (WT1 negative p53 wild-
type IHC expression), 18 (78.3%) clustered in the EnOClike:TP53wt groups (ARID1Awt (n=3), ARID1Amut 
(n=15)), whilst the remaining five clustered across the other groups. Of the 12 WT1 negative p53 
mutated IHC expression low grade EnOC, 11 (91.7%) clustered in the TP53mut groups (EnOClike:TP53mut 
(n=4); EnOCwt:TP53mut (n=7)), whilst only one clustered in the EnOClike:ARID1Awt group. All the high 
grade carcinomas, which comprised eight grade 3 EnOC and three undifferentiated carcinomas, 
clustered across the five molecular groups. Of the 15 WT1 negative HGSOC, three (20.0%) clustered 
in the EnOClike:ARID1Amut, two (13.3%) in the EnOClike:TP53mut group, and ten (66.7%) in the 
EnOCwt:TP53mut group. 
Hierarchical clustering of the Pearson correlation scores across a binary matrix of mutation status for 
the 100 most commonly mutated genes across the cohort resulted in a near identical stratification set 
to the supervised approach (Figure 36), with ARID1A and TP53 status representing the most prominent 
stratifying mutations. 
The EnOClike:ARID1Amut and EnOClike:ARID1Awt subgroups demonstrated significantly prolonged RFS 
compared to the EnOCwt:TP53mut group (HR=0.25 [0.10-0.66], P=0.0051 and HR=0.13 [0.02-0.99], 
P=0.0490; 5-year RFS 72.7% and 90.9% versus 25.0%, respectively) (Table 25, Figure 37).  
DSS was significantly longer in the EnOClike:ARID1Amut cases (HR=0.24 [0.08-0.67], P=0.0063 versus 
EnOCwt:TP53mut group; 5-year DSS 77.0% vs 30.0%). 5-year DSS in the EnOClike:ARID1Awt group was 
100% versus 30.0% in the EnOCwt:TP53mut cases , but the difference did not reach statistical 









Figure 35: Oncoplot displaying single nucleotide variant frequencies identify distinct molecular groups in 









Figure 36: Plot of unsupervised hierarchical clustering of Pearson’s correlation scores across the top 100 
genes mutated across the whole exome dataset against the molecular groups identified in Figure 35. Figure 





Figure 37: Kaplan Meier survival curves for disease specific survival and relapse free survival for each of 
the molecular groups in EnOC. Figure by Dr Robert Hollis. 
 
Table 25: Relapse free survival and disease specific survival in the molecular groups of EnOC. 









HR [95% CI] P-value 
EnOClike:ARID1Awt 
 
90.9 68.1 0.13 
[0.02-0.99] 





72.7 72.7 0.25 
[0.10-0.66] 





80.0 53.3 0.36 
[0.08-1.59] 
0.1780 80.0 53.0 0.38 
[0.09-1.66] 
0.1977 
EnOClike:TP53mut 50 50 0.60 
[0.20-1.82] 













Table 24: Clinical characteristics of the molecular groups in EnOC. 
















P-value:   
 (n=6) (n=22) (n=20) (n=5) 
TP53mut    vs. 
TP53wt 
Age 51(37-62)   54.5(28-70)   61(41-76)   60.5(32-79)   63(37-46)   0.128 
Endometrial cancer 1 16.7 5 22.7 0 0 1 5.0 1 20.0 0.0597 
Endometriosis 2 33.3 8 36.4 3 37.5 3 15.0 2 40.0 0.3208 







G1 EnOC 3 50.0 15 68.2 1 12.5 3 15.0 3 60.0 
G2 EnOC 0 0 1 4.5 4 25.0 5 25.0 0 0 
G3 EnOC 3 50.0 2 9.1 1 12.5 1 5.0 1 20.0 
High grade serous 0 0 3 13.6 2 25.0 10 50.0 0 0 
Undifferentiated 0 0 1 4.5 0 0 1 5.0 1 20.0 
Year of Diagnosis             
  
0.3031 
1980s 3 50.0 5 22.7 1 12.5 1 5.0 1 20.0 
1990s 2 33.3 9 40.9 3 37.5 10 50.0 3 60.0 
2000s 0 0 7 31.8 2 25.0 6 30.0 0 0 
2010s 1 16.7 1 4.5 2 25.0 3 15.0 1 20.0 
Stage             
  
0.0206 
I 3 50.0 11 50.0 3 37.5 5 25.0 2 40.0 
II 3 50.0 5 22.7 2 25.0 5 25.0 3 60.0 
III 0 0 3 13.6 1 12.5 6 30.0 0 0 
IV 0 0 2 9.1 2 25.0 4 20.0 0 0 
UK 0 0 1 4.5 0 0 0 0 0 0 
Surgical Cytoreductiona             
  
0.0351 
<2cm 6 100.0 18 81.8 7 87.5 10 50.0 4 80.0 
≥2cm 0 100.0 3 13.6 1 12.5 9 45.0 1 20.0 
UK 0 0 2 9.1 0 0 1 5.0 0 0 
Received 3 cycles of 
platinum                       
0.5751 
  
Yes 3 50.0 11 50.0 5 62.5 14 70.0 5 100.0 
No 3 50.0 11 50.0 3 37.5 6 30.0 0 0 
.aClassification of optimal surgical cytoreduction changed over time; some of the patients were diagnosed at a time when resection to <2cm was considered optimal. 




5.5 WT1 positive low grade endometrioid ovarian carcinomas 
All six WT1 positive low grade EnOC (G1 EnOC (n=4), G2 EnOC (n=2)) cases clustered in the EnOClike: 
ARID1Awt group (CTNNB1 mutation (n=5), PTEN mutation (n=2)) (Figure 38). All presented with early 
stage disease (stage I (n=5), stage II (n=1)) and were optimally surgically cyto-reduced. Ten year RFS 
and DSS was 100%. Five tumours were ER and PR positive (ER histoscore>200 (n=3), ER 150-200 
(n=1), ER 50-100 (n=1), all 5 tumours PR 250-300). AR histoscores were mostly low (AR 
histoscore<100 (n=4), AR 101-150 (n=1), AR 201-250 (n=1)). No loss of MMR on IHC were observed 
for any tumours. 
 
Figure 38: Oncoplot of the molecular groups identified in EnOC with all six WT1 positive low grade EnOC 












5.6 Copy number variants across molecular subgroups of EnOC 
Copy number across the virtual 75 EnOC gene panel were investigated for CNVs. TP53mut harboured 
greater CNVs across these genes compared to TP53wt tumours (P<0.0001) (Figure 39). The majority 
of identified CNVs were copy number loss events (n=229). These included loss of APC (23.0%), WT1 
(21.3%), BRCA1 (19.7%), and TP53 (9.8%) genes across the 61 tumour samples. Copy number gain 
events (n=157) were most commonly detected in PIK3CA (19.7%) (Figure 39).  
CNVs over EnOClike genes (ARID1A, CTNNB1, PTEN, PIK3CA) were identified in 16 (26.2%) of cases, 
including eight (40.0%) of EnOCwt:TP53mut tumours (Figure 39).  APC loss was common in the 
EnOCwt:TP53mut group (ten cases, 50.0%). Six tumours demonstrated copy number loss over MMR 
genes (PMS2 (n=4), MLH1 (n=2)). Four were not detected by SNV analysis, with two occurring in the 
EnOCwt:TP53mut groups.   
 
Figure 39: Plot of copy number gains and losses over the most commonly mutated genes in EnoC.  




5.7 Hormone receptor expression in TP53 mutant and TP53 wild-type status 
tumours 
In section 4, strong PR (histoscore >150), but not strong ER, was identified as an independent predictor 
of DSS in EnOC. The proportion of strong PR was significantly higher in the TP53wt status group 
compared to TP53mut status (P=0.003). No differences were observed between both molecular groups 
for ER (P=0.1096) or AR (P=0.730). Upon  multivariable analysis of stage, residual disease, age, 
decade of diagnosis, disease grade, PR and TP53 mutation status, strong PR remained an independent 
predictor of DSS (HR 0.26 (95%CI 0.08-0.81); P=0.020) but not RFS (HR 0.49 (95%CI 0.19-1.27); 
P=0.140), whereas TP53 mutation status lost significance for both DSS (P=0.394) and RFS (0.104) 
(Table 26).  
Table 26: Multivariable analysis of PR and TP53 mutation statusa. 
  Relapse Free Survival Disease specific survival  
  HR (95% CI) P HR (95% CI) P 
PR histoscore    
 
  
>150 0.49 (0.19-1.27) 0.140 0.26 (0.08-0.81) 0.020 
≤150 ref ref ref ref 
TP53 status    
 
  
mut ref ref ref ref 
wt 0.43 (0.16-1.19) 0.104 0.61 (0.20-1.89) 0.394 
Stage    
 
  
I 0.34 (0.11-1.04) 0.059 0.47 (0.14-1.60) 0.224 
II ref ref ref ref 
III 2.45 (0.76-7.87) 0.133 3.22 (0.94-11.0) 0.062 
IV 5.18 (1.02-26.3) 0.047 7.41 (1.34-40.8) 0.022 
Grade       
Low grade EnOC (grade 1 and 2) ref ref ref ref 
High grade EnOC (grade 3) 1.20 (0.25-5.81) 0.822 1.06 (0.20-5.69) 0.944 






<2cm 0.19 (0.04-0.90) 0.036 0.18 (0.03-0.94) 0.042 
2-5cm 0.74 (0.17-3.16) 0.687 0.56 (0.14-2.22) 0.405 
>5cm ref ref ref ref 
Decade of diagnosis    
 
  
1980s ref ref ref ref 
1990s 0.43 (0.14-1.27) 0.125 0.61 (0.18-2.05) 0.421 
2000s 0.29 (0.08-1.09) 0.067 0.41 (0.09-1.81) 0.241 
2010s 0.22 (0.04-1.28) 0.093 0.25 (0.03-2.56) 0.245 
Age 0.99 (0.95-1.03) 0.594 0.99 (0.95-1.04) 0.767 
Legend: HGS=high grade serous histology; undiff=undifferentiated histology; HR=hazard ratio; CI=confidence intervals; 
ref=reference; aaccounting for stage, residual disease, decade of diagnosis, disease grade and age. 
TP53 mutant (mut) status= tumours with a TP53 mutation; TP53 wild-type (wt) status= sequenced tumours which are 
TP53 wild-type and non-sequenced low grade EnOC with p53 wild-type expression on IHC  
Table 29: Multivariable analysis of PR and TP53 mutation statusa. 




  HR (95% CI) P HR (95% CI) P 
PR histoscore    
 
  
>150 0.49 (0.19-1.27) 0.140 0.26 (0.08-0.81) 0.020 
≤150 ref ref ref ref 
TP53 status    
 
  
mut ref ref ref ref 
wt 0.43 (0.16-1.19) 0.104 0.61 (0.20-1.89) 0.394 
Stage    
 
  
I 0.34 (0.11-1.04) 0.059 0.47 (0.14-1.60) 0.224 
II ref ref ref ref 
III 2.45 (0.76-7.87) 0.133 3.22 (0.94-11.0) 0.062 
IV 5.18 (1.02-26.3) 0.047 7.41 (1.34-40.8) 0.022 
Grade       
low grade EC (grade I/II) ref ref ref ref 
high grade EC (grade III) 1.20 (0.25-5.81) 0.822 1.06 (0.20-5.69) 0.944 
HGS/undiff 0.71 (0.23-2.25) 0.565 1.04 (0.30-3.53) 0.954 
Surgical  




<2cm 0.19 (0.04-0.90) 0.036 0.18 (0.03-0.94) 0.042 
2-5cm 0.74 (0.17-3.16) 0.687 0.56 (0.14-2.22) 0.405 
>5cm ref ref ref ref 
Decade of diagnosis    
 
  
1980s ref ref ref ref 
1990s 0.43 (0.14-1.27) 0.125 0.61 (0.18-2.05) 0.421 
2000s 0.29 (0.08-1.09) 0.067 0.41 (0.09-1.81) 0.241 
2010s 0.22 (0.04-1.28) 0.093 0.25 (0.03-2.56) 0.245 
Age 0.99 (0.95-1.03) 0.594 0.99 (0.95-1.04) 0.767 
Legend: HR=hazard ratio; CI=confidence intervals; ref=reference;  
aaccounting for stage, residual disease, decade of diagnosis, disease grade and age. 
TP53 mutant (mut) status= tumours with a TP53 mutation; TP53 wild-type (wt) status= sequenced tumours which are 





The molecular landscape of EnOC is poorly defined, particularly in high grade cases, due to under-
investigation and historic misclassification of HGSOC as high grade EnOC in older studies [243, 246, 
247]. WT1 negativity has emerged as an important discriminator of high grade EnOC from HGSOC, 
which displays morphological similarities [226, 229, 230, 244, 245]. Notably, WT1 negative 
undifferentiated carcinomas can co-occur with low grade EnOC as de-differentiated carcinomas, with 
emerging evidence of clonality between both components [258]. They are also associated with Lynch 
syndrome and can be misdiagnosed as high grade EnOC [263]. In order to investigate the landscape 
of EnOC with emphasis on high grade tumours, WES on both WT1 negative low grade EnOC and WT1 





Overall, the frequencies of PTEN (24.6%), ARID1A (41.0%), PIK3CA (23.0%), CTNNB1 (31.1%) and 
KRAS (13.1%) mutations in my study were in line with the published literature of EnOC [220, 227, 228, 
302]. These mutation frequencies did however contrast with that of Cybulska et al [381]. In the latter, 
KRAS (42%) and PIK3CA (39%) mutations were most prevalent in 36 pure EnOC with no concomitant 
endometrial carcinomas that underwent both massively parallel targeted sequencing (n=8) and whole 
genome sequencing (n=28). In contrast to my study, ARID1A (19%) and TP53 (17%) mutations 
occurred at lower frequencies. In Cybulska et al, pathology review was performed by different 
pathologists at different centres and methodology was not described. Furthermore, tumour grade was 
only reported for the eight tumours subjected to targeted massively parallel sequencing. The remaining 
28 tumours (obtained from the study by Wang et al [375]) were also of unknown grade. These unknowns 
limit cross comparisons with my study. However, the differences in mutational frequencies observed 
are most likely due to the inclusion of both EnOC with concomitant endometrial carcinomas, as well as 
enrichment for high grade carcinomas in my study.  
In Cybulska et al, formal comparison of 341 cancer-related genes was performed between pure EnOC 
with MSI-high and POLE exonuclease domain mutated EnOC removed, and HGSOC from TCGA [381]. 
Here, KRAS, PIK3CA, PTEN and PIK3R1 were significantly more frequent in non-hyper-mutated pure 
EnOC compared to HGSOC, whereas TP53 was significantly more frequent in HGSOC. When 
compared to EnEC from TCGA, the genes mutated were similar albeit at different frequencies. PTEN, 
PIK3R1, ARID1A, KMT2D and CTCF were more commonly mutated in EnEC than pure EnOC, whereas 
mutational frequencies of KRAS and PIK3CA were similar [381]. These differences held true when 
comparing pure EnOC to EnOC with synchronous endometrial carcinomas, consistent with the 
emerging data suggesting that EnOC with synchronous endometrial carcinomas are clonally related 
[236, 382]. Due to a higher proportion of grade 2 and grade 3 EnEC in the TCGA cohort, a matched 
analysis with grade 1 and 2 EnEC was performed. Here only PTEN mutations were significantly lower 
in EnOC compared to EnEC [381].   
A formal comparison of the mutational repertoire of EnOC with those of EnEC and HGSOC TCGA was 
not performed in my study as only mutational frequencies of the 75 commonly mutated genes previously 
reported in either endometrial, ovarian or pan cancer studies were investigated. This represents a major 
limitation of this study. Future work should investigate the mutational frequencies and copy number 
variation across the whole exome rather than limiting this to a defined set of genes.  Unlike the study 
by Cybulska et al, my study did not differentiate between pure EnOC and those with synchronous 
endometrial carcinomas. Although tumours with synchronous endometrial carcinomas were not 
systematically identified due to a reliance on pathology reports, ovarian metastases from an endometrial 
primary were excluded based on the Young and Scully criteria, thus limiting any inclusion of metastatic 
endometrial carcinomas. Given the growing body of evidence in the literature demonstrating that pure 
EnOC and those with synchronous endometrial carcinomas may be biologically different, an extension 
of this work could also include evaluating the mutational differences between these two cohorts. 
In this study, TP53 (45.9%) and ARID1A (41.0%) were the most commonly mutated genes. To date, 




381, 414]. This wide variation is due to the heterogeneity of these studies performed. Some studies did 
not perform contemporary pathology review [247, 414], whereas others performed molecular analysis 
in only low grade EnOC [228]. Other studies which underwent pathology review did not report on grade 
[375, 379, 381], thus limiting comparisons across studies. The high frequencies of TP53 in this study is 
most likely explained by the enrichment of WT1 negative high grade carcinomas of endometrioid, high 
grade serous and undifferentiated histology. The morphological overlap of these tumours is well 
described with significant inter-observer variation when diagnosed based on morphology alone [229, 
261]. As such, WT1 negativity, a validated IHC marker, was utilised to exclude classical WT1 positive 
HGSOC, as the main discriminator of these tumours. This high frequency is similarly described in Okuda 
et al [414]. Here, 63% of 29 historically diagnosed EnOC contained TP53 mutations by PCR which were 
an independent prognostic factor. 
In my study, multivariable analysis identified TP53 mutation status as an independent negative 
prognostic biomarker over that of clinical prognostic variables including grade, whilst ARID1A and 
CTNNB1 mutations were not. This finding is in line with several studies [302, 414] [324]. Of these, Parra-
Herran et al is the only study that has evaluated the prognostic role of p53 IHC expression specifically 
in a cohort of pathology reviewed WT1 negative EnOC [302]. Here, the PROMISE algorithm [376], a 
surrogate of the endometrial molecular classifier, was applied and the group with p53 mutant IHC 
expression displayed the worst survival [302]. The molecular classifier was found to be independent of 
tumour grade and stage, although residual disease was not accounted for in this study. 
In my study, a supervised taxonomy, incorporating TP53 and ARID1A mutation status, was used to 
classify the WT1 negative tumour cohort. This approach identified subtypes of EnOC with differential 
clinical outcome, and this classification system was subsequently validated by unsupervised clustering. 
These data support the notion that TP53 and ARID1A, as the most commonly mutated genes, are key 
molecular stratifiers in EnOC. ARID1A mutations have been found in EnOC and contiguous atypical 
endometriosis and postulated to be an early driver event [315, 316]. Liu et al performed a meta-analysis 
of 1432 patients with endometrium-related gynaecological cancers (CCOC, EnOC and EnEC), and 
found that negative ARID1A expression was associated with shorter PFS [417]. Loss of ARID1A protein 
expression on IHC has also been found to be associated with poorer prognosis in CCOC [321-323], 
tumours which share the common pre-cursor of endometriosis with EnOC [418]. Furthermore, Mao et 
al correlated progressive loss of ARID1A IHC expression to different stages of EnEC progression (0% 
complex atypical hyperplasia, 25% low grade endometrioid, and 44% high grade endometrioid)), 
highlighting its role in tumour progression in this closely related  tumour type [325]. Collectively, these 
data suggest that ARID1A may be an important driver mutation in EnOC, and that the lack of observable 
survival differences between the TP53wt cohorts, EnOClike:ARID1Amut  and EnOClike:ARID1Awt may be 
due to the small cohort size. A larger sequencing study is thus warranted to evaluate the prognostic 
role of ARID1A mutations within the TP53wt cohort of EnOC.  
 
Within the TP53mut cohort, tumours with concurrent EnOClike mutations were also identified. The 




however none have described their collective clinical behaviour due to the extreme rarity of these 
tumours. Notably, Madore et al identified two WT1 negative advanced stage high grade EnOC with 
concurrent aberrant p53 and β‐catenin IHC staining [243]. One of these tumours gave rise to the well-
characterised aggressive EnOC cell line, TOV112D. This cell line was derived from a 42 year old patient 
who was diagnosed with stage IIIC EnOC who died within three months of diagnosis despite 
cytoreductive surgery and platinum based chemotherapy. The EnOClike:TP53mut molecular group in my 
study thus represents the largest group of EnOC described to date which displays a molecular profile 
distinct to that of HGSOC, and are associated with poor prognosis. It is however acknowledged that 
seven percent of HGSOC in the TCGA study contained PTEN mutations [131]. In addition to EnOC 
[213], loss of PTEN has also been shown to be early events in the development of STICs, a known pre-
cursor of HGSOC, as well as HGSOC [419-422]. The three tumours in this molecular group with 
concurrent PTEN and TP53 mutations thus conceivably share a HGSOC molecular profile. However, 
all three tumours did display distinct endometrioid histology. It is thus of interest whether these tumours 
are genomically HGSOC with endometrioid differentiation, or PTEN mutated EnOC which have 
acquired a TP53 mutation. Given the rarity of the EnOClike:TP53mut molecular group, a larger scale 
collaborative sequencing effort of EnOC tumours is warranted to characterise this molecular group 
further.  
 
The EnOCwt:TP53mut group displayed the worst DSS and RFS. In particular, the TP53mut tumours 
harboured greater CNV compared to the TP53wt group, a finding which is likely underpinned by genomic 
instability in the context of TP53 inactivation.  Whilst some may argue that the presence of TP53 
mutations and high levels of CNVs in this cohort displays a mutational profile that is synonymous with 
HGSOC [423], a proportion of these cases harboured mutations in MMR genes or KRAS, arguing 
against this hypothesis. Furthermore, a proportion of these tumours displayed CNVs over EnOClike 
genes and MMR genes, with nearly half displaying copy number loss over APC, a key tumour 
suppressor gene involved in the regulation of the Wnt/β-catenin pathway which is frequently disrupted 
in EnOC.  
Furthermore, a few clinical characteristics of this group contrasts with that of HGSOC. 50% of the 
EnOCwt:TP53mut  group presented with stage I and II disease.  A similar proportion were also diagnosed 
as low grade EnOC. This highlights that TP53 mutations occur in tumours which are histologically low 
grade EnOC, and that p53 IHC should be considered as part of routine clinical practice to assist with 
prognostication. The findings of low grade EnOC with p53 mutated expression on IHC are supported 
by several studies. In the study by Parra-herran et al, 71% of the 17 p53 mutated expression WT1 
negative pathology reviewed EnOC tumours were low grade [302].  This contrasts with the study by 
Geyer et al where p53 mutated IHC expression were mainly found in grade 3 tumours, however no 
pathology review was performed in this study [254]. Here, a concurrent KRAS mutation was detected 
in the only grade 2 EnOC tumour with mutated p53 IHC expression [254], a finding which is similar to 
the two tumours with concurrent KRAS and TP53 mutations found in the EnOCwt:TP53mut molecular 




2 EnOC [228]. Here, two tumours were also found to contain TP53 mutations, one of which had no 
EnOClike mutations, whilst the other had concurrent ARID1A, PIK3CA and CTNNB1 mutations. Taken 
together, whilst the EnOCwt:TP53mut molecular group is likely to include a population of true WT1 
negative HGSOC or indeed metastases from uterine high grade serous carcinomas, the mutational, 
copy number and clinical features discussed above may suggest a bonafide subgroup of TP53mut EnOC 
associated with poor prognosis.  
Only four (6.6%) tumours demonstrated POLE mutations. Two of these tumours were ultra- and hyper-
mutated, as defined in this study, in keeping with its known association with POLE mutations.  Notably, 
only one of the POLE mutations (1.6%) was located at the exonuclease domain (EDM) [424]. This is 
relevant as only POLE EDM have been reported to be important drivers of carcinogenesis. This 
frequency is numerically lower than that reported in other studies of EnOC (4.5%-10%) [302, 425, 426], 
and endometrial carcinomas (7%) [356]. In our study, the extremely low frequency of POLE EDM 
suggests it is not an important driver of carcinogenesis in EnOC. The POLE EDM cohorts in both 
endometrial [356] and EnOC [302, 381] have been shown to exhibit excellent prognosis, although 
similar conclusions were unable to be made from this study due to the small size of this cohort. 
Nonetheless, all POLE mutated tumours in our study demonstrated differences in grade, a finding 
similar to that of Parra-Herran et al [221] and that of the endometrial TCGA [356]. This contrasts with 
that of Hoang et al which only found POLE mutations in grade 1 and 2 EnOC but none in grade 3 
tumours [425]. Interestingly, one of the tumours in my study displayed undifferentiated histology with a 
deleterious frame shift POLE mutation. This is a novel finding as POLE mutations have been reported 
in de-differentiated/undifferentiated endometrial carcinomas, but not in ovarian undifferentiated 
carcinomas [427] to date.  In our study, POLE mutations were also mutually exclusive with TP53 
mutations which is akin to other studies [302].   
This study is the first to report on MMR gene mutations in EnOC. The mutational frequencies of MMR 
genes observed in our study (11.6%) were numerically lower than the frequency of MSI in EnOC 
(19.2%-29.0%) reported in systemic reviews and pooled meta-analyses [428], and was also lower than 
reported frequencies of around 30% for MSI observed in EnEC [356]. The frequency of loss of MMR 
IHC expression (7.3%) was however consistent with the literature [255, 302, 352, 361, 372]. 
Interestingly, mutations in MMR genes occurred in both high grade carcinomas as well as TP53 mutated 
tumours. This is in contrast to Wang et al which performed whole genome sequencing of 29 EnOC 
[375]. Here, TP53 mutations were confined to only MSS EnOC. These differences may be explained 
by the lack of MSI testing in my study which represents a major limitation. As most of the MMR gene 
mutations were novel, the uncertain functional consequences of these mutations may have contributed 
to this discrepancy.  In contrast, loss of MMR IHC expression occurred across all grades and occurred 
exclusively in TP53wt tumours in my study.  Similarly, in the study by Parra-herran et al which evaluated 
the endometrial molecular classifier (PROMISE algorithm) in pathology reviewed WT1 negative EnOC, 
none of the tumours had concurrent loss of MMR and p53 mutant expression on IHC [302]. This 




In this study, concordance between mutations in MMR genes and IHC was poor. This may be due to 
the fact that MLH1 promoter hyper-methylation and MSI analysis was not performed [429]. In addition, 
over half of the discordant samples (MMR gene mutation but intact IHC expression) were missense 
mutations, a type of mutation which is known to have subtle effects on protein expression of MMR 
genes [430].  
In my study, MSH6 was the most prevalent gene mutation. The predominance of MSH6 mutations in 
our study is similar to the study performed by Pal et al of MMR gene mutations in 1893 patients with 
EOC [367]. Here, 55 patients had germline mutations in MMR genes. Of these, nine pathogenic variants 
were detected, five of which were in the MSH6 gene with the same proportion represented by EnOC. 
Loss of MMR IHC expression has been demonstrated in between 7-14% of EnOC [352, 368, 370, 372, 
373], which was similar to the frequency found in my study (7.3%).  In contrast to other studies which 
found MSH2/MSH6 IHC loss to predominate [352, 372, 374], the majority in my study were comprised 
of MLH1/PMS2 IHC loss. This finding may be due to the presence of MLH1 promoter hypermethylation, 
a common somatic mechanism of dMMR, which was not performed in my study. In Bennett et al, the 
highest proportion of MMR IHC loss was MSH2/MSH6 in 104 unmethylated EnOC [372]. Over half of 
dMMR EnOC cases (n=25) in Rambau et al, which did not perform methylation analysis, were that of 
MSH2/MSH6 IHC loss [352]. In Chui et al, reflex testing of 48 non-serous cases also found the loss of 
MSH2/MSH6 and MSH6 IHC to predominate [374].   
The predominance of MSH2/MSH6 loss rather than MLH1/PMS2 loss in these studies may reflect 
underlying LS rather than a sporadic etiology [352, 372, 374, 431], providing growing evidence that 
reflex dMMR testing of EnOC should be performed due to the over-representation of endometrioid 
histology in LS associated EOC [361, 367, 368, 371, 432]. In view of this, paired germline mutational 
analysis, MSI testing together with MLH1 promoter hypermethylation analysis would need to be 
performed as an extension of my study to investigate this further. 
In my study, half of the tumours with mutations in MMR genes and/or loss of MMR expression were 
hyper-mutated or ultra-mutated. Wang et al showed higher frequencies of neo-antigens in MSI-high 
EnOC compared to MSS EnOC [375]. In a study by Xiao et al of 419 EOC, higher numbers of CD3 and 
CD8 positive TILs and PD-L1 intratumoural immune cells were found in tumours which were dMMR 
compared to those which were pMMR [361]. Similarly, Rambau et al found higher numbers of CD8 
positive TILs in dMMR EnOC compared to those which were pMMR, although the authors reported poor 
sensitivity (64%) and specificity (81%). Taken together, these data thus suggests that dMMR EnOC 
represents a distinct subset of EnOC which may derive benefit from immune checkpoint inhibition in the 
recurrent or metastatic setting, akin to the growing body of evidence supporting its use in dMMR 
colorectal[433] and endometrial cancer[434]. In particular, identification of this subset of EnOC may 
allow access to pembrolizumab, a PD-1 inhibitor, which has garnered a pan-tumour licence by the 
United States Food and Drug Adminstration for all MSI-high/dMMR tumours [435]. 
Interestingly, BRCA mutations in a fifth of our study cohort, most of which were pathogenic, were 




these tumours thus suggesting mutation of both BRCA alleles and that the majority of these mutations 
are driver mutations. Of these, concurrent mutations in EnOClike and/or MMR genes in two thirds of 
these tumours across all grades and in both TP53mut and TP53wt tumours were found. Only three 
BRCA1/2 mutated tumours displayed a genomic and phenotypic profile of HGSOC.  In particular, the 
only ultra-mutated TP53wt tumour had both concurrent pathogenic BRCA2/MSH2 mutations as well as 
mutations in common genes associated with EnOC. This is similar to the findings in Teer et al which 
performed WES on six EnOC and further panel based sequencing on another 14 EnOC [379]. In both 
cohorts, five EnOC contained concurrent BRCA 2 mutations and other mutations in EnOClike genes. 
Similarly, in Wang et al, 12% of EnOC (grade unspecified) which underwent WGS clustered in the 
molecular cohort associated with HRR deficiency [375]. Together, this data suggest that a subset of 
EnOC, including that of low grade tumours, contain mutations in HRR genes, and may not be solely 
confined to HGSOC [131]. This novel finding raises the hypothesis that a proportion of EnOC, including 
that of low grade EnOC, may also derive benefit from PARP inhibitors.  
As discussed in chapter 1.5.4 and 1.5.8, the molecular profile of high grade EnOC is not well-defined 
as pathological definitions have evolved and many historically diagnosed high grade EnOC are now 
thought to be HGSOC. The unique aspect of this molecular analysis performed in my study lies in the 
fact that WT1 negative high grade carcinomas of endometrioid, high grade serous and undifferentiated 
histology were included. In chapter 1, the challenges of distinguishing high grade EnOC from HGSOC 
on the basis of morphology alone are discussed. The use of WT1 as an important and useful 
discriminator between the two subtypes is well described. In this study, all WT1 positive tumours were 
excluded, most of which were classical HGSOC (WT1 positive, p53 aberrant expression). Large ovarian 
carcinoma re-classification studies have found that over 95% of HGSOC are WT1 positive, and a 
combination of WT1 positivity and p53 aberrant expression is highly specific with 91.7% of these 
tumours displaying this combination compared to <1% in EnOC [229, 253]. As such, it is thus unlikely 
that any EnOC with that IHC profile (WT1 positive, p53 aberrant) were excluded. We did not rely on 
morphology alone to diagnose high grade EnOC and instead, relied solely on WT1 negativity, as the 
main inclusion criteria for high grade carcinomas of both histologies. Undifferentiated ovarian 
carcinomas are extremely rare entities which can be associated with low grade EnOC as de-
differentiated carcinomas, with evidence of clonality between both components [257, 258]. This 
supports the inclusion of these carcinomas as a spectrum of EnOC in our WES cohort.  
In my study, high grade EnOC and undifferentiated carcinomas display substantial molecular 
heterogeneity with no predilection for one molecular group. A third of the WT1 negative tumours with 
high grade serous morphology displayed an EnOClike genotype, of which 20% were in the 
EnOClike:ARID1Amut group, a finding which would not have otherwise been elicited if WES was only 
performed on high grade EnOC diagnosed as per WHO classification. Furthermore, the molecular 
heterogeneity of the high grade EnOC diagnosed in our study is akin to grade 3 EnEC which did not 
segregate in one molecular group, but were represented in all four molecular groups of the endometrial 
TCGA, each with vastly different prognosis [436]. As an extension of the endometrial TCGA study, 




agreement was highest in the copy number low cohort, and lowest in the copy number high cohort. In 
addition, of the six cases diagnosed by both expert pathologists as serous carcinomas, only two 
displayed the serous genotype (TP53 mutations without ARID1A and/or PTEN mutations), whilst the 
remaining displayed an endometrioid genotype, findings which mirror those of my study. Similarly in 
EnOC, there exists some variation on what constitutes high grade EnOC diagnosed by modern criteria. 
For example, in Lim et al, only tumours with either confirmatory endometrioid features or contained 
histologically identical components to that of low grade EnEC were diagnosed as EnOC [226]. Only 
three percent were diagnosed as high grade EnOC and this diagnosis was made without the use of 
IHC.  In Assem et al, most grade 3 EnOC which changed category from HGSOC following the use of 
WT1 and p53 IHC did not contain CEFs [224].  In a large scale pathological re-classification study of 
EOC based on 8 IHC markers, the two largest reclassified groups were EnOC to HGSOC (n=29), and 
HGSOC to EnOC (n=8). These tumours underwent targeted sequencing of 28 genes implicated in 
ovarian cancer. An EnOC-like mutational profile was defined as at least one mutation in CTNNB1, 
PIK3CA, ARID1A, KRAS or PTEN without a TP53 mutation. A HGSOC-like profile was the presence of 
a TP53 mutation without any EnOC-like mutations. The sequencing data confirmed the pathological 
reclassification in 20 cases (16 EnOC to HGSOC, and four EnOC to HGSOC), however disproved five 
cases of EnOC to HGSOC. Taken together, these data is in line with my study which strongly supports 
the use of sequencing to help differentiate between WT1 negative high grade carcinomas of 
endometrioid, high grade serous and undifferentiated histology.  
During the pathology review process, six WT1 positive tumours with histological appearances of low 
grade EnOC were identified. I hypothesised that these were either true WT1 positive low grade EnOC, 
or LGSOC with pseudo-endometrioid appearances. Interestingly, all of them clustered in the 
EnOClike:ARID1Awt group, thus confirming them to be genomically EnOC. This has immediate clinical 
application as it provides pathological confidence to the existence of true WT1 positive low grade EnOC 
that are associated with excellent prognosis. This may also suggest that a subset of EnOC may arise 
from the ovarian surface epithelium (WT1 positive) rather than ectopic endometrial tissue (WT1 
negative) [252]. This is in keeping with the study performed by Stewart et al of 41 grade 1 and 2 EnOC 
in which 20% were positive for WT1 and demonstrated a negative correlation with endometriosis [218].  
Finally, a subset of tumours with CNVs over EnOClike genes in the EnOCwt groups, and CNVs over the 
TP53 gene in the TP53wt groups were identified. This is akin to the study performed by Teer et al [379]. 
Here, one of six low grade EnOC tumours which underwent WES was found to have no mutations in 
common cancer genes but had the most number of CNVs. This tumour had amplification over driver 
genes (PIK3R1, MET, ALK and NOTCH2) and deletion of PMS2. It can therefore be hypothesised that 
employing copy number analysis may help refine molecular stratification of the SNV defined molecular 
groups of EnOC.  
In chapter 4, strong PR was found to be associated with DSS independent of age, stage, residual 
disease, and year of diagnosis. In this chapter, the relationship between strong and weak PR, and TP53 
mutation status was investigated. Here, the degree of PR expression was associated with TP53 




TP53mut cohort. Studies in breast cancer have specifically reported this inverse relationship [437]. PR 
has been shown to be regulated by ER in ovarian cancer cells and mediates the protective effect of 
progesterone on cancer cell invasion and metastases [438, 439]. Loss of PR expression has also been 
associated with increasing grade in EOC which influences survival [440]. The relationship between 
strong PR and TP53 is likely a reflection of this as the majority of TP53 mutant tumours in our study 
were of high grade. This is also in keeping with EnEC, in which loss of PR expression is associated 
with poor prognosis [441, 442]. Lower expression levels of PR have also been found in metastases 
compared to matched primary tumours in several studies of EnEC [442].  
In this chapter, TP53 mutations were independently associated with DSS over clinical variables. 
Interestingly, when accounting for TP53 mutation status and PR expression in a multivariable analysis 
which importantly also accounted for grade, only strong PR expression, but not TP53 mutation status, 
remained independently associated with DSS. These findings draw striking parallels with one 
prospective multicentre study in endometrial carcinomas [441]. It found that ER and PR negativity 
influenced survival independent of tumour grade in lymph node negative EnEC. Notably, p53 IHC status 
lost significance in the multivariable model, whilst ER and PR negativity retained statistical significance. 
Similar to my study, the authors argue that ER and PR status was a stronger predictor of lymph node 
metastases and survival then the use of p53 IHC expression. This highlights strong PR expression to 
be a powerful prognostic biomarker in EnOC which is independent of grade, and should be considered 
for routine testing in clinical practice to inform prognosis and the need for adjuvant treatments.  
5.9 Study Limitations 
The major limitations of this study include the large number of irretrievable tumours samples which may 
have contribute to selection bias. Only a third of reviewed cases had available slide series for pathology 
review, with the remaining tumours reviewed from a single tumour block. This would have posed 
limitations in systematically identifying the presence of endometrioisis as well as pathology review of 
the endometrial tumours in cases with reported synchronous primaries.  
Both SNV and CNV analysis were performed across a targeted 75 gene panel rather than across the 
whole exome which may have also contributed to selection bias in the molecular stratification of EnOC 
in my study. However, despite this, the frequencies of commonly mutated genes in EnOC in this study 
were largely similar to that of the literature. In addition, the molecular groups obtained through 
employing both supervised and unsupervised clustering methods, suggests robust exome data 
obtained from FFPE tumour samples.  
Subsequent to this study, the methodology was further refined through repeating the SNV and copy 
number analysis across the whole exome rather than confining it to the 75 gene panel. As outlined in 
section 2.6, unsupervised analysis was performed across the top 100 differentially mutated genes within 
the total tumour dataset and represented as a binary matrix. Samples were clustered by Euclidian and 
Ward methods based on the overall Pearson correlation score of these binary signatures. In contrast 
to this study, supervised mutational analysis was performed using the most differentially mutated genes 




methodology, the same molecular cohorts were identified suggesting that 75 gene panel used in this 
study were representative as the major driver mutations in EnOC. 
Another major bias in our study was the methodology in which sequenced tumours were selected. WES 
was performed on all WT1 negative tumours with p53 mutated IHC expression as well as all p53 wild-
type expression high grade carcinomas of endometrioid, high grade serous and undifferentiated 
histology. However, due to budget constraints, only a randomly selected proportion of WT1 negative 
p53 wild-type expression low grade EnOC underwent WES, as it was hypothesised that these tumours 
were pathologically homogenous and were thus likely to be similarly so at a molecular level. However 
this methodology lends itself to selection bias and the mutational frequencies reported in my study are 
thus less representative of EnOC due to the exclusion of the remaining classical low grade EnOC. Since 
this study, Professor Gourley’s laboratory group has since proceeded with performing WES on the 
remaining 64 WT1 negative p53 wild-type expression low grade EnOC, following which an unbiased 
comprehensive molecular profiling of EnOC will be performed, molecular subgroups identified and 
correlated with clinical outcome (Hollis et al, unpublished and awaiting peer review).  
It is notable that I did not apply the PROMISE algorithm to my study cohort. As discussed in chapter 1, 
the PROMISE algorithm was developed and validated as a molecular classifier in endometrial 
carcinomas. Parra Herran et al was the first study to apply the PROMISE algorithm to a cohort of WT1 
negative EnOC and found the molecular classifier to correlate with disease free survival in a multivariate 
analysis independent of grade and stage. However, akin to my study (10%), the POLE mutated and 
MMR abnormal cohorts only comprised 18% with the majority of EnOC comprised of the p53 wild-type 
cohort (58%) [302]. The low frequencies of the POLE and MMR abnormal cohorts observed thus 
suggests they are not key drivers within EnOC. Furthermore, as over half of the cohort in the study by 
Parra-Herran had no specific molecular profile, it was therefore critical to investigate if there were other 
molecular drivers within EnOC which could provide additional prognostic granularity through an 
unbiased approach. However, it is acknowledged that applying the PROMISE algorithm to my study 
cohort in addition may have allowed for more direct comparisons to be made in this regard. 
5.10 Conclusion 
In this study, WES was performed on 61 WT1 negative EnOC with particular emphasis on high grade 
carcinomas. The key findings are summarised as follows: 
 TP53 and ARID1A mutations were the most commonly mutated genes and stratified EnOC into 
molecular subgroups with differential clinical outcome.  
 POLE and MMR gene mutations exist at low frequency in EnOC. 
 CNVs in EnOC may be used to refine molecular classification in SNV subgroups of EnOC. 
 EnOC with TP53mut are associated with poor prognosis independent of age, stage, residual 
disease and decade of diagnosis. 
 EnOC with TP53mut have lower levels of PR expression compared to tumours which are TP53wt. 
 Strong PR expression (histoscore >150) defines a cohort of EnOC with superior prognosis 




 WT1 positive low grade EnOC are genomically EnOC and demonstrate good prognosis. 
 WES of the remaining un-sequenced classical low grade EnOC (WT1 negative p53 wild-type 

































To my knowledge, this is the largest study investigating the clinical, pathological and molecular 
correlation in a cohort of contemporary pathology reviewed EnOC. Here, the key findings and the 
potential therapeutic implications of this study are summarised.  
Comprehensive pathology review of 271 tumours historically diagnosed as EnOC utilising WT1 IHC 
was performed. All WT1 positive tumours were excluded leaving a cohort of 125 WT1 negative EnOC 
of all grades. A consistent approach was maintained throughout this study, utilising WT1 and p53 IHC 
on the corresponding whole tissue section during pathology review of every chemotherapy naïve tumour 
rather than a TMA, minimising the impact of tumour heterogeneity or fixation defects. The same 
corresponding tissue section was used for DNA extraction and WES. This is in contrast to other studies 
which did not use the corresponding pathology reviewed slide for WES [379], performed sequencing 
on EnOC of unknown grade [375, 381], included post chemotherapy samples in the analysis [375], or 
utilised different sequencing methods in the same analysis [379, 381]. 
A unique aspect of this study is the inclusion of high grade carcinomas of high grade serous, 
undifferentiated and endometrioid morphology as they display significant inter-observer variation. The 
use of WT1 negativity has been shown to be an important and useful discriminator. As discussed in 
chapter 1, over 95% of HGSOC are WT1 positive, and a combination of WT1 positivity and p53 aberrant 
expression is highly specific  with 91.7% of cases displaying this classical IHC profile, whereas up to 
90-96% of EnOC are WT1 negative [229, 253]. Studies have demonstrated that the use of WT1 IHC, 
which have resulted in a change of histotype assignment, most commonly occurs from EnOC to 
HGSOC. Kobel et al performed a large re-classification exercise of 1626 tumours utilising a panel of 




and HGSOC (29 of 72 misclassified cases), with fewer (n=8) cases reclassified from HGSOC to EnOC. 
Targeted panel sequencing was performed on both these cohorts and confirmed the reclassification in 
the 80% of cases but refuted it in 20% suggesting additional value to mutational analysis in cases with 
discordant histology and IHC. This further supports my rationale for the inclusion of WT1 negative 
tumours of high grade serous morphology in this study. 
In chapter 3, both classical low grade EnOC (WT1 negative, p53 wild-type IHC expression) as well as 
the whole WT1 negative cohort were characterised clinically. Consistent with the literature, patients with 
early stage EnOC in this study had a good prognosis, whereas those with advanced stage classical low 
grade EnOC had a prognosis superior to that of advanced stage HGSOC.  I also reported that relapses 
beyond five years are common in EnOC which may influence the duration of follow up as these patients 
are often discharged from oncology after five years. Furthermore, these tumours commonly relapse as 
a solitary pelvic mass, thus raising the hypothesis as to whether adjuvant radiotherapy may have a role 
in the management of these tumours akin to emerging data of benefit in CCOC.  
In chapter 4, the majority of EnOC display high ER and PR expression as determined by weighted 
histoscores, whilst most tumours display low AR expression. Only a PR histoscore of greater than 150, 
but not ER or AR, was independently associated with prognosis. I also reported on a series of patients 
with EnOC which received endocrine therapy and derived prolonged benefit. This adds to the small 
body of published data demonstrating these tumours to be hormone sensitive and that endocrine 
therapy should be readily used in its management. It also raises the hypothesis of whether there is a 
role of endocrine therapy in the adjuvant setting for patients with EnOC.  
WES on 61 tumours of this cohort was performed. This was comprised of three WT1 negative IHC 
cohorts: i) all p53 wild-type expression high grade carcinomas, ii) all p53-mutant expression low grade 
and high grade carcinomas, and iii) a random selection of p53 wild -type expression low grade EnOC.  
I find that EnOC is molecularly heterogeneous and is stratified by ARID1A and TP53 as the predominant 
mutations, with each group displaying differential clinical outcomes. A subset of both low and high grade 
EnOC with concurrent BRCA mutations was also identified, suggesting that these tumours may derive 
benefit from PARP inhibitors. Of particular interest was the EnOCwt: TP53mut cohort which initially appear 
genomically akin to HGSOC; however the presence of CNVs over EnOClike genes, concurrent mutations 
in MMR genes, with half the cohort presenting as early stage disease with endometrioid histology, 
suggests that this molecular subgroup is unique and warrants further investigation.  
The high grade tumours in this study were found to be genomically heterogeneous, a finding akin to 
that of grade 3 EnEC [436]. In particular, a third of the WT1 negative tumours with high grade serous 
histology displayed an EnOClike mutational profile, a finding which would not have been elicited if only 
grade 3 tumours of endometrioid morphology were solely investigated. This study therefore highlights 
the need to apply molecular stratification strategies to refine pathological diagnoses particularly in WT1 
negative high grade carcinomas of endometrioid, serous and undifferentiated morphology akin to its 




In chapter 1.5.2, the FIGO grading system used in EnOC is described, one which is extrapolated from 
EnEC due to shared morphology. Briefly, this is a three tier architectural grading system based on the 
proportion of solid growth (grade 1 <5%, grade 2 5%-50%, and grade 3 >50%).  The presence of nuclear 
atypia in an otherwise architecturally low grade tumour increases the grade by one level.  
In EnEC, there is a growing body of evidence which casts doubt on the value and reproducibility of 
grade 2 tumours [223, 225, 443-445]. These studies have proposed a binary grading system and 
demonstrated that grade 1 and 2 tumours can be combined as low grade EnEC. The main consideration 
of grading EnEC is to identify grade 3 EnEC in view of its adverse effect on prognosis and not an attempt 
to differentiate grade 1 or 2 tumours.  
A similar story is unfolding in EnOC and the prognostic value of the FIGO grading system has been 
questioned by several retrospective studies. As described in chapter 1.5, Parra-Herran et al found the 
Silverberg grading system to provide superior prognostication to the FIGO grading system with a two-
tier grading system favoured in EnOC [221]. In this study, the survival of patients with FIGO grade 1 
and 2 tumours overlap for the first five years however grade 2 tumours approach survival of grade 3 
tumours beyond five years [221]. This contrasts with that of Assem et al in which no clinical or survival 
differences were observed between FIGO grade 2 and 3 tumours and the authors argue that these 2 
groups of tumours could be grouped together [224]. These findings mirror that of my study in which no 
differences were observed in DSS or RFS between grade 2 and 3 tumours. Taken together, these 
studies suggest that like EnEC, there exists substantial inter-observer variation in the determination of 
grade 2 EnOC. 
In my study, both the presence of TP53 mutations, and a PR histoscore of more than 150 (strong PR), 
were both independent predictors of prognosis over common clinical variables of prognosis. When 
accounting for both variables in a multivariable analysis which also included grade, only strong PR 
remained an independent predictor of prognosis whereas TP53 mutation status lost significance. In 
particular, patients with stage II disease with strong PR demonstrate a five year DSS of over 90%. No 
differences were observed between the strong and weak PR groups in the proportion of patients 
receiving adjuvant platinum based chemotherapy. It can therefore be hypothesised that strong PR 
expression could be used to identify patients with early stage EnOC who can avoid adjuvant 
chemotherapy even in stage II disease.  
In order for a pathological grading system to be successful, it needs to be reproducible, practical and 
provide clinically relevant prognostic information. In accordance with EOC being five distinct biologically 
and molecularly diverse histological subtypes, the grading system is unique to each. For example, 
although CCOC are pathologically well differentiated, they are all considered high grade due to its 
aggressive biology with stage being the main determinant of prognosis [129]. Similarly, as discussed in 
section 1.4, a revised two-tier Silverberg grading system which accounts for nuclear atypia and number 
of mitoses was proposed in 2004 by Malpica et al for serous ovarian carcinomas [157]. This has 
subsequently been proven to be highly reproducible with demonstrable differences in the molecular 




bimodal PR expression exhibited in my study lends itself to being easily reproducible and can be readily 
implemented into clinical practice. This study has demonstrated that PR expression is prognostic even 
when accounting for grade and stage in EnOC, a finding which should be validated in a larger study 
with the aim of utilising this biomarker to guide decisions regarding adjuvant chemotherapy in early 
stage disease.   
I have explored this study’s limitations in the individual chapters. The major limitations relate to the high 
attrition rate with tumour retrieval, and due to constraints in resources, the inherent selection bias in 
selecting tumours for WES, and the evaluation of a 75 gene panel rather than the whole exome gene 
panel which pose limitations in the interpretation of mutation frequencies within this study cohort.  
Nonetheless, this study has demonstrated that EnOC is a heterogeneous disease comprising distinct 
molecular and hormone receptor subgroups with differential clinical outcome. TP53 mutations (or p53 
mutated expression on IHC) and low PR expression (histoscore <150) have been shown in this study 
to be independent poor prognostic factors. Subsequent work should focus on the development of 
molecularly targeted agents for these subgroups of EnOC which display the poorest prognosis. In 
particular, this study raises the hypothesis that WES should be utilised to differentiate WT1 negative 
high grade carcinomas of serous, endometrioid and undifferentiated morphology which display 
molecular heterogeneity. In particular, the EnOCwt:TP53mut tumours identified in this study represent a 
group of poor prognosis which display clinical and molecular features which suggest that they are 
biologically distinct from HGSOC. Worldwide collaborative efforts are required to investigate this rare 
subgroup further. Further work should include WES of the remaining classical low grade EnOC and 
unsupervised clustering across the whole exome to investigate the molecular landscape in an 
unselected population of EnOC in order to validate the molecular and hormone receptor subgroups 



























































Whole Exome Sequencing Report 
Report by: Richard Clark on 04/12/2017 
Number of Samples: 72 
1. Summary of Sequencing Protocol 
Quality Control 
DNA samples extracted from Formalin-Fixed Paraffin-Embedded (FFPE) tissue were provided by the 
Investigator. DNA was quantified using the Qubit 2.0 Fluorometer (Thermo Fisher Scientific Inc, 
#Q32866) and the Qubit DNA BR assay kit (#Q32853). 
Library Preparation 
Libraries were prepared from each DNA sample using the TruSeq Exome Library Prep kit (#FC-150-
1002) according to the provided protocol using modifications for working with FFPE sourced material. 
200ng of DNA was end-repaired to remove 3’ and 5’ overhangs, and fragment length was optimised 
using sample purification beads. A single 'A' nucleotide was added to the 3' ends of the blunt fragments 
to prevent them from ligating to another during the subsequent adapter ligation reaction, and a 
corresponding single 'T' nucleotide on the 3' end of the adapter provided a complementary overhang 
for ligating the adapter to the fragment. Multiple indexing adapters were then ligated to the ends of the 
ds cDNA to prepare them for hybridisation onto a flow cell, before 12 cycles of PCR were used to 
selectively enrich those DNA fragments that had adapter molecules on both ends and amplify the 
amount of DNA in the library suitable for sequencing. Libraries were quantified using the Qubit 2.0 
Fluorometer and the Qubit DNA HS assay (#Q32854) and the size distribution of fragments was 
assessed using the Agilent Bioanalyser with the DNA HS Kit (#5067-4626). 
Whole Genome (WG) DNA libraries containing unique indexes were combined in pools of 6, and then 
target regions of the DNA were bound with capture probes. Streptavidin Magnetic Beads were then 
used to capture probes hybridised to the targeted regions of interest and a series of washes removed 
nonspecific binding from the beads. This process was repeated to ensure high specificity of the captured 
regions. Captured enriched library was then purified before 8 cycles of PCR amplification and a final 
purification step to remove unwanted products. 
Library QC 
Exome-captured sequencing library pools were quantified using the Qubit 2.0 Fluorometer and the 
Qubit DNA HS assay (#Q32854) and the size distribution of fragments was assessed using the Agilent 
Bioanalyser with the DNA HS Kit (#5067-4626). Fragment size and quantity measurements were used 





Sequencing was performed using the NextSeq 500/550 High-Output v2 (150 cycle) Kit (# FC-404-
2002) on the NextSeq 550 platform (Illumina Inc, #SY-415-1002) 
2. Summary of Analysis Pipeline 
Basecall data produced by the NextSeq 550 is automatically uploaded to BaseSpace, a cloud-based 
data management and analysis service provided by Illumina. Here it is converted into FASTQ files in 
order to allow analysis using a number of apps accessible directly through BaseSpace, or to download 
so that alternative analysis pipelines can be used. 
3. Summary 
A 2x75bp sequencing run on the Nextseq 550 using a high output flow cell is expected to generate up 
to 400M reads (50-60Gb) with a data quality of >80% higher than Q30, based on a cluster density of 
170-230K/mm². When multiplexing 6 samples per flow cell we would therefore expect to see up to ~66M 
paired-end (PE) reads per sample. Table 1 below summarises the sequencing metrics for each run. 
Run ID Cluster Density  (K/mm²) % Clusters PF Yield (Gb) % Data > Q30 
170428_NB551016_0077_AHCVFWBGX2 28/04/2017 191 93.7 71.9 
170503_NB551016_0079_AHCMVNBGX2 03/05/2017 216 91.8 79.6 
170505_NB551016_0080_AHCW3YBGX2 05/05/2017 216 93.1 80.9 
170725_NB551016_0093_AHNTYWBGX2 25/07/2017 207 94.1 78.2 
170726_NB551016_0094_AHNTT5BGX2 26/07/2017 235 92.7 87.7 
170727_NB551016_0095_AH5VFFBGX3 27/07/2017 239 93.2 89.5 
170728_NB551016_0096_AH5V7FBGX3 28/07/2017 241 93.5 90.5 
170731_NB551016_0097_AH7K3CBGX3 31/07/2017 252 91.8 93.1 
 
All flow cells performed above expectations, with each producing >70Gb data (Min: 71.9Gb, Max: 
93.1Gb, Mean: 83,7Gb). Data quality was high with at least 91% ≥Q30 for all runs. Coverage of each 
library was variable (Min: 30.1M, Max: 197.4M, Mean: 89.6M), though the majority of libraries generated 






Figure 1: Number of paired-end (PE) generated per library. The box and whiskers show the 4 quartiles, 
and the line dividing the box shows the median. The x marks the mean. Points above or below the 
whiskers show outliers. 
This variation in coverage is due in the main part to the nature of working with DNA extracted from 
FFPE tissue, where the quality of the nucleic acids recovered is dependent on many factors. These 
include: 
 Intraoperative ischemia time 
 Cold ischemia time 
 Transport medium 
 Time to fixation 
 Type/time of fixation 
 pH of formalin 
 Specimen size (penetration of fixation) 
 Type of processor 
 Time in processor 
 Hot wax temperature 
DNA damage caused by the fixation process can include deamination of cytosine to uracil, oxidation, 
thymine dimers, nicks and double-strand breaks. Such damage impacts on the quality of sequencing 
libraries generated from FFPE DNA, and can make accurate quantification a challenge. 
Table 2 below shows the number of PE reads generated per sample. Where a sample ID has an ‘R’ 





Table 2: Library performance 
Sample ID Run ID Sequence Date Number of PE reads 
4081 170428_NB551016_0077_AHCVFWBGX2 28/04/2017 39,625,791 
4080 170428_NB551016_0077_AHCVFWBGX2 28/04/2017 109,940,900 
4046 170428_NB551016_0077_AHCVFWBGX2 28/04/2017 61,155,592 
320 170428_NB551016_0077_AHCVFWBGX2 28/04/2017 61,222,361 
2210 170428_NB551016_0077_AHCVFWBGX2 28/04/2017 99,651,105 
6595 170428_NB551016_0077_AHCVFWBGX2 28/04/2017 79,856,733 
6611 170503_NB551016_0079_AHCMVNBGX2 03/05/2017 51,502,763 
7012 170503_NB551016_0079_AHCMVNBGX2 03/05/2017 110,140,243 
7523 170503_NB551016_0079_AHCMVNBGX2 03/05/2017 84,274,867 
7707 170503_NB551016_0079_AHCMVNBGX2 03/05/2017 54,286,748 
1341 170503_NB551016_0079_AHCMVNBGX2 03/05/2017 95,453,655 
2070 170503_NB551016_0079_AHCMVNBGX2 03/05/2017 101,093,492 
4486 170505_NB551016_0080_AHCW3YBGX2 05/05/2017 73,961,381 
7136 170505_NB551016_0080_AHCW3YBGX2 05/05/2017 74,293,437 
8315 170505_NB551016_0080_AHCW3YBGX2 05/05/2017 104,649,149 
8343 170505_NB551016_0080_AHCW3YBGX2 05/05/2017 82,803,332 
9241 170505_NB551016_0080_AHCW3YBGX2 05/05/2017 89,050,302 
8082 170505_NB551016_0080_AHCW3YBGX2 05/05/2017 75,646,269 
8500 170725_NB551016_0093_AHNTYWBGX2 25/07/2017 64,827,987 
7920 170725_NB551016_0093_AHNTYWBGX2 25/07/2017 86,233,332 
7060 170725_NB551016_0093_AHNTYWBGX2 25/07/2017 114,649,297 
3874 170725_NB551016_0093_AHNTYWBGX2 25/07/2017 49,293,564 
6662 170725_NB551016_0093_AHNTYWBGX2 25/07/2017 102,952,673 
5573 170725_NB551016_0093_AHNTYWBGX2 25/07/2017 69,642,937 
9542 170726_NB551016_0094_AHNTT5BGX2 26/07/2017 118,549,339 
7379 170726_NB551016_0094_AHNTT5BGX2 26/07/2017 81,716,208 
9310 170726_NB551016_0094_AHNTT5BGX2 26/07/2017 121,329,258 
9295 170726_NB551016_0094_AHNTT5BGX2 26/07/2017 87,034,618 
5433 170726_NB551016_0094_AHNTT5BGX2 26/07/2017 87,108,066 
5864 170726_NB551016_0094_AHNTT5BGX2 26/07/2017 53,436,282 
7865 170727_NB551016_0095_AH5VFFBGX3 27/07/2017 75,952,086 
8058 170727_NB551016_0095_AH5VFFBGX3 27/07/2017 98,459,382 
22110 170727_NB551016_0095_AH5VFFBGX3 27/07/2017 142,099,679 
7902 170727_NB551016_0095_AH5VFFBGX3 27/07/2017 98,382,359 
7972 170727_NB551016_0095_AH5VFFBGX3 27/07/2017 115,632,732 
1695 170727_NB551016_0095_AH5VFFBGX3 27/07/2017 30,480,403 
8086 170728_NB551016_0096_AH5V7FBGX3 28/07/2017 71,961,003 
21899R 170728_NB551016_0096_AH5V7FBGX3 28/07/2017 63,613,102 
9231 170728_NB551016_0096_AH5V7FBGX3 28/07/2017 85,540,452 
4629 170728_NB551016_0096_AH5V7FBGX3 28/07/2017 46,962,091 
21729 170728_NB551016_0096_AH5V7FBGX3 28/07/2017 197,457,027 




22106 170731_NB551016_0097_AH7K3CBGX3 31/07/2017 113,285,259 
21860 170731_NB551016_0097_AH7K3CBGX3 31/07/2017 83,205,087 
9079 170731_NB551016_0097_AH7K3CBGX3 31/07/2017 111,900,966 
9305 170731_NB551016_0097_AH7K3CBGX3 31/07/2017 85,818,784 
21770 170731_NB551016_0097_AH7K3CBGX3 31/07/2017 143,556,178 
3817 170731_NB551016_0097_AH7K3CBGX3 31/07/2017 45,925,418 
9332 170809_NB551016_0104_AHGWCNBGX3 09/08/2017 132,901,071 
3785 170809_NB551016_0104_AHGWCNBGX3 09/08/2017 91,906,569 
8460 170809_NB551016_0104_AHGWCNBGX3 09/08/2017 77,421,286 
9735 170809_NB551016_0104_AHGWCNBGX3 09/08/2017 91,013,173 
587R 170809_NB551016_0104_AHGWCNBGX3 09/08/2017 55,745,643 
9693 170809_NB551016_0104_AHGWCNBGX3 09/08/2017 116,017,105 
9801 170810_NB551016_0105_AHGV7CBGX2 10/08/2017 113,548,429 
22299 170810_NB551016_0105_AHGV7CBGX2 10/08/2017 148,534,366 
9759 170810_NB551016_0105_AHGV7CBGX2 10/08/2017 82,434,839 
4006 170810_NB551016_0105_AHGV7CBGX2 10/08/2017 76,983,600 
22270 170810_NB551016_0105_AHGV7CBGX2 10/08/2017 106,138,899 
5071 170810_NB551016_0105_AHGV7CBGX2 10/08/2017 36,103,387 
8429 170811_NB551016_0106_AHGMG7BGX3 11/08/2017 64,033,496 
8462 170811_NB551016_0106_AHGMG7BGX3 11/08/2017 46,688,885 
21776 170811_NB551016_0106_AHGMG7BGX3 11/08/2017 112,135,557 
3362 170811_NB551016_0106_AHGMG7BGX3 11/08/2017 109,294,761 
4319 170811_NB551016_0106_AHGMG7BGX3 11/08/2017 38,816,160 
21636 170811_NB551016_0106_AHGMG7BGX3 11/08/2017 120,837,074 
5183 171201_NB551016_0136_AH23HVBGXJ 01/12/2017 141,916,015 
21562 171201_NB551016_0136_AH23HVBGXJ 01/12/2017 94,853,975 
9610 171201_NB551016_0136_AH23HVBGXJ 01/12/2017 105,651,098 
1695R 171201_NB551016_0136_AH23HVBGXJ 01/12/2017 30,086,676 
4080R 171201_NB551016_0136_AH23HVBGXJ 01/12/2017 39,423,393 
5071R 171201_NB551016_0136_AH23HVBGXJ 01/12/2017 57,057,438 
 
After the data from 11 runs were sequenced and analysed the Investigator selected three samples that 
had performed poorly for repeat library preparation and sequencing alongside the final 3 libraries 
(1695R, 4080R and 5071R). Performance of all three libraries was poor in relation to the other libraries 
in the same sequencing run (5183, 21562 and 9610) with all three repeats failing to generate >60M 





















List of commonly mutated genes previously reported in either endometrial, 
ovarian or pan-cancer studies. 
No. Gene No. Gene No. Gene 
1 AKT1 36 JAK3 71 TERT 
2 AKT2 37 KDR 72 TP53 
3 ALK 38 KIT 73 TSC1 
4 APC 39 KRAS 74 USP9X 
5 AR 40 KSR1 75 WT1 
6 ARAF 41 MAP2K1     
7 ARID1A 42 MAP2K2     
8 ARID1B 43 MATK     
9 ATM 44 MET     
10 BRAF 45 MLH1     
11 BRCA1 46 MSH2     
12 BRCA2 47 MSH6     
13 CCND1 48 MTOR     
14 CCND2 49 NF2     
15 CCND3 50 NFE2L2     
16 CD274 51 NRAS     
17 CDK4 52 NTRK1     
18 CDK6 53 PAK1     
19 CDKN2A 54 PDCD1LG     
20 CTNNB1 55 PDGFRA     
21 EGFR 56 PDGFRB     
22 ERBB2 57 PIK3CA     
23 ESR1 58 PIK3R1     
24 EZH2 59 PMS2     
25 FBXW7 60 POLE     
26 FGFR1 61 PRKD1     
27 FGFR2 62 PTCH1     
28 FGFR3 63 PTEN     
29 FLT1 64 RAF1     
30 FLT3 65 RB1     
31 FLT4 66 RET     
32 GATA3 67 RNF43     
33 IDH1 68 ROS1     
34 IDH2 69 SMAD4     
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